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ABSTRACT 
Parkinson’s disease (PD) is a chronic multifaceted neurodegenerative condition caused 
by a complex interplay of genetic and environmental factors that affects about 1% of 
people over the age of 60. Although the progressive loss of dopaminergic neurons and 
accumulation of aggregated α-Synuclein (αSyn) protein in Lewy bodies are considered 
key pathophysiological features of the disease, the physiological function of αSyn and the 
molecular mechanisms leading to protein aggregation and propagation remain unknown. 
Manganese (Mn) is considered a key inhaled pollutant implicated in environmentally-
linked PD as evidenced by epidemiological studies done on humans exposed to Mn 
during mining, welding metals, and dry battery manufacturing. However, the exact 
molecular mechanisms underlying Mn-induced protein aggregation are not well 
understood. Considering the role of the divalent metal Mn in PD-like neurological 
disorders, we conducted a comprehensive characterization of the role of αSyn in Mn-
induced dopaminergic neurotoxicity, cell-to-cell spreading of αSyn protein aggregates 
and aberrant miRNA delivery via exosomes. Using an αSyn-expressing dopaminergic 
cell model, we show that wildtype αSyn significantly attenuates Mn-induced 
neurotoxicity during the early stages of exposure while prolonged Mn exposure promotes 
αSyn aggregation and dampens its neuroprotective effect. Our subsequent studies show 
that upon Mn exposure, misfolded αSyn-containing exosomes are released to its 
extracellular milieu, which may in turn induce neuroinflammatory, and 
neurodegenerative responses in cell culture and animal models of PD. We also found 
enhanced accumulation of misfolded αSyn species in serum exosomes of welders 
exposed to Mn indicating the possibility of using exosomes as biomarkers of Mn-
vi 
 
neurotoxicity. To further elucidate the regulatory role of exosomes in Mn-induced 
miRNA dysregulation, we performed next-generation miRNA sequencing and identified 
multiple differentially expressed miRNAs in Mn-stimulated exosomes in contrast to 
control exosomes. Herein, our results suggest that Mn induces a novel mechanism of cell 
injury through modulating the protein and miRNA cargo in exosomes and altering gene 
expression. This may contribute to the cell-to-cell transmission of the aggregated αSyn 
protein and progression on neurodegeneration. 
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CHAPTER I: GENERAL INTRODUCTION 
Dissertation Organization 
The alternative format was chosen for this thesis and consists of manuscripts that 
have been published, or are being prepared for submission. The dissertation contains a 
general introduction, two book chapters, three research papers and a conclusions/future 
directions section that briefly discusses the overall findings from all chapters. The 
references for each manuscript chapter are listed at the end of that specific section. 
References pertaining to the background and literature review as well as those used in 
general conclusion section are listed at the end of the dissertation. The introduction 
section under Chapter 1 provides a brief background and overview of Parkinson’s disease 
(PD), manganese (Mn) neurotoxicity and exosomes which this thesis is heavily based 
upon. The Background and Literature Review-I section covers in depth review on the 
recent advances on elucidating cellular and molecular mechanisms of Mn-induced protein 
misfolding, mitochondrial dysfunction and consequent neuroinflammation and 
neurodegeneration; this section will be submitted to Pharmacology and Therapeutics for 
publication. In the background and literature review II section, authors discuss and 
summarize current literature on exosome composition, biogenesis and their potential 
function as intercellular messengers in cell-to-cell transmission of proteins and small-
RNA species.  
The manuscript from Chapter 2 was recently published in the Toxicological 
Science. It demonstrates a potential neuroprotective role of wild-type α-Syn against Mn-
induced neurotoxicity during the early stages of exposure in a dopaminergic neuronal 
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model of PD. Chapter 3 explores how aggregated -synuclein, the major component of 
PD-associated Lewy bodies and a gene linked to the development of familial PD, can 
transfer from one to another through exosomes leading to inflammation and 
neurodegeneration in experimental models on Mn-toxicity. Chapter 4 studies how 
exosomes contributes to cell-to-cell transmission of miRNAs and thereby manipulate 
recipient cell gene expression. Chapters 3 and 4 are in the process of being submitted for 
publication. 
This dissertation also contains three appendix sections. Appendix I is a book 
chapter that was recently published in Manganese in Health and Disease summerizeing 
role of manganese in Prion disease. Appendix II is published in the Jornal Prion 
evaluating the role of oxidative stress-sensitive, pro-apoptotic protein kinase Cδ (PKCδ) 
in prion-induced neuronal cell death using cerebellar organotypic slice cultures (COSC) 
and mouse models of prion diseases. Appendix III is a book chapter that was recently 
published in the Inflammation, Oxidative Stress and Age-Related Disease summarizing 
the recent discoveries of antioxidant therapeutics, including mitochondria-targeted 
antioxidants for modulating oxidative damage in PD and its potential as a possible 
treatment for PD.  
This dissertation contains the experimental data and results obtained by the author during 
his Ph.D. study under the supervision of his major professor Dr. Anumantha G. 
Kanthasamy at Iowa State University, Department of Biomedical Sciences. 
. 
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Introduction 
Parkinson’s disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease, and is the most common movement disorder in people over the age 
of 65.  PD also recognized as one of the most common neurologic disorders, affecting 
approximately 1% of individuals older than 60 years causing progressive disability 
characterized by severe motor symptoms including uncontrollable tremor, postural 
imbalance, slowness of movement and rigidity (Lotharius and Brundin, 2002). 
Pathologically, this disease is characterized by a progressive degeneration of 
dopaminergic neurons projecting from the substantia nigra pars compacta (SNpc) to the 
striatum resulting in pronounced loss of neurotransmitter dopamine resulting above 
mentioned extrapyramidal features. Disease also often associated with abnormal 
accumulation of misfolded proteins in cytoplasmic inclusions called Lewy bodies (LB) 
and Lewy neurites, association between Lewy pathology and pathogenesis of the disease 
is poorly understood. Although aging appears to be the greatest risk for the development 
of PD, pathogenesis of the disease remains incompletely understood and remains to be 
elucidated. Recent evidence has implicated several genes such as α-synuclein (PARK1), 
Parkin (PARK-2), PINK1(PARK6), DJ-1(PARK7), ATP13A2 (PARK9), and SLC30A10 
with early-onset Parkinson’s whereas LRRK2 (PARK8) and VPS35 (PARK-17) are 
accounted for late-onset PD (Dawson et al., 2010; Roth, 2014). While major emphasis 
has been given to the familial PD caused by gene mutations, more than 90% of PD 
occurrences count for the sporadic form of PD which is likely caused by a complex 
interplay of genetic and environmental factors. During the last couple of decades a 
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number of epidemiological and clinical studies have suggested potential environmental 
risk factors for PD. These include: repeated head injury, heavy metal exposure, excess 
body weight, exposure to pesticides and some surrogate measures such as living in rural 
areas, drinking well water, farming etc (Dick et al., 2007; Priyadarshi et al., 2001). 
Although PD is classically defined as a movement disorder associated with degeneration 
of neurons in the nigrostriatal system, non-motor symptoms have been recognized in 
recent years. During the early stages of the disease or the presymptomatic phase, patients 
develop non-motor deficits including cognitive changes, behavioral/neuropsychiatric 
changes autonomic nervous system failure, olfactory impairment and sleep disturbances. 
Non-motor symptoms can represent some of the greatest challenges to quality of life and 
appropriate management in PD since they usually do not respond to dopamine therapy as 
well as motor symptoms. 
α-Synuclein 
α-Synuclein (α-Syn) is a small, acidic protein of 14.5kDa and 140-amino acids that 
highly is conserved in vertebrates and predominantly expressed presynaptically in 
neurons throughout the mammalian brain and cerebrospinal fluid (CSF). Physiological 
functions of a-Syn are poorly understood, but evidence has suggested a role for it in 
synaptic plasticity, dopamine regulation, and membrane trafficking. α-Syn is belongs to 
the synuclein family composed of α-, β-, and γ-synuclein. Structurally, α-Syn is a 
natively unfolded protein which lacks defined secondary structure and therefore belongs 
to the intrinsically unstructured protein family. The α-Syn protein has three distinct 
structural domains. The amphipathic N-terminal region (residues 1 to 60) contains 11 
amino acid repeats including the consensus sequence KTKEGV, which is important in α- 
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helix formation. The central hydrophobic region (residues 61 to 91) contains the 
nonamyloid component region (NAC), which is important in protein aggregation. Finally, 
the C-terminal region (residues 91 to 140) is highly acidic proline rich and is responsible 
for the intrinsically disordered nature of αSyn (Harischandra et al., 2015). The  -Syn 
protein has three metal binding sites: one at N- terminus, one at central region and one at 
C-terminus of the protein. The metal binding sites near 49–52 and 110–140 are known to 
interact with divalent metals including manganese (Uversky et al., 2001). 
 
The link between αSyn and PD pathogenesis is based on case studies of familial PD and 
the observation that misfolded αSyn is a major constituent of Lewy bodies and Lewy 
neurites in both familial and sporadic PD. Also, there is compelling evidence that 
mutations in the gene encoding αSyn directly linked to the onset of PD.  The 
overexpression of αSyn due to duplication or triplication of the SNCA gene or single 
nucleotide polymorphisms in the SNCA gene resulting Ala53Thr, Ala30Pro, and 
Glu46Lys mutations are linked to causes rare familial forms of PD. The idea that αSyn 
can pathologically propagate throughout the CNS recently gained much attention with the 
finding of αSyn species in human plasma and CSF (El-Agnaf et al., 2003; Kordower et 
al., 2008) and host-to-graft propagation of αSyn-positive Lewy bodies in fetal ventral 
Figure 1: Structure of α-synuclein protein indicating its metal binding sites 
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mesencephalic and embryonic nigral neurons transplanted in human PD patients. 
(Kordower et al., 2008; Li et al., 2008).  Even though several models have postulated the 
cell-to-cell transmission of pathological propagating αSyn species (Desplats et al., 2009; 
Dunning et al., 2013; Lee et al., 2008), the exact mechanism of PD pathogenesis and 
related synucleinopathies largely remains unknown. Growing evidence indicates that 
extracellular αSyn induces pathogenic actions by activating neuroinflammatory and 
neurodegenerative responses in vitro (Emmanouilidou et al., 2010; Su et al., 2008). 
 
Manganese neurotoxicity 
Manganese is considered a key inhaled pollutant in the environment and recently gained 
importance as a putative risk factor for environmentally linked PD and related 
neurodegenerative disorders.  Being the 12
th
 most abundant element which composes 
approximately 0.1% of the earth crust, makes manganese ubiquitously present in the 
environment (Martinez-Finley et al., 2012). In trace amounts, manganese is an essential 
metal found in all body tissues as it is essential for many ubiquitous enzymatic reactions, 
including synthesis of amino acids, lipids, proteins, and carbohydrates. It also plays a key 
nutritional role in bone formation, fat and carbohydrate metabolism, blood sugar 
regulation, and calcium absorption in the body (Bowman et al., 2011b). Primary route of 
manganese exposure in humans is through diet, as it is present in whole grains, rice, nuts, 
tea, leafy green vegetables and manganese-containing nutritional supplements. However, 
chronic excessive exposure by occupational or environmental sources of manganese 
cause a neurodegenerative disorder known as Manganism, characterized by severe 
neurological deficit that often resembles the involuntary extrapyrimydal symptoms 
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associated with PD. Manganese is also highly present in the environment through 
common human uses, such as use of methylcyclopentadienyl manganese tricarbonyl 
(MMT) as an antiknock gasoline additive, use in fertilizers, use in paint and cosmetics 
known as manganese violet (Martinez-Finley et al., 2012). The other major 
anthropogenic sources of environmental manganese include municipal wastewater 
discharges, welding, mining and mineral processing, emissions from alloy, steel, and iron 
production, combustion of fossil fuel and dry-cell manufacturing. Although exact 
mechanisms through which manganese is absorbed into the body are not fully 
understood, it has been shown to accumulate in the brain, specifically in the basal ganglia 
region, exerting its neurotoxic effects. Despite the prevalence and potential risk to human 
health, the mechanisms by which manganese exerts its neurotoxic effects are not well 
understood and mechanisms by which manganese cause neuronal dysfunction and death 
are yet to be elucidated. However, manganese neurotoxicity suggested exerting 
nigrostriatal cell death by causing oxidative damage, protein misfolding, and 
neuroinflammation mediated apoptotic cell death 
 
Exosomes 
Exosomes are cell-derived vesicles of 50-200nm in size with endosomal origin. They are 
released into the extracellular space as a result of fusion of multivesicular bodies (MVBs) 
with plasma membrane. Exosomes were initially thought to serve simply as “garbage 
bags” for cells to get rid of unwanted constituents. However, an increasing body of 
evidence indicates that they play a pivotal role in cell-to-cell communication and 
influence both physiological and pathological processes.  Exosome could directly 
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stimulate target cells by receptor-mediated interactions or may transfer from the cell of 
origin to various bioactive molecules including membrane receptors, proteins, mRNAs 
and microRNAs. Importantly, recent studies have shown that exosomes carry misfolded 
protein cargo which could induce deleterious effects on targets cells in neurodegenerative 
disorders (Arellano-Anaya et al., 2015; Grey et al., 2015; Kong et al., 2014) suggesting 
that exosomes may be involved in cell-to-cell transmission of pathogenic proteins in 
pathogenesis of progressive neurodegenerative disorders. Since central 
pathophysiological mechanism of many neurodegenerative diseases including 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Prion Disease 
involves protein aggregation and its transmission, exosomes may play central role in 
progression of these protein misfolding diseases. 
 
Background and Literature Review – I 
Manganese; its role and significance in Parkinsonism Spectrum Disorders 
A review to be submitted to Pharmacology and Therapeutics  
Dilshan S. Harischandra, Shivani Ghaisas, Huajun Jin, Arthi Kanthasamy, Vellareddy 
Anantharam, Anumantha G. Kanthasamy* 
Department of Biomedical Sciences, Iowa Center for Advanced Neurotoxicology, Iowa 
State University, Ames, Iowa 50011 
Abstract 
Metal ions (zinc, copper, magnesium, manganese, etc.) are important components of 
various metalloenzymes that function in many biological processes, such as synaptic 
9 
 
communication, respiration, free radical generation and hypoxia detection. Most of these 
ions are required in minute doses that are frequently met by proper nutrition. However, if 
present in large amounts, they can inhibit different enzymatic reactions as well as 
interfere with metabolic processes. Manganese is a co-factor of manganese superoxide 
dismutase, an enzyme that efficiently removes reactive oxygen species from cells. In 
contrast, high concentrations of manganese are known to impair cellular antioxidant 
mechanisms thus exacerbating oxidative damage in cells, particularly astrocytes and 
neurons. Growing evidence also suggests that manganese can bind to α-synuclein, a 
presynaptic protein that plays a central role in the pathogenesis of Parkinson's disease 
(PD), causing conformational changes in this protein thus leading to protein aggregation 
and subsequent mitochondrial toxicity and cell death. Chronic manganese exposure by 
either ingestion or inhalation can lead to neurological symptoms similar to idiopathic PD. 
While there have been recent advances in the understanding of its pathophysiology, 
manganese neurotoxicity is still poorly understood. The aim of this review is to concisely 
accrue what we know about its effect primarily on the nervous system with respect to its 
role in protein misfolding, mitochondrial dysfunction and consequently 
neuroinflammation and neurodegeneration.  
 
Metals in biology 
At least 13 metals have been identified as essential for life, and four of these (sodium, 
potassium, magnesium and calcium) are present in large quantities. The remaining nine 
trace metals (manganese, iron, cobalt, vanadium, chromium, molybdenum, nickel, copper 
and zinc) assume vital roles in building organic biomolecules. In the last couple of 
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decades, the importance of metal ions in protein biology has been an increasingly 
attractive research subject given their association with many human diseases, for which 
metals have been identified as the causative or stimulatory agent. Metals are essential 
because of their integral role in enzymes that catalyze the basic metabolic or biochemical 
processes shared by all forms of life on earth. It has been estimated that a third of all 
proteins require metal ions to carry out their biological functions (Holm et al., 1996).  
 
When considering all six classes of enzymes - oxidoreductases, transferases, hydrolases, 
lyases, isomerases, ligases, over 40% of all enzymes contain metals (Andreini et al., 
2008). Moreover, the chemistry of metals allows for a broader set of protein-metal 
reactions. For instance, redox-active metal ions are often interchangeable depending on 
the metal concentration and their affinities to protein. The affinities of proteins for the 
different trace metals are substantially determined by universal series, which for divalent 
metals is the Irving-Williams series (Mn
2+
 < Fe
2+
 < Co
2+
 < Ni
2+
 < Cu
2+
 >Zn
2+
), wherein 
Cu
2+
 is highly competitive and can replace lower order metals (Tottey et al., 2008).   
These “metalloproteins” are involved in many key biological processes, such as gas 
transport, photosynthesis, cell respiration, antioxidant defense and many other vital redox 
reactions driven by their interaction with metals. Well-characterized examples for redox 
active metalloprotein systems are blue-copper proteins, heme-binding proteins and iron-
sulfur-cluster proteins. Moreover, recent advances in synthetic chemistry have focused on 
the study of metal sites in metalloproteins and metalloenzymes to influence biological 
processes in the battle against many daunting human diseases. Advanced medicinal 
chemistry approaches have given us new, innovative medicinal applications of metal 
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complexes and organometallic agents. Prime examples for such uses of metals include 
the platinum-containing anticancer drugs (e.g., Cisplatin), lithium-containing depression 
drugs (e.g., Camcolit), and manganese-containing anticancer drugs (e.g., SOD mimics; 
Farrell, 2003). 
 
Presumably, all metalloproteins would bind to their desired metal ligands, and this 
binding can regulate their folding. However, despite the wealth of structural information, 
the coupled protein folding-metal binding pathways for metalloproteins remain largely 
unknown (Wittung-Stafshede, 2002). Proper protein folding is critical to the 
conformational integrity and function of proteins. However, metal ligand binding can 
also induce undesirable structural transitions in proteins that eventually lead to the 
formation of protein aggregates associated with several diseases. The pathologies of 
Alzheimer's disease (AD), PD, and prion diseases are linked to abnormal misfolding of 
otherwise harmless neural proteins. For example, in AD it has been shown that increased 
levels of metals such as Cu
2+
 and Zn
2+
 are linked to the aggregation of Aβ protein in vitro 
(Kenche and Barnham, 2011). The theory of metal-induced aggregation has gained 
credence following numerous studies tying metal concentrations in the brain with AD, 
PD and amyotrophic lateral sclerosis (ALS) in in vivo and in vitro studies employing 
recombinant proteins (Brown, 2011; Brown et al., 2005).  
In this review we will focus on α-Synuclein, one of the major proteins implicated in PD, 
and its interactions with metals; specifically its interaction with manganese in oxidative 
stress, protein aggregation and neurodegeneration.  
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Parkinson’s disease 
PD is the second most common neurodegenerative disorder after Alzheimer’s disease, 
and is the most common movement disorder in people over the age of 65, causing 
progressive disability characterized by severe motor symptoms including uncontrollable 
tremor, postural imbalance, slowness of movement and rigidity (Lotharius and Brundin, 
2002). Pathologically, this disease is characterized by a progressive degeneration of 
dopaminergic neurons projecting from the substantia nigra pars compacta (SNpc) to the 
striatum, resulting in a pronounced loss of the neurotransmitter dopamine and hence the 
above-mentioned extrapyramidal symptoms. Even though the disease is also often 
associated with the abnormal accumulation of misfolded proteins in cytoplasmic 
inclusions called Lewy bodies (LB) and Lewy neurites, the association between Lewy 
pathology and disease pathogenesis is poorly understood. Similar neuropathological 
lesions involving the deposition of abnormal proteins also characterize other neurological 
disorders (Ross and Poirier, 2004), including AD (Kotzbauer et al., 2001; Uchikado et al., 
2006), Lewy body dementia (LBD) (McKeith et al., 2004), Huntington’s disease (HD) 
(Davis et al., 2014), multiple system atrophy (MSA) (Shoji et al., 2000) and some prion 
diseases (Aguzzi and Calella, 2009; Aguzzi and O'Connor, 2010).  
Although aging appears to be the greatest risk factor for developing PD, its pathogenesis 
remains incompletely understood. Recent evidence has implicated several genes to the 
onset of PD, such as α-synuclein (PARK1), parkin (PARK-2), PINK1(PARK6), DJ-
1(PARK7), ATP13A2 (PARK9) and SLC30A10 associated with early-onset PD as well as 
the genes LRRK2 (PARK8) and VPS35 (PARK-17) (Dawson et al., 2010; Roth, 2014) 
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linked with late onset of the disorder. While major emphasis has been given to the 
familial PD caused by gene mutations, the sporadic form of PD accounts for more than 
90% of PD occurrences whose onsets were likely caused by a complex interplay of 
genetic and environmental factors. A growing number of epidemiological and clinical 
studies have identified potential environmental risk factors for PD, including repeated 
head injury, heavy metal exposure, excess body eight, exposure to pesticides and some 
surrogate measures such as rural living, drinking well water and farming (Dick et al., 
2007; Priyadarshi et al., 2001). Interestingly, some of these environmental triggers and 
toxins induce pathophysiological features that mimic PD when they are administered in 
experimental animal settings. One such toxin is methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), a compound produced as an impurity during the illicit 
synthesis of the narcotic Desmethylprodine. MPTP causes chronic and severe 
Parkinsonism by selectively damaging the substantia nigra, resulting in all the motor 
features of PD (Appendino et al., 2014; Ballard et al., 1985; Langston et al., 1983). Other 
compounds widely used in experimental models to study the etiopathogenesis of PD 
include the narcotic methamphetamine, the dopamine derivative 6-hydroxydopamine, and 
pesticides such as rotenone, paraquat and dieldrin. These neurotoxins cause nigrostriatal 
cell death by interfering with mitochondrial function, inducing oxidative stress, inducing 
protein aggregation and modifying proteasomal function (Ghosh et al., 2013; Jin et al., 
2015b; Kanthasamy et al., 2008; Latchoumycandane et al., 2011). In addition, exposure 
to heavy metals such as iron, lead, mercury, cadmium, arsenic and manganese, as well as 
exposure to metal-based nanoparticles, has been shown to increase the risk of PD through 
the neurotoxic accumulation of metals in the SNpc and by increasing oxidative stress-
14 
 
mediated apoptosis (Aboud et al., 2014; Afeseh Ngwa et al., 2009; Afeseh Ngwa et al., 
2011; Harischandra et al., 2015; Kanthasamy et al., 2012; Milatovic et al., 2009).  
Manganese 
Manganese is considered a key inhaled pollutant in the environment and recently gained 
importance as a putative risk factor for environmentally-linked PD and related 
neurodegenerative disorders.  Being the 12
th
 most abundant element, composing 
approximately 0.1% of the earth’s crust, manganese is ubiquitously present in the 
environment (Martinez-Finley et al., 2012). Although the earth’s crust is the major source 
pool of manganese in the environment, other sources include direct atmospheric 
deposition, wash-off from plant and other surfaces, leaching from plant tissues, ocean 
spray, and volcanic activity.  Manganese occurs in trace amounts in all body tissues as it 
is an essential trace metal for many ubiquitous enzymatic reactions, including the 
synthesis of amino acids, lipids, proteins, and carbohydrates. It also plays a key 
nutritional role in bone formation, fat and carbohydrate metabolism, blood sugar 
regulation, and calcium absorption in the body (Bowman et al., 2011). Being present in 
whole grains, rice, nuts, tea, leafy green vegetables and manganese-containing nutritional 
supplements, the primary route of manganese exposure in humans is through dietary 
intake. The abundance of manganese-enriched food in the typical daily diet makes it 
relatively easy to accrue the daily reference intake (DRI) of 2.3 mg/day for men and 1.8 
mg/day for women (Aschner and Aschner, 2005), thereby minimizing the risk of 
manganese deficiency-related birth defects, impaired fertility, osteoporosis and enhanced 
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susceptibility to seizures (Aschner and Aschner, 2005; Dendle, 2001; Sarban et al., 
2007).  
Despite its nutritional benefits, prenatal and postnatal exposure to high levels of 
manganese affects infant neurodevelopment, exemplifying the role of manganese as both 
an essential nutrient and a toxicant (Claus Henn et al., 2010; Zota et al., 2009). High 
manganese exposure in early life is associated with poorer cognitive performance, 
especially in the verbal domain of children (Menezes-Filho et al., 2011). In older cohorts, 
chronic excessive exposure by occupational or environmental sources of manganese 
causes a neurodegenerative disorder known as Manganism, which is characterized by a 
severe neurological deficit that often resembles the involuntary extrapyramidal symptoms 
associated with PD.  In 1837, Dr. John Couper at the University of Glasgow reported the 
first case of manganese-induced neurotoxicity, which was discovered in employees of 
Charles Tennant and Co., a manufacturer of bleaching powder (Couper, 1837). Later, 
public awareness of manganese neurotoxicity arose as more clinical studies identified a 
PD-like syndrome in workers employed at a manganese ore crushing plant and a 
ferromanganese factory (Cook et al., 1974; Huang et al., 1989). Manganese also enters 
human-impacted environments through its use as an antiknock gasoline additive 
(methylcyclopentadienyl manganese tricarbonyl, MMT), in fertilizers, and in paint and 
cosmetics known as manganese violet (Martinez-Finley et al., 2012). Manganese 
neurotoxicity has often been found in agricultural workers exposed to organic 
manganese-containing pesticides, such as manganese ethylene-bis-dithiocarbamate 
(Maneb) and in chronic abusers of the street drug called ‘Bazooka’, a cocaine-based drug 
contaminated with manganese carbonate (Ensing, 1985). The other major anthropogenic 
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sources of environmental manganese include municipal wastewater discharges, welding, 
mining and mineral processing, emissions from alloy, steel and iron production, 
combustion of fossil fuel and dry-cell manufacturing. Although the precise mechanisms 
through which manganese is absorbed into the body are not fully understood, it has been 
shown that it accumulates in the brain’s basal ganglia region. Although manganism 
shares many commonalities with PD, it is also worth pointing out the differences. 
Behaviorally, manganism is mainly characterized by milder and less frequent resting 
tremor that tends to be postural or actional, a propensity to fall backward, excessive 
salivation and frequent dystonia consisting of facial grimacing, hand dystonia and/or 
plantar flexion of the foot (Calne et al., 1994). Patients were also reported to have 
symptoms of irritability, emotional lability, illusion, hallucinations and psychoses, 
referred to as “manganese madness” (Huang, 2007). Pathologically, manganese 
neurotoxicity affects primarily neurons in both the globus pallidus and striatum, whereas 
PD predominantly affects dopaminergic neurons in the SNpc (Roth, 2014). Therefore, in 
fact, the PD-like behavior deficits in manganism result from manganese’s capability to 
suppress dopamine release from the striatum, thus generating fundamental behavioral 
dysfunctions common to both PD and manganism (Fitsanakis et al., 2006; Kim et al., 
2002; Racette et al., 2005; Roth et al., 2013).   
 
Manganese in oxidative stress and neurodegeneration  
Although the mechanisms by which manganese induces nigrostriatal cell death are not 
well defined, its neurotoxicity appears to be regulated by a number of factors, including 
oxidative injury, mitochondrial dysfunction, protein misfolding and neuroinflammation. 
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Manganese is a redox-active metal with high reduction potential, giving it an important 
role in oxygen chemistry. As a cofactor forming manganese superoxide dismutase 
(MnSOD), it aids the removal of harmful byproducts of oxygen metabolism such as 
superoxide (O2
.-
) and hydrogen peroxide (H2O2). However, when allowed to accumulate, 
manganese exacerbates oxidative damage. At just 2% of body weight while consuming 
20% of the total oxygen and calories, the brain is highly metabolically active and hence 
highly susceptible to oxidative damage. As mentioned before, manganese is known to 
accumulate in the globus pallidus and striatum. These regions are especially vulnerable to 
oxidative injury because of their intense oxygen consumption, significant dopamine 
content and their high content of non-heme iron. A recent study evaluating the effect of 
Mn on DAT transfected and non-transfected HEK cells showed that Mn prevents 
dopamine reuptake in the transfected cells and also mobilize DAT receptors, from the cell 
surface to the intracellular compartments. Consequently, dopamine-induced cell toxicity 
is observed (Roth et al., 2013). Studies conducted with N27 mesencephalic dopaminergic 
neuronal cells have shown that manganese treatment increases reactive oxygen species 
(ROS) production (Harischandra et al., 2015). This ROS production resulted in the 
sequential activation of mitochondrial-dependent proapoptotic events, including 
cytochrome c release, caspase-3 activation and DNA fragmentation, but not caspase-8 
activation, indicating that the mitochondrial-dependent apoptotic cascade primarily 
triggers manganese-induced apoptosis as shown in Figure 1 (Latchoumycandane et al., 
2005). Moreover, protein kinase C delta (PKCδ), a redox-sensitive kinase involved in 
neurodegenerative disorders such as Alzheimer’s disease, prion disease and PD 
(Ciccocioppo et al., 2008; Harischandra et al., 2014; Jin et al., 2011; Kanthasamy et al., 
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2006), is reported to be a key mediator in manganese-induced apoptosis (Anantharam et 
al., 2002; Latchoumycandane et al., 2005). Later studies in differentiated N27 cells also 
demonstrated that chronic low-dose manganese exposure impairs tyrosine hydroxylase 
(TH), the rate-limiting enzyme in dopamine synthesis, through activation of PKCδ and 
protein phosphatase-2A (PP2A) activity (Zhang et al., 2011). Notably, in vitro and in vivo 
studies conducted with the hydrophilic antioxidant vitamin E analog, Trolox (6-hydroxy-
2,5,7,8-tetramethylchroman-2-carboxylic acid) reversed manganese-induced 
neurotoxicity and rescued dysfunctional dopaminergic transmission and manganese-
induced motor coordination deficits (Cordova et al., 2013; Milatovic et al., 2011), further 
emphasizing the relationship between oxidative stress and manganese-related 
neurodegeneration. 
Dopamine belongs to the catecholamine and phenethylamine families and serves as a 
neurotransmitter under physiological conditions. However, the chemical structure of 
catecholamines predisposes them to oxidation, and their well-characterized metabolic 
routes can yield quinones and free radicals providing evidence that dopamine may also 
serve as a neurotoxin contributing to the neurodegenerative process through oxidative 
metabolism. By promoting dopamine auto-oxidation, manganese as a transition metal 
potentiates dopamine toxicity in high manganese-accumulating areas of the brain (globus 
pallidus and striatum). Under normal physiological conditions, dopamine is oxidized 
enzymatically through monoamine oxidases (MAO) to dihydroxyphenylacetic acid 
(DOPAC) and subsequently methylated by catechol-O-methyltransferase (COMT) to 
homovanillic acid (HVA) or else dopamine is converted to 3-methoxytyramine (3-MT) 
via COMT and then further oxidized to HVA through MOA. During this MAO-mediated 
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dopamine turnover process, hydrogen peroxide (H2O2) is a byproduct of the deamination 
of dopamine, generating inherent oxidative stress conditions in nigrostriatal system. 
Dopamine can also be non-enzymatically oxidized by molecular oxygen, yielding 
quinones and H2O2. These quinones also undergo intramolecular cyclization, which is 
immediately followed by a cascade of oxidative reactions culminating in a black, 
insoluble polymeric pigment known as neuromelanin (Graham, 1978; Hermida-
Ameijeiras et al., 2004).  Neuromelanin in dopaminergic neurons augments the 
vulnerability to auto-oxidation through quinone modification of dopamine leading to high 
basal levels of oxidative stress in the SN (Graham, 1978). Therefore, the degradation of 
dopamine, either enzymatically or non-enzymatically, produces H2O2. Two prominent 
manganese valence states, Mn
2+
 and Mn
3+
, are found in biological systems. In the 
presence of high levels of divalent manganese (Mn
2+
), H2O2 can convert via the Fenton 
reaction to highly toxic hydroxyl radicals (•OH). But because of its higher oxidative state, 
Mn
3+ 
was an order of magnitude more cytotoxic than Mn
2+ 
in studies conducted in rats 
dosed with manganese (Ali et al., 1995). In fact, oxidation of dopamine by Mn
3+
, 
generating
 
quinones and H2O2, has been shown to be independent of oxygen and far more 
rapid than that mediated by Mn
2+ 
(Archibald and Tyree, 1987). Since Mn
2+
 can readily 
oxidize to Mn
3+
 in the human brain via superoxides, the autoxidation of catecholamines 
can only further potentiate oxidative stress.   
Impairment of the cellular antioxidant machinery, causing an imbalance between ROS 
generation and its elimination, plays a major role in the development of certain 
neurodegenerative processes. The antioxidant glutathione (GSH), present in both neurons 
and astrocytes, provides the first line of cellular defense against ROS. GSH actively 
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disposes off exogenous peroxides by acting as a co-substrate in reactions catalyzed by 
glutathione peroxidase (GPx), thus playing important functional roles in the central 
nervous system (CNS). Altered striatal concentrations of GSH, glutathione disulfide 
(GSSG), ascorbic acid (AA), malondialdehyde (MDA), and the activities 
of glutathione reductase (GR) and GPx have been previously reported with manganese 
neurotoxicity, suggesting that impairment in the neuronal antioxidant system renders the 
brain susceptible to manganese-induced neurotoxicity (Chen and Liao, 2002; Dukhande 
et al., 2006; Maddirala et al., 2015). Moreover, inhibition of GSH synthesis potentiated 
the manganese-induced increase in inosine, hypoxanthine, xanthine and uric acid levels 
in the striatum and brainstem of aged rats (Desole et al., 2000), indicating that 
manganese-induced cytotoxicity was mediated through mitochondrial dysfunction. 
Therefore, the specific vulnerability of dopamine neurons to manganese plays a pivotal 
role in the impairment of cellular antioxidant defenses, wherein disruption of the 
mitochondrial oxidative energy metabolism cascade leads to dopaminergic cell death. 
Excessive production of ROS induces the oxidation of membrane polyunsaturated fatty 
acids (PUFA), yielding a multitude of lipid peroxidation products including reactive 
aldehydes such as 4-hydroxy-trans-2-nonenal (4-HNE), 4-oxo-trans-2-nonenal (4-ONE), 
malondialdehyde (MDA) acrolein, F2-isoprostanes (F2-IsoPs), and isofurans (Aluru et al., 
2015; Esterbauer et al., 1991). These markers are derived from free radical-mediated 
peroxidation of arachidonic acid (ARA), which is released from neural membrane 
glycerophospholipids through the activation of cytosolic phospholipases A2 (cPLA2), 
which are enzymes coupled to NMDA receptors through a G-protein independent 
mechanism (Farooqui and Horrocks, 2007; Farooqui and Farooqui, 2011). Since most 
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biological membranes of cells and organelles are composed of PUFA, lipid peroxidation 
is considered as the main molecular mechanisms involved in the oxidative damage to cell 
structures and in the toxicity process that leads to cell death. Consistent with these 
observations, primary rat cortical neurons exposed to a very high manganese dose (500 
µM) for 6 hours showed structural damage to neurons and a significant increase in F2-
IsoPs levels (roughly 50%) compared to controls (Milatovic and Aschner, 2009). 
Likewise, in primary astrocyte cultures exposed to the same experimental conditions, F2-
IsoPs levels increased 51% compared to control cultures (Milatovic et al., 2007). 
However, the direct role of manganese in CNS toxicity associated with lipid peroxidation 
remains debatable as some investigators argue that in vivo administration of manganese 
alters cellular Ferrous (Fe
2+
), which plays a permissive role in increasing lipid 
peroxidation and augmenting neuronal vulnerability (Chen et al., 2006; Chen et al., 2000; 
Shukla and Chandra, 1981). 
Moreover, dopamine quinones have been shown to bind and modify several proteins 
implicated in PD pathophysiology such as α-synuclein, DJ-1 and parkin (Conway et al., 
2001; Girotto et al., 2012; LaVoie et al., 2005). However, among the multitude of cellular 
macromolecules prone to oxidative damage, damaged nucleic acids are particularly 
hazardous due to compromised genetic information. Among the five nucleobases, namely 
uracil, thymine, cytosine, adenine and guanine, guanine is the most susceptible to 
oxidation by hydroxyl radicals (Cerchiaro et al., 2009; Cooke et al., 2003). Hydroxyl 
radical-mediated insults to DNA strands produce 8-hydroxyguanosine (8-OHG), 
presently the most studied oxidized DNA product. Interestingly, DNA damage in PD also 
involves 8-OHG as well as 8-hydroxyl-2-deoxyguanosine (8-OHdG) as elevated 8-OHG 
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and reduced 8-OHdG have been observed in the SN and cerebrospinal fluid (CSF) of PD 
patients (Isobe et al., 2010; Zhang et al., 1999). In contrast, in vitro studies of manganese 
toxicity reported increased 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) content in 
the DNA of PC12 cells treated with dopamine (Oikawa et al., 2006). Stephenson and 
colleagues have also shown that manganese catalyzes the auto-oxidation of 
catecholamines in SH-SY5Y cells with the ensuing oxidative damage to thymine and 
guanine DNA bases, further indicating the effect of manganese-induced semi-quinone 
radical ions and ROS production on DNA damage (Stephenson et al., 2013). 
Manganese and neuroinflammation  
Although much emphasis has been placed on oxidative stress in the manganese-induced 
dysfunction of dopaminergic neurons, the activation of glial cells also plays an important 
role in potentiating manganese neurotoxicity by inducing the release of non-neuronal-
derived ROS and inflammatory mediators such as proinflammatory cytokines. The state 
of glial activation is defined by its morphology and by the proliferation, migration and 
expression of immune modulatory molecules. The two major types of glial cells in the 
CNS are astrocytes and microglia with the latter constituting about 10% of all glial cells 
in CNS.  
It is now well documented that glial activation is prominent in the brains of humans 
exposed to manganese, as well as in non-human primate and rodent models of manganese 
neurotoxicity (Cordova et al., 2013; Erikson and Aschner, 2006; Huang, 2007; Perl and 
Olanow, 2007). Neuroinflammation is regarded as a key mediator in mechanisms leading 
to the loss of dopaminergic neurons in PD. The activation of microglia plays a major role 
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in the response to environmental stresses and immunological challenges by scavenging 
excess neurotoxins, removing dying cells and cellular debris, and releasing 
proinflammatory cytokines (Carson et al., 2007; Tansey et al., 2008). Inducible nitric 
oxide synthase (iNOS), which produces large amounts of nitric oxide (NO), is released 
by microglia in response to inflammatory mediators such as LPS and cytokines. The 
levels of NO are reported to be higher in the CNS of human PD cases and in animal 
models of PD (Mogi et al., 1994). Consistent with this finding, iNOS knockout animals 
were resistant to MPTP-induced dopaminergic neuronal loss in the substantia nigra 
(Przedborski and Vila, 2003). Recent reports suggest that NF-κB, a transcription factor 
required for transcribing proinflammatory molecules, is also activated in the substantia 
nigra of PD patients and MPTP-treated mice (Ghosh et al., 2007). In contrast to 
microglia, astrocytes do not attack any pathological targets, but instead produce factors 
that are important in inflammatory reactions seen in the SN of PD brains (Miklossy et al., 
2006). Activated astroglial cells were recently found in human PD brains and in the 
MPTP mouse model of PD (Ghosh et al., 2007; Ghosh et al., 2009). 
 
In terms of manganese toxicity, astrocytes play a major role in neuroinflammation as they 
represent a “sink” for brain manganese (Wedler and Denman, 1984), with concentrations 
10–50 fold greater in these cells than neurons, making them more susceptible to 
manganese toxicity than other cell types. Since astrocytes have transferrin receptors, 
which readily bind to Tf-Mn
3+
, it is not surprising to find higher levels of manganese in 
astrocytes than in any other neural cell type (Aschner et al., 1999; Erikson and Aschner, 
2006). It is thought that excess glutamate, which leads to glutamate-induced 
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excitotoxicity, abruptly increases intracellular Ca
2+
 levels. This increase in Ca
2+
 blocks 
Mn
2+
 uptake, prompting a release of mitochondrial Mn
2+
 into the cytosol. Finally, high 
levels of cytosolic Mn
2+
 in astrocytes activates glutamine synthetase, which removes 
excess glutamate (Wedler et al., 1994).  However, excessive extracellular Mn
2+
 can 
disrupt intracellular Ca
2+
 signaling in astrocytes by competitively occupying Ca
2+
 binding 
sites, thus interfering with mitochondrial Ca
2+
 homeostasis (Farina et al., 2013). Loss of 
Ca
2+
 homeostasis leads to astrogliosis. In addition, Mn
3+
 causes astrocyte swelling via 
oxidative/nitrosative pathways (Rama Rao et al., 2007). Increased manganese levels in 
astrocytes elevate the expression of proinflammatory signals such as iNOS and IL-6 
(Moreno et al., 2008). In vitro studies have shown that manganese-treated astrocytes use 
larger amounts of L-arginine, which is a substrate for nitric oxide (NO) (Hazell and 
Norenberg, 1998). While timely expression of these signals is necessary in response to 
neuronal stress or cellular damage, excessive production is counter-productive, often 
exacerbating the toxic insult. Microarray gene expression profiling of primary human 
astrocytes exposed to manganese showed an upregulation of genes encoding 
proinflammatory cytokines with a concurrent downregulation of genes involved in cell 
cycle regulation and DNA replication and repair (Sengupta et al., 2007).  
The Glutamate-GABA cycle (GGC) is important especially in the context of astrocyte-
neuron metabolism. The amino acid glutamine is a precursor for the production of 
Glutamate and GABA (Bak et al., 2006). Deamidation of neuronal glutamine to 
glutamate produces ammonia, which is then transferred to astrocytes and utilized in the 
amidation of glutamate. Glutamine released by astrocytes is taken up by Glutamatergic 
and GABAergic neurons that incidentally show projections in the basal ganglia among 
25 
 
other brain regions and are involved in the regulation of voluntary movements (Sidoryk-
Wegrzynowicz and Aschner, 2013). However, in response to elevated levels of 
manganese in the brain, there is a rapid entry of manganese into the astrocytic 
mitochondria. As mentioned in the previous section, high levels of mitochondrial 
manganese impair cellular respiration and prevent the production and activation of 
glutathione peroxidase. Taken together, astrocytes appear to be particularly affected by a 
disruption of manganese homeostasis in the brain. This in turn could have a negative 
impact on the GABAergic and Glutamatergic projections in the basal ganglia leading to 
the motor deficits characterizing manganese neurotoxicity. 
 
Manganese and α-synuclein protein misfolding 
Belonging to a family that includes β- and γ-synuclein, α-synuclein (α-Syn) is a small, 
14.5-kDa acidic protein comprising 140 amino acids. Encoded by a single gene 
consisting of seven exons located on Chromosome 4, it is highly conserved in 
vertebrates. α-Syn is predominantly expressed presynaptically in neurons throughout the 
mammalian brain and CSF and is estimated to account for as much as 1% of total protein 
in soluble cytosolic brain fractions. The physiological functions of α-Syn are poorly 
understood, but evidence suggests a role for it in synaptic plasticity, dopamine regulation, 
and membrane trafficking. The link between α-Syn and PD pathogenesis is based on case 
studies of familial PD as well as the observation that misfolded α-Syn is a major 
constituent of Lewy bodies and Lewy neurites in both familial and sporadic PD  (Roth et 
al., 2013). Also, compelling evidence demonstrates that mutations in the gene encoding 
α-Syn are directly linked to the onset of PD (Liu et al., 2012).  Furthermore, rare familial 
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forms of PD also have been linked to the overexpression of α-Syn due to duplication or 
triplication of the SNCA gene. 
 
The aggregation and fibrillation of α-Syn, forming intracellular proteinaceous aggregates, 
have been implicated in several other neurodegenerative disorders besides PD, including 
LBD, Lewy body variant of AD, MSA and Hallervorden-Spartz disease. The study of 
synucleinopathies and the idea that α-Syn aggregates can pathologically propagate 
throughout the CNS recently gained much attention with the finding of α-Syn species in 
human plasma and CSF (El-Agnaf et al., 2003; Kordower et al., 2008) and the host-to-
graft propagation of α-Syn-positive Lewy bodies in fetal ventral mesencephalic and 
embryonic nigral neurons transplanted in human PD patients (Kordower et al., 2008; Li 
et al., 2008).  Even though several models have postulated the pathological cell-to-cell 
transmission of propagating α-Syn species (Desplats et al., 2009; Dunning et al., 2013; 
Lee et al., 2008), its exact mechanistic role in PD pathogenesis and related 
synucleinopathies largely remains unknown. Available in vitro evidence thus far 
indicates that extracellular α-Syn induces pathogenic actions by activating 
neuroinflammatory and neurodegenerative responses (Emmanouilidou et al., 2010; Su et 
al., 2008). 
The natively unfolded α-Syn protein lacks a defined secondary structure, and therefore, 
belongs to the intrinsically unstructured protein family. However, upon interaction with 
lipid membranes, it adopts an α-helical conformational change, and under conditions that 
trigger aggregation, α-Syn undertakes the characteristic crossed β-conformation and self-
aggregates into soluble oligomers, which gradually form insoluble amyloid-like fibrils. 
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As shown in Figure 2, the α-Syn protein has three distinct structural domains. The 
amphipathic N-terminal region (residues 1-60) contains 11 amino acid repeats including 
the consensus sequence KTKEGV, which is important in α-helix formation. The central 
hydrophobic region (residues 61-91) contains the hydrophobic and three additional 
KTKEGV repeats and the highly amyloidogenic nonamyloid component (NAC) region, 
which is important in protein aggregation. Specifically, within this region a hydrophobic 
GAV motif (residues 66-74) mainly consisting of glycine, alanine and valine residues has 
been identified as the critical core for the fibrillization and cytotoxicity of α-Syn (Du et 
al., 2006). Finally, the highly acidic C-terminal region (residues 91-140) is proline-rich 
and is responsible for the intrinsically disordered nature of α-Syn (Harischandra et al., 
2015). The N-terminal and NAC regions form a membrane-binding domain, whereas the 
C-terminal tail is thought to contain protein–protein and protein–small molecule 
interaction sites.  
 
Importantly, α-Syn protein has three metal binding sites providing its metalloprotein 
properties: one at the N-terminus, one in the central region and one at the C-terminus. A 
systematic analysis of mono-, di- and trivalent metal ligands (Li
+
,  K
+
, Na
+
, Cs
+
, Ca
2+
, 
Co
2+
, Cd
2+
, Cu
2+
, Fe
2+
, Mg
2+
, Mn
2+
, Zn
2+
, Co
3+
, Al
3+
 and Fe
3+
) revealed that 
conformational changes occur upon metal binding that cause normally benign α-Syn 
protein to aggregate (Uversky et al., 2001). Out of the 15 metal cations studied, Uversky 
et al determined  Al
3+
 to be the most effective stimulator of protein fibril formation 
followed by Cu
2+
, Fe
2+
, Co
3+
 and Mn
2+
, with each causing conformational changes 
detectable by intrinsic protein fluorescence and far UV-circular dichroism (Uversky et 
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al., 2001). Furthermore, Uversky et al also showed that Mn
3+
 induced immediate di-
tyrosine formation, suggesting that manganese is responsible for the metal-induced 
oxidation of α-Syn protein. Among the three metal binding sites, binding sites located at 
the N-terminal domain, specifically the 
1
MDVFMKGLS
9
 and 
48
VAHGV
52 
regions, 
demonstrated high-affinity binding for Cu
2+
 (Kd ∼ 0.1 μM) (Rasia et al., 2005) whereas 
metal binding sites near 49–52 and 110–140 are known to interact with divalent metals 
including manganese (Binolfi et al., 2008; Binolfi et al., 2006; Uversky et al., 2001). In a 
detailed study, the metal ions Mn
2+
, Fe
2+
, Co
2+
 and Ni
2+ 
bound preferentially to the 
119
DPDNEA
124
 motif, in which Asp121 acted as the main anchoring site with low affinity 
(mM) to metal ligands (Binolfi et al., 2006). These findings regarding the structural basis 
of metal interaction with α-Syn provide a tighter link with PD and suggest that 
perturbations in metal homeostasis may constitute a more widespread element in 
neurodegenerative disorders than previously recognized (Binolfi et al., 2006). 
 
How manganese affects the expression of α-synuclein and induces cytotoxicity has been 
studied in in vitro, in vivo and ex-vivo models of PD (Gitler et al., 2009; Verina et al., 
2013; Xu et al., 2013). Figure 3 provides a pictorial representation of the impact that 
acute and prolonged exposure to Mn have on α-synuclein. Our previous studies have 
shown that physiological levels of human wild-type α-Syn protein attenuate manganese-
induced dopaminergic neuronal degeneration in cell culture models during early stages of 
manganese toxicity. However, prolonged manganese exposure promotes α-Syn 
aggregation and dampens its neuroprotective effect (Harischandra et al., 2015). 
Furthermore, using a genetically modified Caenorhabditis elegans model system, 
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Borhorst and colleagues have shown enhanced manganese accumulation and oxidative 
stress in the pdr1 and djr1.1 mutants, which were reduced by α-Syn expression 
(Bornhorst et al., 2014). Taken together, these studies uncover a novel, neuroprotective 
role for human wild-type α-Syn in attenuating acute manganese toxicity. This observed 
neuroprotective role of α-Syn may be a direct effect of its metal binding capability. In 
biological environments, free roaming manganese cations could induce oxidative stress, 
free radical formation and downstream mitochondria-dependent apoptotic signaling.  
 
Manganese preferentially accumulates in the mitochondria via the mitochondrial Ca
2+
 
uniporter. In the mitochondria, it is mainly bound to the membrane or matrix proteins 
(Gavin et al., 1999). Succinate, malate as well as glutamate are important substrates for 
mitochondrial respiration. At high concentrations, manganese (Mn
2+
) binds to these 
substrates effectively inhibiting mitochondrial respiration (Gavin et al., 1999). 
Interference in oxidative phosphorylation triggers the downstream release of 
inflammatory signals leading ultimately to apoptosis. Recent evidence sheds light on 
manganese-induced endoplasmic reticular (ER) stress and ER-mediated cellular 
apoptosis. Rats given three different doses of manganese for four weeks showed a dose-
dependent increase in apoptotic cells in the striatum, as evidenced by chromatin 
condensation, as well as up-regulation of markers of mitochondrial and ER stress-
mediated apoptosis (Wang et al., 2015). Furthermore, manganese induces the 
transcriptional and translational up-regulation of α-Syn (Li et al., 2010), promoting 
susceptibility to manganese-induced neurotoxicity through  ERK1/2 MAPK activation, 
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NF-κB nuclear translocation and activation of apoptotic signaling cascades leading to 
dopaminergic cell death (Cai et al., 2010; Prabhakaran et al., 2011).  
 
Manganese affects not only cellular viability but also affects various factors involved in 
neurotransmitter regulation. Acetylcholine esterase (AChE) is an enzyme that hydrolyses 
acetylcholine (ACh) thus regulating its availability in the synaptic cleft (Pohanka, 2012; 
Whittaker, 1990). Chronic exposure to high levels of manganese inhibited the activity of 
AChE, thereby allowing ACh to accumulate in the synaptic cleft and subsequently 
overstimulating muscarinic and nicotinic ACh receptors. While the precise mechanism 
has not been determined, inhibiting AChE increases levels of ROS and RNS (Milatovic et 
al., 2006; Santos et al., 2012), which further lead to lipid peroxidation as well as 
production of citrulline, a marker of RNS activity. It has been reported that manganese 
overexposure in rats on a low protein diet reduces the level of GABA in the brain while 
increasing the animals’ susceptibility to seizures (Ali et al., 1983). However, the changes 
in brain GABA levels depended on the treatment regime and age of animals used. For 
instance, low-dose manganese given thrice weekly for five weeks increased GABA levels 
(Takagi et al., 1990). Additional mechanistic studies need to be conducted to understand 
the role played by manganese in GABA dysregulation. In the case of glutamate, high 
levels of manganese in the brain may lead to constitutive NMDA activation leading to 
excitotoxic-related neuronal death. Once released into the synaptic cleft, most of the 
glutamate is removed by astrocytes via the glutamate:aspartate transporter (GLAST). 
However, high levels of extracellular Mn
2+
 decrease the expression of GLAST and 
induce astrocyte apoptosis (Erikson et al., 2002). Chronic exposure to manganese can 
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also increase the amplitude of excitatory postsynaptic potentials (EPSPs) in striatal 
neurons. With respect to the neurotransmitter dopamine, Ingersoll et al. (1999) 
demonstrated manganese transport to dopaminergic neurons via the Dopamine 
transporter (DAT) (Ingersoll et al., 1999). Another study done on DAT -\- mice 
administered high doses of manganese reported a lower amount of manganese in the 
striatum compared to wild type mice given the same dose. Interestingly, only the 
normally DAT-rich region of the striatum showed this contrasting pattern, which was not 
seen in areas that do not express DAT (Erikson et al., 2005).  Young non-human primates 
exposed to a low dose of Mn twice weekly for about nine weeks showed retracted 
microglial processes even while initially dopaminergic neurons remained unchanged 
(Verina et al., 2011). Perhaps a prolonged study would give us more information on the 
effect of this microglial disturbance on nigrostriatal neurons.  
To conclude, manganese influx and efflux are tightly controlled in the body by various 
receptors and ion channels. However overexposure of manganese can lead to the toxic 
accumulation of manganese in the brain especially in the basal ganglia. High levels of 
manganese in the brain cause hyperactivity of cortico-striatal neurons. While 
contradictory evidence arises from different dose regimens, in general Mn also affects the 
regulation of neurotransmitters such as dopamine, glutamate and GABA. Manganese 
inhibits the activity of various enzymes involved in regulating optimum neurotransmitter 
levels. High levels of glutamate and/or acetylcholine in the synaptic cleft overstimulate 
NMDA receptors leading to excitotoxic neuronal death. Mn may get transported into 
dopaminergic neurons via DAT. Excess cellular Mn
2+
 disrupts Ca
2+
 homeostasis in cells, 
leading to decreased dopamine production and neuronal death. Manganese also causes 
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ER and mitochondrial stress leading to neuronal apoptosis and/or gliosis. Thus there is 
mounting evidence of the deleterious effects of Mn on neurons and glia. Various studies 
have been conducted on the use of metal chelators and antioxidants as therapeutic 
interventions against manganism.  
Manganese homeostasis  
The homeostasis of manganese and other metal ions is maintained through tightly 
regulated mechanisms of uptake, storage and secretion that strictly limit their abundance 
in the cellular compartment. The distribution and neurotoxicity of manganese is governed 
largely by the routes of exposure, which are primarily ingestion and inhalation. In 
humans, the primary route of exposure is through manganese-enriched food and well 
water. However, the molecular mechanisms of oral manganese absorption are not well 
understood. Roughly 3-5% of the manganese ingested gets absorbed into the body from 
the gastrointestinal tract (Finley et al., 1994). Under normal physiological conditions, 
manganese enters the portal circulation through either passive diffusion (Bell et al., 1989) 
or active transport via Divalent metal transporter 1 (DMT1) (Erikson and Aschner, 2006; 
Fitsanakis et al., 2007). DMT1 (formerly known as Nramp2 and DCT1) is the first 
mammalian transmembrane iron transporter to be identified. It is a 12-transmembrane 
domain protein responsible for the uptake of various divalent metals including Fe
2+
, 
Mn
2+
, Zn
2+
, Co
2+
 and Ni
2+
, and it transfers ions across the apical surface of intestinal cells 
and out via transferrin (Tf)-cycle endosomes (Andrews, 1999). Besides using a 
mechanism similar to that for iron, there are no known metal transporters specific for 
transporting manganese into cells. In plasma, approximately 80% of manganese in the 2+ 
oxidation state (Mn
2+
) is bound to α-macroglobulin or albumin, while only a small 
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fraction (<1%) of Mn
3+
 is bound to Tf. It has been proposed that, like iron, manganese in 
plasma is oxidized from the Mn
2+
 to the Mn
3+ 
valence state by the ferroxidase enzyme 
ceruloplasmin and loaded onto plasma Tf for circulating into tissues (Davidsson et al., 
1989). Circulating manganese diffuses throughout the body including bone, kidney, 
pancreas, liver and brain (Martinez-Finley et al., 2012).  
 
Once in the brain, manganese (Mn
3+
) entry into neurons occurs by Tf-Mn
3+
 complex 
binding to the transferring receptor (TfR) and it becomes localized in endosomes. 
Subsequent recruitment of v-ATPases acidifies endosomes and dissociates Mn
3+ 
from the 
Tf/TfR complex, reducing it to Mn
2+
, which is quite stable at physiological pH, and 
thereafter neuronal transport occurs via DMT1 independent of the Tf pathway. In the 
brain, DMT1 is highly expressed in the DA-rich basal ganglia, putamen, cortex and 
substantia nigra (Huang et al., 2004; Salazar et al., 2008), which may account for 
manganese’s pattern of accumulation and neurotoxicity. Other primary transport 
mechanisms for manganese are through capillary endothelial cells of the blood-brain-
barrier (BBB) (Crossgrove et al., 2003) or through the CSF via the choroid plexus 
(Murphy et al., 1991). Since manganese neurotoxicity primarily occurs through 
occupational exposure, such as inhalation of manganese fumes or dust in welding, dry-
cell battery manufacturing and the smelting industry, the nasal space through the 
olfactory epithelium to the olfactory nerve is another major manganese transport 
mechanism in to the brain (Tjalve et al., 1996). In fact, DMT1 is highly expressed in the 
olfactory epithelium and is required for manganese transport across the olfactory 
epithelium as has been shown in the rat (Thompson et al., 2007). Evidence also exists for 
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transport of manganese into the CNS through store-operated calcium channels 
(Crossgrove and Yokel, 2005), ionotrophic glutamate receptor calcium channels 
(Kannurpatti et al., 2000) and manganese citrate transporters (Crossgrove et al., 2003).   
 
Another mechanism regulating manganese homeostasis in the brain involves manganese 
being transferred with high affinity into cells by the Zinc transporters ZIP-8 and ZIP-14, 
Zrt-/Irt-related protein (ZIP) family metal transporters encoded by SLC39A8 and 
SLC39A14, respectively. These transporters are highly expressed in the liver, duodenum, 
kidney, testis, and are localized on apical surfaces of brain capillaries (Girijashanker et 
al., 2008; Wang et al., 2012). Taking advantage of its particular magnetic properties, 
Aoki and colleagues showed that manganese uptake also occurs through the choroid 
plexus as visualized by magnetic resonance imaging (MRI) (Aoki et al., 2004).  One day 
after they systemically administered Mn
2 +
 to rats, the distribution of manganese in the 
brain extended to the olfactory bulb, cortex, basal forebrain, and basal ganglia, 
overlapping specific brain structures vulnerable to manganese-induced neurotoxicity 
(Aoki et al., 2004). In cells, toxic accumulations of manganese are found primarily in the 
mitochondria, heterochromatin and nucleoli in both neurons and astrocytes (Lai et al., 
1999; Morello et al., 2008). 
 
Manganese also shares the Ca
2+
 uniporter mechanism and the rapid mode (RaM) of Ca
2+ 
uptake of mitochondrial calcium influx, resulting in manganese sequestration in 
mitochondria, which is cleared only very slowly from the brain (Gavin et al., 1990). This 
manganese accumulation inhibits the efflux of calcium, decreases MAO activity and 
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inhibits the respiratory chain and ATP production (Zhang et al., 2003), which may partly 
explain the role of mitochondrial dysfunction in manganese neurotoxicity. Previously, 
manganese detoxification and efflux from cells was thought to be primarily regulated by 
ferroportin (Fpn), also known as HFE4, MTP1, IREG1, encoded by the SLC40A1 gene. 
Although Fpn was initially identified as the iron exporter, recent data suggest that Fpn 
also interacts with manganese, zinc and cobalt to export them from the cell (Madejczyk 
and Ballatori, 2012; Troadec et al., 2010; Yin et al., 2010). Furthermore, manganese 
exposure increases Fpn mRNA levels in mouse bone marrow macrophages (Troadec et 
al., 2010) and it significantly increases Fpn protein levels in HEK293T cells (Yin et al., 
2010). Increasing Fpn levels were linked to reduced manganese accumulation in both the 
cerebellum and cortex of mice treated with manganese (Yin et al., 2010), further 
confirming that Fpn removes manganese and reduces manganese-induced neurotoxicity. 
 
Recently, the secretory pathway of the Ca
2 +
/Mn
2 +
 ATPases SPCA1 and SPCA2, which 
are localized at the Golgi, was suggested as an alternative way of cytosolic manganese 
detoxification by sequestering into the Golgi lumen (Sepulveda et al., 2009). 
Overexpressing SPCA1 in HEK293T cells conferred tolerance of manganese (Mn
2 +
) 
toxicity by facilitating Mn
2 + 
accumulation in the Golgi, thereby increasing cell viability 
(Leitch et al., 2011). However, the degree to which SPCA1 and SPCA2 regulates 
manganese homeostasis has yet to be determined. Another mode for manganese egress 
through Golgi has been attributed to SLC30A10 in humans (Tuschl et al., 2012). 
Recently, SLC30A10 was shown to be localized on the cell surface where it acted as a 
manganese efflux transporter to reduce cellular manganese levels and protect against 
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manganese-induced toxicity (Leyva-Illades et al., 2014). Mutations in the SLC30A10 
gene have been associated with hepatic cirrhosis, dystonia, polycythemia, Parkinsonian-
like gate disturbances and hypermanganesemia in cases unrelated to environmental 
manganese exposure (Tuschl et al., 2012). Importantly, these recent discoveries involving 
SLC30A10 and its mutations reinforce its crucial role as a manganese transporter in 
humans, shedding further light on our understanding of familial Parkinsonism as a result 
of mutations in SLC30A10. 
 
The p-type transmembrane ATPase protein ATP13A2 (also known as PARK9) located at 
the lysosome also protects cells from manganese-induced toxicity (Tan et al., 2011). 
Although the physiological function of ATP13A2 in mammalian cells remains elusive, 
loss-of-function mutations in ATP13A2 cause an autosomal recessive form of early-onset 
Parkinsonism with pyramidal degeneration and dementia called Kufor-Rakeb Syndrome 
(KRS) (Ramirez et al., 2006). Overexpression of wild-type ATP13A2, but not the KRS 
pathogenic ATP13A2 mutants, protected mammalian cell lines and primary rat neuronal 
cultures from Mn
2 +
-induced cell death by reducing intracellular manganese 
concentrations and cytochrome c release, suggesting a role of ATP13A2 in manganese 
detoxification and homeostasis (Tan et al., 2011). A summary of the above-mentioned 
receptors and channels that play a part in cellular Mn homeostasis is shown in Figure 4. 
 
Manganese in other diseases 
Until the last decade, manganese neurotoxicity was mainly associated with Parkinsonism 
and very little attention had been given to its potential role in other neurodegenerative 
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diseases. However, with growing interest in the neurobiology of heavy metals, 
manganese has now been linked to other major neurodegenerative diseases such as 
Huntington’s disease (HD) and Prion disease (Choi et al., 2010; Kumar et al., 2015; 
Martin et al., 2011). Furthermore, gene expression studies in the frontal cortex 
of cynomolgus macaques exposed to various manganese doses indicated that Amyloid-β 
(Aβ) precursor-like protein 1 (APLP1), a member of the amyloid precursor family, was 
highly up-regulated, providing an association between manganese exposure and AD 
(Guilarte et al., 2008). Along with this gene array analysis, immunochemistry revealed 
the presence of Amyloid-β plaques and α-Syn aggregates, which have been linked to PD 
as well as AD, and which have also been seen in the gray and white matter of manganese-
exposed animals (Guilarte, 2010).   
 
In contrast to manganese-induced Parkinsonism, a deficiency in manganese transport has 
been implicated in the pathogenesis of HD, an autosomal dominant neurodegenerative 
disorder characterized by the loss of medium spiny neurons in the striatum (Kumar et al., 
2015). Recent experiments carried out with immortalized mutant HD cell lines 
(SThdh
Q7/Q7
 and SThdh
Q111/Q111
) showed reduced TfR levels and substantial deficits in net 
manganese uptake, even under basal conditions (Williams et al., 2010). In follow-up 
studies, YAC128 HD transgenic mice accumulated less manganese in their basal ganglia, 
including the striatum, which is a common target for both HD neuropathology and 
manganese accumulation (Madison et al., 2012). Furthermore, transition metal analysis of 
HD patients has shown significantly increased iron together with significantly decreased 
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cortical copper and manganese (Rosas et al., 2012), further supporting the role of 
manganese in HD.     
Prion protein is also widely known for its association with transmissible spongiform 
encephalopathies (TSE), a class of neurodegenerative diseases caused by the 
accumulation of an abnormal isoform of the prion protein known as PrP
Sc
 (Jin et al., 
2015a). The cellular prion protein PrP
C
 has a high binding affinity to divalent metals and 
plays an important role in the biological function and pathogenesis of prion diseases. 
Interestingly, increased manganese content has been observed in the blood and brains of 
humans infected with Creutzfeldt–Jakob disease (CJD), in mice infected with scrapie, 
and in cattle infected with bovine spongiform encephalopathy (BSE) (Hesketh et al., 
2008; Hesketh et al., 2007; Wong et al., 2001). The binding of manganese to prion 
protein mitigates against Mn’s neurotoxicity during the early acute phase of manganese 
exposure (Choi et al., 2007). In contrast, prolonged manganese exposure alters the 
stability of prion proteins without any change in gene transcription (Choi et al., 2010), 
suggesting manganese may play a role in prion protein misfolding and prion disease 
pathogenesis. Interestingly, exposure to manganese in a soil matrix significantly increases 
prion protein survival (Davies and Brown, 2009). Thus, manganese is an environmental 
risk factor for both the survival of the PrP
Sc
 and its transmissibility. The role of 
manganese in TSE was further validated with the findings that it enhances the ability of 
the pathogenic PrP
Sc
 isoform to regulate manganese homeostasis (Martin et al., 2011) and 
that it increases the infectivity of scrapie-infected cells (Davies and Brown, 2009). 
Therefore, understanding the interaction of metals with disease-specific proteins may 
provide further insight to the pathogenesis of neurodegenerative diseases. 
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Conclusion 
Chronic exposure to large amounts of manganese has been shown to induce various 
neurological and psychiatric symptoms. While the body especially the gut and liver can 
efficiently remove excess manganese, the brain cannot. Inhalation of large doses of 
manganese can lead to its accumulation in the basal ganglia in the brain. Astrocytes are 
particularly sensitive to manganese toxicity and may compound neuroinflammation by 
releasing pro-inflammatory cytokines in response to excess manganese. Manganese can 
also bind to substrates of oxidative phosphorylation thus inhibiting mitochondrial 
respiration. Chronic exposure to manganese causes benign α-synuclein monomers, which 
are present in all neurons, to undergo a conformational change to the toxic oligomeric 
structures that are toxic to neurons. Taken together, we can effectively conclude that 
manganese toxicity impairs key biochemical events necessary for neuronal survival. 
Elsewhere in the body, excess manganese also interferes with the body’s iron metabolism 
and can cause kidney failure. Early detection and chelation therapy can effectively 
reverse the harmful effects caused by this metal; however, if it progresses untreated, it 
can cause severe neurological and physiological defects. As with any metal, there is a 
possibility of bioaccumulation and teratogenic effects of manganese. However this aspect 
has not been studied in detail. Similarly, an in-depth study on the role of manganese in 
protein misfolding and upregulation of genetic markers for various neurological diseases 
in humans must be conducted. By combining the results of epidemiological surveys, 
human case studies as well as mechanistic studies done in in vitro and animal models of 
manganese toxicity, we can better understand the causes and symptoms as well as 
determine effective therapeutic strategies to treat early and advanced states of 
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neurodegeneration caused by manganese toxicity. 
 
Figure 1: Molecular mechanisms of Mn-induced cell death: Cellular Mn homeostasis 
is dependent upon efficient uptake, retention and excretion by various cell receptors 
and/or ion channels. Under normal conditions, in the presence of excess Mn, the 
receptors involved in the uptake of this metal are down-regulated while those involved in 
its release from the cell are up-regulated. However, during chronic exposure to high 
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concentrations of Mn, these system checks are not maintained. Increased uptake of Mn 
under these conditions increases the production of reactive oxygen species (ROS) leading 
to mitochondrial dysfunction. Impaired mitochondrial function leads to release of 
cytochrome C that activates the apoptosis initiator caspase-9 which in turn cleaves 
caspase-3. The cleaved fragment of caspase-3 interacts with Protein kinase delta, a pro-
apoptotic protein. Caspase-3 mediated proteolytic cleavage of PKCd leads to DNA 
fragmentation and apoptosis.  
 
Figure 2: Structure of the α-synuclein protein 
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Figure 3: Effect of chronic Mn overexposure on α-synuclein misfolding. Metal 
binding sites on a-synuclein allow it to become a metal sink for free roaming metals in 
the cells. During an acute exposure to   Mn, free-roaming Mn binds to the metal binding 
sites on the C-terminus of this protein. In this way a-synuclein effectively works as a 
chelator for different metal ions including Mn. However continued exposure to Mn can 
lead to saturation of this chelating property. Following additional binding of Mn to the C-
terminus, the natively conformed protein misfolds. Misfolded a-synuclein leads to the 
production of pro-inflammatory factors. Thus Mn overexposure leads to progressive 
protein misfolding in the neurons and induces inflammation and finally 
neurodegeneration. 
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Figure 4: Receptors/ Channels involved in Mn hoemostasis: Various cellular receptors 
such as divalent metal transporter 1 (DMT1) and transferrin receptor (Tfr R) as well as 
ion channels such as store operated Ca
+2
 channels (SOCC) or voltage gated Ca
+2
 channels 
(VGCC) facilitate the entry of divalent Mn into the cells whereas SLC40A (ferroportin) 
and Ca
+2 
facilitate its expulsion from the cell and mitochondria respectively. Mn
+2 
is 
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passively transported via VGCC and glutamate activated ionic channels while Mn
+3
 entry 
is facilitated via transferri.  
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Background and Literature Review II 
Exosomes: Nanoscale dumpsters or delivery trucks? 
Brief History  
Exosomes, previously considered as microvesicles (MV) were first identified in the mid 
40’s as one of the pro-coagulant components in blood (Chargaff and West, 1946). 
Between 1960 to 1980, MV’s were identified in epiphyseal cartilage as plasma-
membrane derived vesicles (Wuthier, 1975) as a part of blood serum (Dalton, 1975) or 
seminal plasma (Ronquist et al., 1978) as well as an important pool of vesicles generated 
from various cancerous cells including hepatoma cells (Davidova and Shapot, 1970), 
rectal adenomas (De Broe et al., 1975), melanomas and gliomas (Trams et al., 1981). In 
fact, Trams et al first used the term “exosomes” in describing the microvesicles released 
from various neoplastic cell lines. They also hypothesized that these membrane vesicles 
might serve a physiological function rather than simply being waste baskets or excess 
cellular material exfoliated from a cell (Trams et al., 1981). This hypothesis gained more 
credence when Harding and colleagues showed that distinct from endosomes and other 
MV’s, exosomes collected from the media in which reticulocytes were grown, had the 
transferrin receptor – a marker of intracellular vesicles (endosomes) present on its surface 
(Harding et al., 1983; Pan et al., 1985). Time-dependent electron microscopic images and 
pulse-chase experiments showed these vesicles fusing with the plasma membrane leading 
to their secretion in the medium. Peters et al also showed presence of intercellular clefts 
into which internal vesicles were present awaiting extracellular release (Peters et al., 
1989). In 1996 Raposo, G. et al showed that B lymphoblastoid cells released exosomes 
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containing MHC class II molecules, inducing antigen-specific MHC class II –restricted T 
cell responses (Raposo et al., 1996). This was a novel form of antigen presentation and 
provided an insight into the role it can play in immune cell activation and cell-to-cell 
transmission of biologically active components. Another type of immune cell- the 
dendritic cell was found to release exosomes that contained tumor specific antigens that 
could promote anti-tumor responses in mice (Zitvogel et al., 1998). While exosomes were 
primarily studied in immune cells in the context of antigen presentation, they were soon 
found to play an important role in disease pathogenesis and progression in various 
diseases notably leishmaniasis (Silverman et al., 2010), malaria (Coltel et al., 2006; 
Mantel et al., 2013), trichomoniasis (Twu et al., 2013), trypanosomiasis (Cestari et al., 
2012; Goncalves et al., 1991), schistosomiasis (Wang et al., 2015) as well as infections 
caused by fungi such as Cryptococcus neoformans (Rodrigues et al., 2008a), 
Paracoccidioides brasiliensi (Vallejo et al., 2011) and Candida albicans (Rodrigues et 
al., 2008b). Since then, exosomes have been implicated in other diverse diseases such as 
AIDS, Alzheimer’s (Rajendran et al., 2006), Parkinson’s (Tomlinson et al., 2015), prion 
diseases (Fevrier et al., 2004) etc. At present, exosomes have been identified in all 
biological fluids including blood (Caby et al., 2005), urine (Pisitkun et al., 2004), saliva 
(Keller et al., 2011) and breast milk (Admyre et al., 2007).  
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Difference between microvesicles, endosomes and exosomes 
There is some confusion over the appropriate terminology to discern exosomes from 
other microvesicles. As shown in Fig.1 based on their approximate size, origin and cargo 
the different vesicles can be differentiated into endosomes, microvesicles, exosomes and 
apoptotic bodies. For the purpose of this review we will only delineate the properties of 
exosomes.  
Most recent papers agree that exosomes range in size between 40 – 150 nm in diameter. 
A common way of isolating and selectively enriching exosomes from different biological 
fluids or cell supernatants is by filtering the sample through a 0.22 μm filter followed by 
differential ultracentrifugation using a sucrose gradient (Thery et al., 2001). The initial 
filtration removes most extracellular proteins, intact cells and larger cell debris. Having a 
high content of lipid, the exosomes float on the sucrose and can be differentiated from 
multivesicular bodies (MVB’s) that are larger in size (~ 1000 nm in diameter) or 
apoptotic bodies, which are much smaller in size (~ 10 – 50 nm in diameter)(Aalberts et 
al., 2012; Escola et al., 1998). However, the size and density of most exosomes is similar 
to intraluminal vesicles (ILV’s) and some extracellular microvesicles thus contaminating 
a supposedly enriched pool of exosomes. An alternative is to immunoselect exosomes by 
using a antibody targeted to a common exosomal protein such as CD63 (Escola et al., 
1998). By immunoselection, it is possible to isolate exosomes with greater purity. 
However, the flip side to using this method is that depending on how ubiquitously is the 
target molecule expressed in these vesicles, it might exclude other exosomes not rich in 
the target protein. Another important factor that distinguishes exosomes from endosomes 
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or intra luminal vesicles are the contents present in these vesicles. Exosomes usually have 
cytosolic or plasma membrane proteins and are devoid of mitochondria, endoplasmic 
reticulum or nuclear material (Raposo and Stoorvogel, 2013; Thery et al., 2002). This is 
in direct contrast to endosomes that have the above-mentioned proteins too that are 
ultimately degraded during the lysosomal pathway. The cytosolic proteins present in 
exosomes also include those that are a part of the endocytic pathway including RAB 
proteins, GTPase, annexins, flotllin, alix, heat shock proteins (HSP’s) etc (Gruenberg and 
Maxfield, 1995; van Niel et al., 2006). Compared to MVB’s or apoptotic bodies, 
exosomes are enriched in cholesterol, sphingomyelin and ceramide (Thery et al., 2006). 
In contrast, apoptotic bodies usually contain a higher percentage of phosphatidylcholine 
and phosphatidylethanolamine while endosomes contain cholesterol, diacylglycerol and 
phosphatidylserine (Gasser et al., 2003; Thery et al., 2001).  
Exosome Biogenesis 
Biomolecules such as proteins, lipids as well as immunomodulatory molecules such as 
antigens are taken up by cells by phagocytosis, micro- or macropinocytosis as well as 
endocytosis. Phagocytosis is the main mode of uptake of immune cells such as 
macrophages and microglia. Non-immune cells mainly use endocytosis as the main route 
of intercellular uptake. Endocytosis is mainly through clathrin coated vesicles although 
caveolin mediated vesicular internalization are also known to occur. Following 
internalization via clathrin coated vesicles; these vesicles fuse to form the early endosome 
(EE). EE are characterized by presence of early endosomal antigen 1 (EEA1), Rab4, 5 
and 14 as well as transferrin receptor (TfR) and have a mildly acidic pH (between 6.0 – 
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6.5). Since EE’s lack degradative enzymes, the cargo in these vesicles such as receptors 
can be recycled back to the surface when the tubular endosome buds off during 
membrane recycling. The internalized proteins are also sorted with some fated to 
recycling while others are transported to late endosomes (LE) for degradation via the 
lysosomal pathway.  
Switching of Rab5 for Rab7 leads to the transitioning of EE to LE (Poteryaev et al., 
2010). LE’s are circular and have a more acidic environment compared to early 
endosomes (pH = 4.9 – 6.0). In this environment recycling receptors are lost and the 
vesicular cargo is exclusively targeted for degradation. Acid hydrolases can begin protein 
degradation although the high pH allows only a small percentage of degradation to occur 
in the LE’s. Incredibly, when LE formation is initialized, they begin moving from the 
peripheral cytoplasm to the perinuclear area. This movement is initiated by dynein-
dynactin via the Rab7 interacting lysosomal protein (RILP) (Granger et al., 2014). 
Through bi-directional shuttling with the trans golgi network, lysosomal components are 
added to the LE while endosomal components such as RAb5 and other proteins 
associated with EE’s are removed (Huotari and Helenius, 2011). An important aspect in 
the maturation of endosomes is the formation of intraluminal vesicles (ILV’s). The 
endosomal sorting complex required for transport (ESCRT), Alix and Vps4 among other 
protein complexes are required for the formation of ILV’s. Unlike endosomes that have a 
limiting membrane, which is highly glycosylated, ILV’s do not have glycocalyx on their 
membrane. In this way the cargo that is fated for degradation is easily accessible to the 
acid hydrolases. A number of ILV’s present together in the endosome forms what is 
known as multivesicular body (MVB). 
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Proteins required for the formation of lysosomes as well as those integral for its 
functioning are generated in the endoplasmic reticulum and transported via the trans golgi 
network to the LE’s leading to the formation of lysosomes (Appelqvist et al., 2013).  The 
pH in lysosomes is about 4.0 -4.5. This highly acidic environment provides an optimum 
condition for the action of acid hydrolases including cathepsins, peptidases, sulfatases, 
lipases, phosphatases, glycosidases etc, which results in the degradation of almost all 
molecules. The lysosomes themselves are resistant to this acidic degradation due to the 
presence of a heavily glycosylated membrane containing proteins such as lysosome 
associated membrane proteins (LAMP’s), lysosomal integral protein (LIMP2) and CD63 
(Eskelinen et al., 2003). Following the action of the various hydrolases, the end products 
are either reused by the cells or removed via exocytosis.  
Besides transporting the endosomal cargo to the lysosome for degradation, MVB’s can 
also fuse with the cell membrane and essentially release the IV’s outside the cell. These 
exocytosed ILV’s are now called exosomes. The mechanism by which exosomes are 
released has only become clear in the past few years. In particular switching of specific 
Rab proteins is thought to determine the fate of ILV’s in the MVB’s; Rab27b on the 
membrane of MVB’s leads to lysosomal degradation pathway. Exosome secretion 
involves the presence of various Rab GTPases such as Rab27, Rab35 and Rab11. 
Importantly, switching of Rab27b to Rab27a is required for the release of exosomes in 
the intercellular environment. This was shown by Ostrowski et al who demonstrated that 
knockdown of Rab27a and Rab27b reduced exosome release while exogenous addition of 
Rab27a and Rab27b lead to greater numbers of peripheral vesicles or perinuclear 
endosomes respectively (Ostrowski et al., 2010; Pfeffer, 2010). A general scheme of 
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exosome release involves the concerted action of the following mechanisms: 1) Inward 
budding of LE’s to form ILV’s containing cytosolic, ubiquinated proteins. 2) A number 
of budding incidences leading to a number of ILV’s in what is now called an MVB. 3) 
Recruitment of the ESCRT proteins ESCRT I (recognizes the ubiquinated cargo in 
developing MVB’s), II (involved in membrane budding of the LE’s to form ILV’s in the 
MVB) and III (involved in cleavage of MVB to release their cargo) as well as Alix and 
Vps4 among other proteins during the formation of MVB’s. 4) For most cell types 
recruitment of Rab11 and Alix as well as flotillin and glycosphingolipids or lipid rafts 
leads to the docking and fusion of the MVB to the inner membrane of the cell and finally 
release of the ILV’s now - termed exosomes, outside the cell. (Colombo et al., 2013; 
Phuyal et al., 2014; Pisitkun et al., 2004; Savina et al., 2005) The above steps are an over 
simplified version of exosome formation and release, indeed studies carried out in 
different cell types report different sets of proteins involved in exosome biogenesis and 
release. However, in general the proteins from the ESCRT and retromer complexes and 
their associated effector molecules are the main components that drive this phenomenon. 
While the above-mentioned phenomenon can be considered constitutive, exosome release 
can also be caused by stress stimuli including lipopolysaccharide (LPS) stimulation, heat-
shock, hypoxia etc (Chen et al., 2011; Malik et al., 2013; Momen-Heravi et al., 2015). 
Role of exosomes in disease pathogenesis 
Earlier, exosomes were mainly studied in immune cells such as T cells and monocytes 
mainly in the context of immunomodulation and cancer propagation (Farsad, 2002; 
Graves and Valente, 1991; Taylor and Gercel-Taylor, 2005). They have been implicated 
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in propagating tumor-causing or tumor-supressing proteins to distant cells and tissues as 
they move in the extra cellular milieu. For example, metastatic tumor cells released 
exosomes that suppressed the expression of class II MHC antigens by macrophages in a 
dose-dependent manner, while similar vesicles from early stage tumor cells did not 
(Taylor and Black, 1985; Taylor et al., 1988). Interestingly, these exocytosed vesicles 
contained anti-CD3 and concavalinA thus suppressing T cell activation. However, the 
molecular mechanism involved in the packaging of specific proteins and their release via 
exosomes had not been elucidated. Today, we know that Rab27 plays an important role in 
exosome release and propagation of tumorigenic proteins, leading to the propagation of 
cancer (Bobrie et al., 2012). Moreover, exosomes have been implicated in part in the 
development and progression of diverse pathological conditions including AD, PD, 
various cancers as well as cardiac diseases (Buzas et al., 2014; Emmanouilidou et al., 
2010; Kahlert and Kalluri, 2013; Kharaziha et al., 2012; Record et al., 2014; Vingtdeux et 
al., 2012).  
Cell-to-cell transfer of exosomes 
Since exosomes contain a lipid membrane with moieties similar to those seen on the 
plasma membrane of various cells, it is easy for a distant cell to either engulf these 
extracellular vesicles or simply allow entry via plasma membrane fusion and diffusion 
into the cell cytosol. This cell-to-cell transfer of potential tumorigenic, 
immunomodulatory or aggregated proteins is thought to cause the progression of various 
metastatic cancers and neurodegenerative diseases. 
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In the case of pancreatic ductal adenocarcinomas (PDAC’s), Costa-Silva and colleagues 
found that exosomes isolated from metastatic PDAC’s showed high expression of 
macrophage migration inhibitory factor (MIF) compared to exosomes isolated from non-
metastatic PDAC’s. They also showed that Kupfer cells present in the liver were able to 
take up these PDAC-derived exosomes which lead to the development of a fibrotic 
environment due to heightened secretion of fibronectin and transforming growth factor 
β(Costa-Silva et al., 2015). By developing a fibrotic environment, the exosomes 
inherently made a “tumor- favorable” niche resulting in liver metastasis. Such a niche 
was not made by exosomes isolated from normal pancreatic cells thus proving that 
exosomes can prime the target organ/s to develop and propagate cancer. Curiously, 
despite being injected retro-orbitaly, the only organ affected was the liver. So how does 
this targeting and specific uptake take place?  
It turns out that the transport of exosomes and their uptake is not as random as it seems 
and is mediated in some cells by the tetraspanin-integrin complex (Nazarenko et al., 
2010; Rana et al., 2012). Exosome transfer of αvβ6 integrin to surrounding cells has 
shown to increase the probability of developing metastatic prostrate cancer (Fedele et al., 
2015). Curiously, even tumor cell migration is dependent to a certain extent upon 
autocrine secretion and adhesion of exosomes. A recent study conducted by Sung et al, 
demonstrated that cancer cells required exosomes to provide the direction for cell 
migration. Disrupting exosome secretion caused constant directional switching leading to 
defective cell migration and consequently lowered incidence of metastasis. The same 
paper found that autocrine secretion of cancer cell derived exosomes and specifically the 
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presence of increased fibronectin in these vesicles promoted tumor cell migration in an 
efficient manner (Sung et al., 2015).  
 Exosomes have been also linked in the transfer of aggregated proteins in various 
neurodegenerative diseases such as AD, PD and prion disease. Aggregated proteins are 
caused either by mutations in certain proteins that cause them to spontaneously misfold 
or due to cellular stress that may induce protein misfolding. Misfolded proteins typically 
acquire a β-sheet rich structure where-in the cell cannot degrade them and are instead 
accumulate in the cell interfering with cellular activities and ultimately leading to cell 
apoptosis. There have been a number of in-vitro studies that have shown that aggregated 
proteins can be transferred from one neuron to another via exosomes (Danzer et al., 2012; 
Saman et al., 2012; Vella et al., 2007). This “seeding” effect can cause widespread 
neuronal damage leading to neuroinflammation and neurodegeneration. Prion diseases 
are fatal, transmissible neurodegenerative disorders. These diseases develop when the 
prion protein, present in all tissues with the highest expression in the tissues of the central 
nervous system (CNS)  
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Abstract 
The pathological role of alpha-synuclein (α-Syn) aggregation in 
neurodegeneration is well recognized, but the physiological function of normal α-Syn 
remains unknown. Since α-Syn protein contains multiple divalent metal binding sites, 
herein we conducted a comprehensive characterization of the role of α-Syn in 
manganese-induced dopaminergic neurotoxicity. We established transgenic N27 
dopaminergic neuronal cells by stably expressing human wild-type α-Syn at normal 
physiological levels. Alpha-Syn-expressing dopaminergic cells significantly attenuated 
Mn-induced neurotoxicity for 24-h exposures relative to vector control cells. To further 
explore cellular mechanisms, we studied the mitochondria-dependent apoptotic pathway. 
Analysis of a key mitochondrial apoptotic initiator, cytochrome c, revealed that α-Syn 
significantly reduces the Mn-induced cytochrome c release into cytosol. The downstream 
caspase cascade, involving caspase-9 and caspase-3 activation, during Mn exposure was 
also largely attenuated in Mn-treated α-Syn cells in a time-dependent manner. Alpha-Syn 
cells also showed a dramatic reduction in the Mn-induced proteolytic activation of the 
pro-apoptotic kinase PKCδ.  The generation of Mn-induced reactive oxygen species did 
not differ between α-Syn and vector control cells, indicating that α-Syn exerts its 
protective effect independent of altering ROS generation. Inductively coupled plasma-
mass spectrometry (ICP-MS) revealed no significant differences in intracellular Mn 
levels between treated vector and α-Syn cells. Notably, the expression of wild-type α-Syn 
in primary mesencephalic cells also rescued cells from Mn-induced neurotoxicity. 
However, prolonged exposure to Mn promoted protein aggregation in α-Syn-expressing 
cells. Collectively, these results demonstrate that wild-type α-Syn exhibits 
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neuroprotective effects against Mn-induced neurotoxicity during the early stages of 
exposure in a dopaminergic neuronal model of PD.  
 
Keywords: alpha-synuclein, protein aggregation, Parkinson’s disease, metals, 
neuroprotection, neurotoxicity  
Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder 
characterized by the death of dopaminergic neurons projecting from the substantia nigra 
pars compacta (SNpc) to the striatum and by the presence of cytoplasmic eosinophilic 
inclusions, termed Lewy bodies and Lewy neurites (Gasser, 2009), throughout the 
nigrostriatal pathway. It is the second most common neurodegenerative disorder, 
affecting about 1.8% of the population over the age of 65 years. It is also characterized 
clinically by several extrapyramidal features such as bradykinesia, postural instability, 
resting tremor, and rigidity. Manifestation of non-motor symptoms at early stages of PD 
has been recognized in recent years. Although aging is the greatest risk for developing 
PD, pathogenesis of the disease remains unclear. Nevertheless, current etiological 
understanding suggests that PD likely results from genetic susceptibility combined with 
various environmental factors (Aschner et al., 2009). 
Recent evidence has implicated several gene defects (SNCA, PRKN, PINK1, DJ-
1, MAPT, UCH-L1, LRRK2 and ATP13A2) directly contributing or enhancing 
susceptibility to PD (Dawson et al., 2010). The first gene identified as a genetic risk 
factor for autosomal-dominant PD was α-Syn (PARK1/SNCA), which strongly interacted 
with gene multiplications or three-point mutations (Gasser, 2009). Alpha-Syn is a 140-
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amino acid protein predominantly expressed presynaptically in neurons throughout the 
mammalian brain and cerebrospinal fluid (CSF). Moreover, recent studies have shown 
that α-Syn is transported between neurons or from neurons to various glial cell types and 
that the blood-CSF barrier regulates α-Syn uptake from CSF, thus maintaining α-Syn 
homeostasis in the CSF and brain parenchyma (Bates and Zheng, 2014). However, 
physiological functions of α-Syn are poorly understood, but evidence has suggested a role 
for it in synaptic plasticity, dopamine regulation, and membrane trafficking (Auluck et 
al., 2010). The link between α-Syn and PD pathogenesis is based on case studies of 
familial PD and the observation that misfolded α-Syn is a major constituent of Lewy 
bodies and Lewy neurites in both familial and sporadic PD (Dawson et al., 2010). Despite 
this, there is a growing body of evidence that contradicts the current understanding of α-
Syn, which suggests that wild-type α-Syn is perhaps neuroprotective rather than 
detrimental. In fact, some studies have shown α-Syn pathology in Lewy bodies and Lewy 
neurites to be neuroprotective (Tanaka et al., 2004), and findings of postmortem studies 
(Jellinger, 2004) done with aged individuals have shown formation of Lewy bodies 
without any signs of PD or any other neurodegenerative disorders, thus challenging the 
relevance of α-Syn as a classical neuropathological hallmark of PD. Moreover, recent 
studies have demonstrated neuroprotective effects of wild-type α-Syn against the 
classical Parkinsonian toxin MPP
+
 (Kaul et al., 2005a), the oxidative stress inducer 
hydrogen peroxide (Lee et al., 2001), or the agro-chemicals (Choong and Say, 2011). 
Although genes are an important risk factor, at least in many familial cases, 
exposure to toxins or other environmental factors may influence when symptoms of the 
disease appear and/or how the disease progresses. Manganese (Mn) is an essential trace 
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mineral vital for normal development and for biological functions of a number of 
enzymes (Aschner and Aschner, 2005; Karki et al., 2013). Manganese is essential in bone 
formation, fat and carbohydrate metabolism, blood sugar regulation, and calcium 
absorption (Bowman et al., 2011). Manganese deficiency can contribute to birth defects, 
impaired fertility, bone malformation and weakness, and enhanced susceptibility to 
seizures (Aschner and Aschner, 2005). However, excessive exposure to manganese is a 
well-recognized occupational and environmental neurotoxic hazard.  
A link has been established between manganese exposure and PD or PD-related 
disorders (Cowan et al., 2009; Dydak et al., 2011; Guilarte, 2013), suggesting neurotoxic 
effects of manganese on the nigrostriatal system. Several mechanisms have been 
identified in manganese neurotoxicity, including mitochondrial impairment, oxidative 
and nitrative damage, astroglial- and microglial-mediated inflammation and dopamine 
metabolism impairment (Filipov and Dodd, 2012; Sidoryk-Wegrzynowicz and Aschner, 
2013). We and others have shown that manganese can also interact with disease-specific 
proteins such as Huntington and prion proteins (Madison et al., 2012; Martin et al., 
2011). Since the potential interaction of manganese with α-Syn is not well defined, 
herein, we systematically characterized the role of α-Syn in the early and late stages of 
manganese neurotoxicity in dopaminergic neuronal cells.  
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Materials and Methods 
Reagents 
Manganese chloride (MnCl2) and mouse β-actin antibody were purchased from 
Sigma (St. Louis, MO). SYTOX Green nucleic acid dye was purchased from Molecular 
Probes (Eugene, OR). Cell Death Detection ELISA plus assay kit was purchased from 
Roche Molecular Biochemicals (Indianapolis, IN). Bradford protein assay kit was 
purchased from Bio-Rad Laboratories (Hercules, CA). RPMI 1640 medium, fetal bovine 
serum, L-glutamine, penicillin/streptomycin, hygromycin B, Lipofectamine Plus, LTX, 
and 2000 reagents and pCEP4 empty vector were purchased from Invitrogen (Carlsbad, 
CA). The pmaxGFP vector was purchased from Lonza. The primary antibodies against α-
Synuclein 211, protein kinase Cδ (PKCδ), caspase-3, and transferrin (Tf) were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). Divalent metal transporter (DMT-1) 
antibody was obtained from Alpha Diagnostic International (San Antonio, TX), and α-
Synuclein monoclonal antibody (Syn-1) was purchased from BD Biosciences (San 
Diego, CA). Alexa Fluor 680-conjugated anti-mouse secondary antibody was purchased 
from Invitrogen. IR800-conjugated anti-rabbit secondary antibody was purchased from 
Rockland Immunochemicals (Gilbertsville, PA). Caspase-3 substrate (Ac-DEVD-AFC) 
was obtained from Bachem Biosciences (King of Prussia, PA). The {γ-32P} ATP was 
purchased from Perkin-Elmer Life Science (Boston, MA). 
Cell culture and stable expression of α-synuclein 
The immortalized rat mesencephalic dopaminergic cell line 1RB3AN27, also 
referred to as N27 cells, was a kind gift from Dr. Kedar N. Prasad (University of 
Colorado Health Sciences Center, Denver, CO). N27 cells were grown in RPMI 1640 
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medium containing 10% fetal bovine serum, 2 mM L-glutamine, 50 units of penicillin, 
and 50 μg/ml of streptomycin in a humidified atmosphere of 5% CO2 at 37°C as 
described previously (Ghosh et al., 2013; Jin et al., 2011b; Kaul et al., 2005a; Kaul et al., 
2003). Dr. Eliezer Masliah (University of California, San Diego, CA) kindly provided the 
pCEP4-α-Syn expression vector containing the full-length human α-synuclein sequence. 
The pCEP4-α-Syn and pCEP4 empty vector (Vec) were transfected into N27 cells using 
Lipofectamine 2000 reagent following the procedure recommended by the manufacturer 
and as described previously (Kaul et al., 2005a). The stable transfectants were selected 48 
h post-transfection in 400 μg/ml of hygromycin B and further maintained in N27 growth 
media supplemented with 200 μg/ml of hygromycin B. Expression levels of α-Syn were 
confirmed by Western blot and immunocytochemistry. 
DNA fragmentation assays 
DNA fragmentation was measured using a Cell Death Detection ELISA Plus 
assay kit as described previously (Afeseh Ngwa et al., 2009; Jin et al., 2011a; Jin et al., 
2011b). This method measures the amount of histone-associated low–molecular-weight 
DNA in the cytoplasm and is more sensitive than DNA ladder analysis. Briefly, cells 
were collected and lysed using the lysis buffer supplied with the kit. The lysate was spun 
down at 200 x g, and 20 μl of supernatant were then incubated for 2 h with the mixture of 
HRP-conjugated antibody that recognizes histones and single- and double-stranded DNA. 
After washing away the unbound components, the final reaction product was measured 
colorimetrically with 2,2′-azino-di-[3-ethylbenz-thiazoline sulfonate] as an HRP substrate 
using a spectrophotometer at 405 nm and 490 nm. The difference in absorbance between 
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405 and 490 nm was used to determine the amount of DNA fragmentation in each 
sample. 
Sytox Green cytotoxicity assays 
Cytotoxicity was assayed using Sytox Green, a membrane-impermeable DNA dye 
that enters dead cells via their damaged plasma membranes and intercalates with nucleic 
acids, as described previously (Afeseh Ngwa et al., 2009; Jin et al., 2011b; Martin et al., 
2011). Excitation and emission wavelengths of 485 and 538 nm, respectively, were used 
to detect the DNA-bound Sytox Green using a fluorescence microplate reader (Synergy 
2, BioTek Instruments, Winooski, VT). The fluorescence intensity is directly proportional 
to the number of dead cells. Equal numbers of subconfluent α-Syn and Vec cells were 
grown in 24-well plates for 16-18 h and then incubated with 1 μM Sytox Green and 300 
μM manganese (MnCl2) for the indicated time periods. Fluorescence intensity was 
monitored at appropriate time points during the experiments to quantify the resulting cell 
death, and fluorescence images were taken using an inverted fluorescence microscope 
(Nikon, Tokyo, Japan) equipped with a SPOT digital camera (Diagnostic Instruments, 
Sterling Heights, MI). 
Immunofluorescence staining 
Expression of human α-Syn in the stably-transfected N27 cells and transiently-
transfected primary mesencephalic cultures was determined by immunocytochemistry. 
Briefly, the cells were seeded on a poly-D-lysine-coated cover slip. After 24 h, cells were 
washed with PBS and incubated in 4% paraformaldehyde (PFA) for 30 min at room 
temperature. After fixing, the cells were washed with PBS and blocked for 45 min with 
the blocking agent (2% BSA, 0.05% Tween-20, and 0.5% Triton X-100 in PBS). Cells 
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were then incubated overnight at 4°C with the mouse monoclonal antibody against 
human α-synuclein (α-Syn211 Santa Cruz, 1:1000) or GFP (ab6673 Abcam, 1:2000). The 
following day, cells were incubated for 90 min in the dark with Alexa Fluor 555-
conjugated anti-mouse or Fluor 488-conjugated anti-goat secondary antibody (1:1500). 
Hoechst 44432 was used as a nuclear stain and the cover slips were then mounted on 
glass slides and viewed using a Nikon TE2000 microscope (Tokyo, Japan). Images were 
captured with a SPOT color digital camera (Diagnostic Instruments, Sterling Heights, 
MI). 
Measurements of intracellular reactive oxygen species 
The cytosolic levels of reactive oxygen species (ROS) were measured by 
dichlorofluorescein-diacetate (DCF-DA) (Molecular Probes) as previously described 
(Afeseh Ngwa et al., 2009). Briefly, 2 x 10
4
 Vec and α-Syn cells were plated in 96-well 
plates. After roughly 18 h, the media was removed, and cells were then washed with PBS 
and co-treated with 300 μM MnCl2 and 10 μM DCF-DA in Hank's buffered salt solution 
(HBSS) and fluorescence measurements were taken at time points up to 90 min.  The 
DCF-DA dye is a cell permeable, non-fluorescent probe, but after cellular oxidation and 
removal of acetate groups by cellular esterases, it becomes fluorescent. Fluorescence of 
the cells was measured at various time points using the Synergy 2 fluorescence plate 
reader with 485 nm excitation and 538 nm emission filters.  
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Determinations of intracellular manganese concentrations 
Intracellular manganese concentrations were measured by inductively coupled 
plasma-mass spectrometry (ICP-MS) as described in our recent publications (Afeseh 
Ngwa et al., 2009; Martin et al., 2011). Cells expressing α-Syn and Vec control cells 
were treated with 300 μM manganese for 24 h and washed three times with ice-cold PBS. 
ICP-MS was used to determine the concentrations of Mn at m/z 55 in each sample. The 
high-resolution double-focusing ICP-MS device (ELEMENT 1, Thermo Finnigan) was 
operated at medium resolution (m/Δm = 4,000) to resolve the isotopes of interest from 
any interferences. Each sample was placed in an acid-washed 5-ml Teflon vial and 
digested in 150 μl high purity nitric acid (Ultrex II, J.T. Baker). Following digestion, the 
samples were diluted to 5 ml with 18.2 MΩ deionized water to give a final acid 
concentration of approximately 3% nitric acid. The supernatant was analyzed with the 
ICP-MS. Gallium (Ga) was chosen as the internal standard because its m/z ratio of 69 is 
similar to that of the manganese, and it has no major spectroscopic interferences. A small 
spike of Ga standard solution was added to each sample for a final Ga concentration of 10 
ppb and manganese standard (10-ppb) was prepared. The nitric acid blank, the Mn 
element standard, and each of the samples were introduced into the ICP-MS via a 100 
μl/min self-aspirating PFA nebulizer (Elemental Scientific, Inc.). The nitric acid blank 
was used to rinse the nebulizer between each sample. The results for each sample were 
calculated using the integrated average background-subtracted peak intensities from 20 
consecutive scans. To correct for differences in elemental ionization efficiency in the 
ICP, the manganese standard was used and concentrations of Mn were then calculated for 
each sample.  
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Measurements of caspase-3 and caspase-9 activities 
After manganese exposure, cells were resuspended in caspase lysis buffer (50 mM 
Tris-HCl, pH 7.4, 1 mM EDTA, 10 mM EGTA, and 10 μM digitonin) at 37°C for 20 
min. Lysates were centrifuged at 20,000 x g and the cell-free supernatants were incubated 
with 50 μM caspase-3 substrate (Ac-DEVD-AFC) or caspase-9 substrate (Ac-LEHD-
AFC) at 37°C for 1 h (Afeseh Ngwa et al., 2009; Jin et al., 2011a). Formation of 7-
amino-4-methylcoumarin (AFC), resulting from caspase-3 or caspase-9 activity, was 
measured at a 400 nm excitation and a 505 nm emission wavelength using a fluorescence 
plate reader. All fluorescence signals from the samples were normalized to protein 
concentration, as determined with the Bradford protein assay. 
Western blot analysis 
Whole cell lysates were prepared using modified RIPA buffer containing protease 
and phosphatase inhibitor cocktail (Thermo Scientific, Waltham, MA) as previously 
described (Ghosh et al., 2013; Kanthasamy et al., 2012). Mitochondrial and cytoplasmic 
extracts were isolated using the mitochondria isolation kit for cultured cells (Thermo 
Scientific, Waltham, MA). The protein concentrations were determined with the Bradford 
protein assay. Cell lysates containing equal amounts of protein were separated on a 10-to-
15% SDS-polyacrylamide gel. After separation, proteins were transferred to a 
nitrocellulose membrane, and non-specific binding sites were blocked by treating with 
LI-COR blocking buffer. The membranes were then incubated overnight with primary 
antibodies directed against PKCδ (rabbit polyclonal; 1:2000 dilution), α-Synuclein 211 
(mouse monoclonal; 1:500 dilution), transferrin (Tf, rabbit polyclonal; 1:500 dilution), 
caspase-3 (rabbit polyclonal; 1:1000 dilution), cytochrome c (rabbit polyclonal; 1:2000 
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dilution), COX-IV (mouse monoclonal; 1:2000 dilution) or DMT-1 (rabbit polyclonal; 
1:2000 dilution). The primary antibody treatments were followed by treatment with 
IR800-conjugated anti-rabbit or Alexa Fluor 680-conjugated anti-mouse secondary 
antibody for 1 h at room temperature. To confirm equal protein loading, blots were 
reprobed with β-actin antibody (1:15000 dilution). Western blot images were captured 
with the Odyssey IR Imaging system (LI-COR) and data were analyzed using Odyssey 
2.0 software. 
Slot blot analysis 
After manganese exposure, protein aggregation and accumulation were evaluated 
with anti-oligomeric antibody (A11) via slot blot analysis. Cell lysates were prepared as 
described for Western blot analysis, and equal amounts of protein were loaded to each 
well and adsorbed onto the nitrocellulose membrane using a slot blot apparatus (Bio-Dot 
and Bio-Dot SF Microfiltration apparatus, Bio-Rad). Following adsorption, the 
membranes were pre-incubated with LI-COR blocking buffer and incubated overnight at 
4°C with anti-A11 (1:1000 dilution, Invitrogen). After incubation with primary antibody, 
membranes were incubated with an IR800-conjugated anti-rabbit secondary antibody. 
Slot blot images were captured with the Odyssey IR Imaging system (LI-COR) and data 
were analyzed using Odyssey 2.0 software. 
Assessments of aggresomes and inclusion body formation 
Assessment of aggresome formation was performed using a ProteoStat aggresome 
detection kit according to the manufacturer’s instructions (Enzo Life Sciences). Briefly, 
1.5 x 10
4
 α-Syn cells were plated on poly-D-lysine-coated glass coverslips and treated 
with 300 µM manganese for 36-48 h. After treatment, cells were fixed with 4% PFA, 
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permeabilized with 0.5% Triton X-100 and incubated with ProteoStat aggresome dye and 
Hoechst 33342 nuclear stain as directed by the manufacturer. Analysis was done with a 
NIKON TE2000 fluorescence microscope using a Texas Red filter for imaging the cell 
aggresome signal and a UV filter for imaging the nuclear signal. Following prolonged 
manganese exposure, cytoplasmic protein aggregation or inclusion body formation was 
analyzed by a newly developed microplate-based ProteoStat inclusion body cytotoxicity 
kit (Enzo Life Sciences) following the procedure recommended by the manufacturer. 
Briefly, 2.5 x 10
3
 α-Syn and Vec cells were plated in 96-well plates, treated with 300 µM 
manganese for 36-48 h, and then fixed with 4% PFA for 15 min.  At the end of fixation, 
cells were washed with PBS and incubated at room temperature for 15 min with 
permeabilization buffer. Cells were then incubated in dual-color detection buffer for 30 
min, and fluorescence was measured using the Synergy 2 fluorescence plate reader with 
500 nm excitation and 600 nm emission filters for aggresome readings and 350 nm 
excitation and 450 nm emission filters for Hoechst nuclear readings. Increases in the ratio 
of the ProteoStat aggresome signal (500/600 nm), relative to the Hoechst signal (350/450 
nm), indicate the formation of aggregated proteins within aggresomes and related 
inclusion bodies in response to manganese exposure. 
Primary mesencephalic neuronal cultures 
All procedures involving animal handling were approved by the Institutional 
Animal Care and Use Committee (IACUC) at Iowa State University. Primary 
mesencephalic neuronal cultures were prepared as described in our previous publications 
(Ghosh et al., 2013; Jin et al., 2011a). Briefly, 24-well plates containing coverslips were 
coated 2 h with 0.1 mg/ml of poly-D-lysine. Mesencephalon tissues were dissected from 
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gestational 14-day-old mouse embryos and kept in ice-cold DMEM. Cells were then 
dissociated in DMEM containing trypsin–0.25% EDTA for 30 min at 37°C. After 
incubation, 10% heat-inactivated fetal bovine serum in DMEM was added to inhibit 
trypsin digestion. The cells were triturated and suspended in neurobasal medium 
supplemented with 2% B27 supplement, 500 μM L-glutamine, 100 IU/ml penicillin, and 
100 μg/ml streptomycin, plated at 7.5 × 105 cells/well and incubated in a humidified CO2 
incubator. Half of the culture medium was replaced every 2 days, and transfections of 
primary neuronal cultures were conducted on the fourth day.  
Transfection of human -Syn in primary mesencephalic neuronal cultures 
Transfection of primary mesencephalic cultures was carried out on the fourth day 
of culture ex vivo using Lipofectamine LTX and PLUS Reagent per manufacturer’s 
instructions. Briefly, 1.0 μg pmaxGFP-α-Syn or pmaxGFP control plasmid was diluted in 
100 μL of Opti-MEM-I media and 2.5 μL of PLUS Reagent was added. This mixture was 
incubated for 5 min at room temperature. After incubation, 1.5 µL of Lipofectamine LTX 
reagent was added to the above diluted Opti-MEM:DNA solution, mixed gently and 
incubated for 30 min to form DNA-Lipofectamine LTX Reagent complexes. Then 100 
µL of the DNA-Lipofectamine LTX complexes was added directly to each well and 
incubated in a humidified CO2 incubator for 18-24 h before expose to manganese. GFP-α-
Syn expression was confirmed through fluorescence microscopy. 
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Quantification of neurite processes 
Primary mesencephalic neuronal cultures transfected with human wild-type α-Syn 
were treated with 50 μM manganese for 24 h, and coverslips were processed for GFP 
immunofluorescence staining as described above. MetaMorph image analysis software, 
version 5.0 (Molecular Devices, Sunnyvale, CA), was used to measure the neurite length 
of primary dopaminergic neurons from each coverslip in the control and treatment groups 
as described in our previous publications (Afeseh Ngwa et al., 2009; Ghosh et al., 2013). 
Data from at least six different cultures per experimental group were pooled and analyzed 
using Prism 4.0 software (Graphpad Software, San Diego, CA).   
[
3
H]-Dopamine uptake assays 
The neuroprotective effect of human wild-type α-Syn on dopaminergic neurons in 
fetal mouse mesencephalic cultures exposed to manganese was quantified using the 
3
H-
DA uptake assay (Harischandra et al., 2014). This functional assay is more sensitive than 
TH-positive neuron counting (Afeseh Ngwa et al., 2009; McCoy et al., 2006) and 
overcomes difficulties in TH-positive cell counting associated with transfection studies. 
Briefly, human wild-type α-Syn-transfected primary mesencephalic neuronal cultures 
were treated with 50 μM manganese for 24 h. After washing the cells twice with Krebs 
Ringer buffer (5.6 mM glucose, 1.3 mM EDTA, 1.2 mM MgSO4, 1.8 mM CaCl2, 4.7 mM 
KCl, 120 mM NaCl, 16 mM Na3PO4), cells were incubated with 10 μM 
3
H-DA (30 
Ci/mol) for 30 min at 37°C in Krebs Ringer buffer. The dopamine reuptake blocker 
Mazindol (1 nM) served as a positive control to assess the efficiency of 
3
H-DA uptake. 
The uptake was stopped by removing the reaction mixture followed by a triple wash with 
fresh ice-cold Krebs Ringer buffer. Cells were then lysed with 1 N sodium hydroxide, 
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and their radioactivity was measured by liquid scintillation counter (Tri-Carb 4000; 
Packard, Meriden, CT) after adding a 5-mL scintillation cocktail to each vial.  
Statistical analysis 
Prism 4.0 software was used to analyze data from two or more independent 
experiments, each with n ≥ 6.  Bonferroni’s multiple comparison testing was used to find 
significant differences between treatment and control groups. Differences with p < 0.05 
were considered significantly different. 
 
Results 
Generation of N27 dopaminergic cells stably expressing wild-type human α-Syn 
The α-Syn protein has three metal binding sites: one at N-terminus, one at central 
region and one at C-terminus of the protein (Fig. 1A). The metal binding sites near 49-52 
and 110-140 are known to interact with divalent metals including manganese (Uversky et 
al., 2001). To understand the role of α-Syn in manganese neurotoxicity, we first 
established a rat mesencephalic N27 dopaminergic cell model stably expressing human 
wild-type α-Syn by transfecting them with the plasmid pCEP4-α-Syn or pCEP control 
vector. Stable expression of human α-Syn in N27 cells was determined by Western blot 
analysis (Fig. 1B) using an α-Syn antibody as described previously (Kaul et al., 2005a). 
Endogenous α-Syn levels were too low to detect in N27 Vec cells, whereas strong 
expression of a single 19-kDa human α-Syn band could readily be detected in α-Syn-
expressing N27 cells comparable to that described in  our  previous publications (Jin et 
al., 2011b; Kaul et al., 2005a). Western blot analysis comparing α-Syn expression in N27 
cells to rat brain lysates (Fig. 1B) showed that α-Syn was not overexpressed in N27 cells, 
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but was within physiologic relative to rat brain. Additional analysis through 
immunocytochemistry demonstrated brightly stained subcellular localization of α-Syn 
corresponding to its even distribution in α-Syn-expressing N27 cells, whereas no 
immunoreactivity was observed in Vec cells (Fig. 1C). 
 
Human wild-type α-Syn expression attenuates Manganese-induced cytotoxicity 
To evaluate the effect of wild-type α-Syn expression on manganese-induced 
neurotoxicity, α-Syn-expressing and Vec N27 cells were treated with 300 µM manganese 
and cell death was measured at various time points over a 24 h period. As revealed by the 
SYTOX Green cytotoxicity assay (Fig. 2A), α-Syn-expressing cells showed ~50% 
protection against manganese neurotoxicity (at 24 h) as compared to that of Vec cells. To 
confirm the results obtained with the fluorescence plate readings, SYTOX Green-positive 
cells were also imaged using fluorescence microscopy (Fig. 2B), where phase-contrast 
(bottom panels) and Sytox FITC fluorescence (top panels) images were captured from 
random fields to compare cell death between manganese-treated α-Syn and Vec cells. 
Vec cells treated with manganese experienced significantly higher cell death compared to 
manganese-treated α-Syn cells, as evidenced by the bright SYTOX positive cells.  
Further analysis of α-Syn’s neuroprotective effect at later time points (36 h and 48 
h) indicates that its ability to withstand manganese-induced cytotoxicity is gradually 
reduced (Figs. 2A and 2C). As shown in Fig. 2C, determination of the percentage 
reduction in neuroprotection by subtracting the rate of cell death in α-Syn cells from that 
in Vec cells at 24, 36 and 48 h revealed a gradual loss of α-Syn’s neuroprotective 
function over time.   Together, we observed a novel observation that wild-type α-Syn 
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expression is neuroprotective against early stages of manganese cytotoxicity in a 
dopaminergic cell model but the proective effect declines during prolonged manganese 
exposure.  
 
α-Syn expression attenuates manganese-induced cytochrome c release without 
augmenting manganese-induced oxidative stress in N27 dopaminergic cells 
Several studies, including our previous work, have shown that various 
dopaminergic toxicants such as MPP
+
, dieldrin, MnCl2, V2O5 and 
Methylcyclopentadienyl manganese tricarbonyl (MMT), induce cell death through early 
oxidative events resulting in mitochondrial depolarization accompanied by cytochrome c 
release (Afeseh Ngwa et al., 2009; Kaul et al., 2005a; Latchoumycandane et al., 2005). 
Therefore, we examined by DCF-DA assay whether increased α-Syn expression 
modulates manganese-induced early ROS production in α-Syn and Vec cells. 
Quantitative analysis of ROS generation revealed that exposure of both α-Syn and Vec 
cells to manganese resulted in time-dependent early ROS generation (Fig. 3A). However, 
levels of manganese-induced ROS generation did not differ significantly between these 
two cells (Fig. 3A). This suggests that the neuroprotective effects induced by the cellular 
expression of wild-type human α-Syn in N27 dopaminergic cells may occur 
independently of manganese-induced early ROS production.   
Increased intracellular ROS production is known to trigger mitochondrial 
depolarization and the release of cytochrome c very rapidly, thereby activating 
downstream apoptotic pathways. Therefore, we examined whether α-Syn expression can 
reduce manganese-induced cytochrome c release from the mitochondria, thereby rescuing 
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dopaminergic cells from apoptotic cell death. After 300 μM manganese exposure for 6 h, 
cytosolic and mitochondrial fractions were isolated and subject to Western blot analysis.  
Exposure to 300 μM manganese caused cytochrome c release from both Vec and α-Syn 
cells, however, the release was significantly less in α-Syn cells (Figs. 3B and C).Thus, 
these data indicate that α-Syn expression can indeed attenuate the release of the key 
mitochondrial proapoptotic molecule cytochrome c into the cytosol during early stages of 
manganese exposure.  
 
α-Syn expression suppresses manganese-induced caspase cascade activation and 
DNA fragmentation and attenuates manganese-induced proteolytic activation of 
PKCδ 
Cytochrome c is known to play a key regulatory role in activating apoptotic cell 
death during neurotoxic stress (Afeseh Ngwa et al., 2009; Kaul et al., 2003). Cytosolic 
cytochrome c first activates caspase-9, thereby initiating an intrinsic apoptotic caspase 
cascade, resulting further in the activation of caspase-3, the major effector caspase that is 
responsible for proteolytic cleavage of apoptotic cell signaling molecules. Previous 
studies in our laboratory have shown that dopaminergic neurotoxicants can activate the 
caspase cascade in dopaminergic cells (Afeseh Ngwa et al., 2009; Ghosh et al., 2013; 
Kaul et al., 2005b). Herein, we examined whether α-Syn expression blocks caspase 
cascade activation induced by manganese. For this study, we treated α-Syn-expressing 
and Vec control N27 cells with 300 μM manganese for 12 h, and then caspase-9 and -3 
activities were determined using one of the fluorometric substrates Ac-LEHD-AFC or 
Ac-DEVD-AFC. Caspase-9 and caspase-3 were significantly activated (>2.5 fold) in Vec 
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cells after 12 h of exposure to 300 μM manganese, whereas their activation was 
suppressed in α-Syn-expressing cells (Figs. 4A-B). These results show that α-Syn 
expression attenuates manganese-induced sequential activation of caspase-9 and caspase-
3. 
DNA fragmentation is one of the hallmarks of apoptosis, resulting from 
endonuclease activation and the breakdown of chromatin. Therefore, we further 
characterized the neuroprotective effect of human α-Syn by quantifying DNA 
fragmentation. As shown in Fig. 4C, manganese exposure significantly increased DNA 
fragmentation in manganese-treated compared to untreated Vec cells, whereas α-Syn 
cells almost completely suppressed the manganese-induced DNA fragmentation at the 
24-h time point. These results, together with caspase cascade activation, clearly indicate 
that α-synuclein protects dopaminergic cells against early stages of manganese toxicity.    
Previously, we had reported that caspase-3-mediated proteolytic activation of 
PKCδ serves as a key proapoptotic effector in manganese-induced dopaminergic 
neurodegeneration (Latchoumycandane et al., 2005). In a more recent publication, we 
also showed that α-Syn downregulates PKCδ expression by negatively modulating p300- 
and NFκB-dependent transactivation in N27 dopaminergic cells (Jin et al., 2011b). 
Therefore, we next examined whether α-Syn expression attenuates manganese-induced 
proteolytic activation of PKCδ. For this, we treated α-Syn and Vec cells with 300 µM 
manganese for 6-24 h and examined PKCδ proteolytic cleavage by Western blot analysis. 
As shown in Fig. 4D, a significant proportion of the native PKCδ (72–74 kDa) protein in 
Vec cells was proteolytically cleaved to yield a 41-kDa catalytically active fragment. At 
24 h, a significant amount of the native PKCδ protein had been cleaved as evidenced by a 
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less intense native 72–74-kDa band and a concomitant increase in the catalytically active 
41-kDa cleaved fragment. In contrast, proteolytic cleavage of PKCδ in α-Syn cells was 
significantly attenuated compared to vector control cells (Fig. 4D).  More importantly, 
the manganese-induced PKCδ proteolytic cleavage band observed in Vec cells at 24 h 
was almost completely absent in α-Syn-expressing cells, suggesting that α-Syn negatively 
regulates PKCδ signaling in N27 dopaminergic cells. This finding could explain the 
neuroprotective effect of α-Syn on manganese neurotoxicity. 
We had previously demonstrated that phosphorylation of PKC at Tyr-311 
precedes caspase-3-mediated PKCδ proteolytic activation (Kaul et al., 2005b). In 
examining whether α-Syn expression alters Tyr-311 phosphorylation of PKCδ in 
response to manganese exposure, we show that manganese significantly increased the 
phosphorylation of PKCδ Tyr-311 in Vec cells, while it was markedly attenuated in α-
Syn cells (Fig. 4E). To further determine whether the attenuations, both of Tyr-311 
phosphorylation and PKCδ proteolytic activation, in α-Syn cells are reflected in 
decreased kinase activity, we determined kinase activity by an in vitro kinase assay using 
[
32
P]-ATP following PKCδ immunoprecipitation. In agreement with the observed effects 
on PKCδ proteolytic cleavage and Y311 phosphorylation, α-Syn overexpression also 
significantly reduced the Mn-induced PKCδ kinase activity (Fig. 4F-G). These findings 
suggest that α-Syn attenuates PKCδ tyrosine phosphorylation, kinase activity and its 
proteolytic cleavage during an acute manganese insult in dopaminergic cells.     
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α-Syn protects against manganese-induced dopaminergic degeneration in primary 
mesencephalic neuronal cultures  
To understand the biological relevance of the study, we extended our studies to 
include primary neuronal cultures. For this, we transfected pmaxGFP-α-Syn, encoding 
human α-Syn fused to eGFP or pmaxGFP empty vector, into cultured primary nigral cells 
obtained from mesencephalic tissues of E14-16 mouse embryos. After 18-24 h post-
transfection, cells were exposed to 50 μM manganese for 24 h and primary mesencephalic 
nigral cultures were processed for GFP immunocytochemistry. (Fig. 5A). A low dose of 
Mn (50 μM) was used because primary mesencephalic neuronal cultures are more 
sensitive to manganese than are clonal cell lines. Images were taken with a NIKON 
TE2000 microscope, and neurite lengths were analyzed using the Morphometry Analysis 
(IMA) function of MetaMorph image analysis software. Once threshold values were 
determined, at least 10 neurons were analyzed from different slides of both control and 
treatment groups of pmaxGFP-α-Syn or pmaxGFP empty vector transfected cells. The 
loss of neuronal processes was measured as an indication of manganese-induced 
neurotoxicity. Primary neurons transfected with pmaxGFP-α-Syn displayed significantly 
less manganese-induced loss of neuronal processes compared to pmaxGFP-transfected 
cells (Figs. 5A-B). Under control conditions, both transfected cells had comparable 
neuronal process lengths, suggesting that expression of α-Syn alone did not induce 
cytotoxicity in primary neuronal cells. We also assessed the functional neurotoxic 
response of dopaminergic neurons in primary dopaminergic neuronal cultures by 
dopamine uptake assay. The uptake of tritiated [
3
H] dopamine was measured in empty 
vector- or pmaxGFP-α-Syn-transfected primary cultures after manganese treatment. 
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Compared to pmaxGFP-transfected neurons, pmaxGFP-α-Syn-transected neurons 
significantly attenuated the manganese-induced decrease in dopamine uptake (Fig. 5C). 
Collectively, these results demonstrate a significant protection by human α-Syn against 
acute manganese toxicity in primary neuronal cultures. 
 
Effect of α-Syn expression on manganese uptake and metal transporters  
Since expression of human α-Syn in N27 dopaminergic cells may interfere with 
metal uptake, we measured intracellular manganese uptake by ICP-MS (Fig. 6A). 
Exposure to 300 μM manganese for 24 h resulted in about an 80-fold increase in 
intracellular manganese levels in both α-Syn (408±64 ppb) and Vec (402±44 ppb) cells. 
Similarly, intracellular manganese levels did not differ significantly between untreated 
Vec (11±0.5 ppb) and untreated α-Syn (17±1.7) cells, suggesting that α-Syn expression 
does not interfere with manganese uptake. To further demonstrate that stable transfection 
of α-Syn did not interfere with the expression of major metal ion transporters, we 
assessed the endogenous expression of transferrin (Tf) and divalent metal ion transporter 
(DMT1) (Afeseh Ngwa et al., 2009; Aschner and Aschner, 2005) in Vec and α-Syn cells. 
Immunoblot results indicate that both of these cells expressed these transporters at 
comparable levels (Fig. 6B-C), suggesting that both cells have the same ability to 
transport manganese into the cells and that α-Syn expression did not interfere with 
manganese transport to the cells.  
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Prolonged exposure to manganese promotes α-synuclein protein aggregation  
Interestingly, even though dopaminergic cells expressing human α-Syn are 
neuroprotective against acute (<24 h) manganese toxicity, we observed through 
immunocytochemistry that prolonged (>36 h) exposure induced α-Syn protein to 
aggregate in dopaminergic cells as evidenced by punctate aggregates of the protein (Fig. 
7A). Slot blot analysis (Figs. 7B-C) with the oligomeric-specific antibody A11 indicated 
significant accumulation of misfolded oligomeric proteins after 36 h and 48 h exposures 
to manganese. We further validated these observations via fluorescence microscopy using 
the newly available aggresome-specific ProteoStat dye, which showed an enhanced 
fluorescence signal of aggregated protein accumulation following prolonged manganese 
exposure (Fig. 7D). Moreover, our ProteoStat inclusion body microplate assay showed 
that α-Syn cells accumulated significantly more aggregated protein compared to Vec cells 
after both cells were exposed to manganese for an extended time (>36 h) (Fig. 7D-E). 
Collectively, these results indicate that α-Syn protects against acute manganese 
neurotoxicity, but loses its protective ability during prolonged exposure to manganese 
due to misfolding.   
 
Discussion 
Alpha-synuclein is a primary component of Lewy bodies and Lewy neurites in 
Parkinson’s pathology, but the exact physiological function of wild-type α-Syn remains 
unclear. Various hypotheses have been proposed to explain whether α-Syn is 
neuroprotective or cytotoxic. Furthermore, the role of α-Syn’s multiple metal binding 
sites has not been well studied. In this context, protein aggregation has been recognized 
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as a major mechanism of neurotoxicity in many neurodegenerative diseases, including 
PD, but the role of manganese in α-Syn aggregation is not well established. To this end, 
we developed an α-Syn-expressing dopaminergic neuronal cell model for examining the 
role of α-Syn in both acute and prolonged manganese neurotoxicity. Our results 
demonstrate for the first time that human wild-type α-Syn plays a neuroprotective role 
against manganese neurotoxicity in its early stages, but the protein becomes increasingly 
susceptible to aggregation during prolonged metal exposure.  
We provide direct evidence for the neuroprotective effect of human α-Syn in 
dopaminergic neurons during acute manganese toxicity. We observed this effect at 300 
µM manganese, a dose consistent with previously published work (Exil et al., 2014; 
Latchoumycandane et al., 2005; Martin et al., 2011). Relatively higher doses of test 
compounds are needed to elicit responses in in vitro studies due to the acute nature of the 
treatments compared to long-term animal dosing experiments. However, we were able to 
elicit a neurotoxic response with 300 µM manganese in N27 dopaminergic cells, which is 
a low dose relative to the 0.5-1 mM manganese used in hippocampal and mesencephalic 
dopaminergic neuronal cells (Tamm et al., 2008; Yoon et al., 2011). Moreover, 
manganese dosimetry vastly depends on treatment conditions, and its toxicokinetics in 
biological systems depends on its absorption, distribution, metabolism, and elimination. 
Indeed, our current understanding of the health risks posed by manganese was 
dramatically improved by mechanistic studies of manganese-induced neurotoxicity 
conducted at different doses across an array of both in vitro and in vivo model systems 
exploring a phylogenetic range of alternative animal species such as 
Caenorhabditis elegans. Depending upon the dose, duration, and route of exposure, 
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manganese concentrations can reach up to 350 µM in certain brain regions (Ingersoll et 
al., 1999), and thus the concentration used in our study was within the toxicologically 
relevant range.  It is estimated that the adequate intake of manganese for adult men and 
women is 2.3-1.8 mg/day, and children aged between 1-3 and 4-8 years have intakes of 
1.2-1.5 mg/day of manganese respectively (Aschner and Aschner, 2005). Manganese is 
essential for regulating some key enzymes (e.g. manganese superoxide dismutase) and 
many normal biological functions. A manganese deficiency could lead to severe health 
consequences such as impaired growth, skeletal abnormalities, reproductive deficits, 
ataxia in newborns and defects in lipid and carbohydrate metabolism (Aschner and 
Aschner, 2005). However, since adequate manganese is present in many common foods 
including leafy vegetables, nuts, grains and animal products, manganese deficiency is 
very rare in humans. In contrast, manganese over-exposure seems to be the major heath 
concern since it is used in the manufacture of iron and steel alloys, fertilizers, varnish, 
fungicides and livestock nutritional supplements. Human manganese exposure in well 
water, as a gasoline additive, and in welding fumes has been documented (Aschner et al., 
2009; Bowman et al., 2011; Karki et al., 2013).   
Several epidemiological studies report a significant correlation between 
manganese exposure and the risk of developing Parkinson-like symptoms (Cox, 2006; 
Goldman et al., 2005). Recent studies have shown that manganese exposure leads to the 
aggregation of α-Syn protein in cell free systems  as well as in animal models (Uversky et 
al., 2001; Verina et al., 2013), providing direct experimental evidence for a close 
relationship between manganese and the proteins implicated in PD. In our current study, 
dopaminergic cells expressing human wild-type α-Syn exhibited significantly lower 
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apoptotic cell death compared to vector control N27 cells upon acute manganese toxicity. 
Our α-Syn-expressing N27 cells had roughly the same levels of α-Syn protein expression 
as found in rat midbrain tissues, suggesting that human α-Syn was being expressed in 
these cells at physiological expression levels. To further characterize the mechanism 
underlying the neuroprotective effect of α-Syn against manganese-induced apoptotic cell 
death, and because manganese is known to impair mitochondrial function (Gunter et al., 
2009; Latchoumycandane et al., 2005), we systematically examined the mitochondria-
dependent apoptotic signaling events. Interestingly, α-Syn does not hamper the cells’ 
ability to produce ROS when exposed to manganese (Fig. 3A). Although α-Syn has been 
shown to act as an antioxidant in preventing lipid oxidation in membranes containing 
phospholipids with unsaturated fatty acids in cell-free systems (Zhu et al., 2006), in our 
study α-Syn does not possess antioxidant properties. Instead, we found a significant 
attenuation of cytochrome c release to cytosol from the mitochondrial inner-membrane in 
α-Syn-expressing cells, suggesting that α-Syn interferes with the process of cytochrome c 
release during early phases of manganese neurotoxicity. It is possible that a previously 
described (Elkon et al., 2002) protein-protein interaction between α-Syn and the 
mitochondrial complex IV enzyme, cytochrome c oxidase (COX), contributes to the 
neuroprotection of α-Syn at the mitochondrial level, attenuating the downstream 
apoptotic cascade involving initiator caspase-9 and effector caspase-3 activity, which are 
early and essential steps in the manganese-triggered apoptotic signaling pathway 
(Latchoumycandane et al., 2005).   
As previously demonstrated, PKCδ is an oxidative stress-sensitive kinase that 
plays a causal role in apoptotic cell death in neuronal cells (Afeseh Ngwa et al., 2009; 
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Harischandra et al., 2014; Kaul et al., 2003). In our current study, we observed a time-
dependent proteolytic cleavage of PKCδ in vector control cells but not in α-Syn-
expressing cells, indicating that α-Syn interferes with PKCδ by reducing its proteolytic 
cleavage and kinase activity, thereby protecting cells from manganese-induced toxicity. 
Recently, we reported that α-Syn modulates PKCδ expression in dopaminergic neurons 
by reducing p300 histone acetyltransferase activity (Jin et al., 2011b). The observed 
downregulation of PKCδ in α-Syn cells (Fig. 4D) is consistent with our previously 
reported in vitro and in vivo data (Jin et al., 2011b) and may also contribute to the 
neuroprotective role of α-Syn.  As shown in Figs. 2A, 2C and 7C, the neuroprotective 
response of α-Syn declined over prolonged manganese exposures. The observed 
neuroprotective effect in our study is not due to any possible interference with 
intracellular manganese transport by α-Syn because intracellular concentrations of 
manganese and the expression levels of the metal transporters DMT and Tf proteins did 
not differ significantly between vector control and α-Syn-expressing N27 cells.   
In this study, the neuroprotective effect of wild-type human α-Syn protein was 
also evaluated by its ectopic expression in mouse primary mesencephalic cells.  
Manganese-induced neurotoxicity in α-Syn expressing cells was attenuated as evidenced 
by longer and healthier neurites compared to those of vector-transfected neurons. Since 
the cell bodies of neurons remained intact while neurites shrank in response to 
manganese exposure, our results show that α-Syn expression retained primary neuronal 
morphology after manganese-induced cytotoxicity. A functional dopamine uptake assay 
further validated that wild-type α-Syn rescues primary dopaminergic cells from 
manganese toxicity.  
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Alpha-Syn protein misfolding and accumulation have been recognized as major 
pathological features of PD. Our immunocytochemistry data indicate intracellular protein 
aggregates immunoreactive to α-Syn during prolonged manganese exposure in 
dopaminergic neuronal cells (Fig. 7A). The slot blot analysis indicates increased 
accumulation of misfolded protein in α-Syn cells at 36 and 48 h, but not at 24 h of 
manganese exposure (Fig. 7B). These observations were validated using the ProteoStat 
aggresome detection kit (Enzo) and the ProteoStat inclusion body kit (Enzo) to indicate 
the accumulation of aggregated proteins in α-Syn cells compared to Vec cells after 
prolonged manganese exposure. These protein aggregates may be relevant to Lewy body 
pathology seen in postmortem PD brains. Whether these aggregates are cytotoxic or 
cytoprotective to neuronal cells remains debatable. Nevertheless, the loss of α-Syn’s 
neuroprotective effect clearly correlates with the rate of formation of protein aggregates 
in our study. Alpha-Synuclein has several metal binding sites (Fig. 1A) (Uversky et al., 
2001), and binding to certain divalent metals, including manganese, causes α-Syn 
aggregation in cell-free in vitro experiments (Uversky et al., 2001). Moreover, the central 
hydrophobic domain (residues 66-95), also known as the non-amyloid-β component 
(NAC) domain, is highly amyloidogenic and appears to be essential for α-Syn 
aggregation (Auluck et al., 2010). Specifically, a GAV motif (residues 66-74) within this 
region has been identified as the critical core for fibrillization and cytotoxicity of α-Syn. 
Our results support the idea that α-Syn initially protects against manganese-induced 
neurotoxicity by reducing mitochondria-dependent apoptotic signaling, whereas 
prolonged exposure to manganese significantly alters the stability of α-Syn protein, 
increasing the amount of aggregated α-Syn protein.  
110 
 
In conclusion, we demonstrate that physiological levels of human wild-type α-Syn 
protein attenuate manganese-induced dopaminergic neuronal degeneration in cell culture 
models at early stages of manganese toxicity. However, prolonged manganese exposure 
promotes α-Syn aggregation and dampens its neuroprotective effect. These findings may 
have important implications in our understanding of the physiological functions of α-Syn 
protein as well as the pathogenesis of environmentally-linked Parkinson’s disease. 
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Figure 1.  Generation of N27 cells stably expressing human wild-type α-synuclein 
protein. (A) Structure of α-Syn indicating metal binding sites. (B) Stable expression of 
α-Syn was determined by Western blot analysis. A 19-kDa band corresponding to the 
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molecular mass of human α-syn was detected in α-Syn-expressing cells, whereas no 
expression appeared in vector cells. (C) Immunocytochemical analysis depicting stable 
expression of wild-type human α-Syn protein in N27 dopaminergic cells. Alpha-Syn-
expressing cells exhibit strong ubiquitous expression of α-Syn, whereas vector cells 
showed no detectable α-Syn immunoreactivity. Magnification, 40 X. Scale bar, 20 μm. 
 
 
Figure 2. Human wild-type α-synuclein expression attenuates manganese-induced 
cytotoxicity. (A) α-Syn and Vector cells were treated with 300 μM manganese, and 
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neurotoxicity was assessed at various time points (3, 6, 9, 12, 24 and 36 h) using SYTOX 
Green cytotoxicity assays. Cell death was expressed as a percentage of the time-matched 
control groups. Results are represented by the mean ± SEM from at least six samples in 
each treatment group (**p<0.01, ***p<0.001). (B) In situ measurement of cell death by 
SYTOX Green dye during Mn exposure. Alpha-Syn and vector cells were treated with 
300 μM manganese for 24 h. After treatment, SYTOX Green-positive cells were viewed 
via fluorescence microscopy. Phase-contrast (lower panels) and Sytox FITC fluorescence 
(upper panels) images were captured on random fields to compare cell death between 
manganese -treated α-Syn and vector cells. Magnification, 20 X. Scale bar, 50 μm. (C) 
Determination of change in percent protection (Δ protection) as determined  by 
subtracting the percentage of cell death of α-Syn cells from the percentage of cell death 
of Vec cells at 24, 36 and 48-h time points (***p < 0.001 vs 24-h time point). 
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Figure 3. Effect of α-synuclein expression on oxidative stress induced by manganese 
exposure and attenuation of manganese-induced cytochrome c release. (A) 
Manganese induced a time-dependent ROS generation in α-Syn and vector cells. The 
measurements were conducted in a 96-well plate containing the α-Syn and Vec cells 
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exposed to 300 μM manganese for up to 90 min. ROS generation was measured at 15, 30, 
45, 60 and 90-min time points during manganese treatment in HBSS, co-treated with 10 
μM H2DCF-DA reagent.  Both α-Syn and vector cells generated ROS in a time-
dependent manner and ROS generation did not differ significantly between α-Syn and 
Vec cells. (B) Mitochondrial release of cytochrome c in manganese-treated α-Syn and 
Vec cells. The cells were treated with 300 μM manganese for 6 h, cytosolic fractions 
were isolated, and cytochrome c was measured by Western blot. To confirm equal 
protein-loading in each lane, the membranes were reprobed with β-actin antibody. (C) 
Quantification of cytosolic cytochrome c band intensities reveals a reduced release of 
mitochondrial cytochrome c in α-Syn-expressing cells when compared to vector-treated 
cells. Each group represented by the mean ± SEM from at least four separate 
measurements (*p < 0.05 vs control). 
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Figure 4. Suppression of manganese-induced caspase-9 and caspase-3 activations, 
PKCδ proteolytic activation and DNA fragmentation. Exposure to 300 μM 
manganese induced (A) caspase-3 and (B) caspase-9 enzyme activities up to 24 h in a 
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time-dependent manner in Vec cells compared to α-Syn cells. Caspase-9 activation 
precedes caspase-3 activation, peaking at 12 h or later. Results represented as mean ± 
SEM from at least six samples in each treatment group (** p<0.01, and *** p<0.001). (C) 
Quantitative analysis of DNA fragmentation by ELISA after treating α-Syn and Vec cells 
with 300 μM manganese for periods of 24 h. Data represented as mean ± SEM from three 
separate observations, and * p < 0.05 or ** p < 0.01 represents significant differences 
between the Vec and α-Syn cells treated with 300 μM manganese, or between Vec-
treated and Vec-untreated control cells. (D) A time-dependent increase of PKCδ 
proteolytic cleavage was observed over 24 h in vector control cells treated with 300 μM 
manganese, whereas similarly treated α-Syn cells showed minimal amounts of PKCδ 
proteolytic cleavage. (E) Western blot analysis of PKCδ phosphorylation (Tyr311) after 
manganese insult.  (F-G) PKCδ in vitro kinase activities 24 h after 300 μM manganese 
treatment. To confirm equal protein-loading in each lane, the membranes were reprobed 
with β-actin antibody. Results were compiled from at least three individual experiments.  
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Figure 5. Neuroprotective effect of α-synuclein in manganese-induced dopaminergic 
degeneration in primary mesencephalic neuronal cultures. Mouse primary 
mesencephalic neuronal cultures were transfected with pmaxGFP_EV or pmaxGFP-α-
Syn plasmids and treated with 50 μM manganese for 24 h. (A) GFP immunocytochemical 
analysis of neuronal morphology. Magnification, 60 X. Scale bar, 20 μm. (B) 
Measurements of neurite length as an indication of α-Syn neuroprotection. (C) Neuronal 
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CHAfunction after manganese treatment was assessed by dopamine uptake assay. Each 
group represented as mean ± SEM from at least 10 measurements from two separate 
experiments (* p < 0.05 ,**
 
p < 0.01 and , ***
 
p < 0.001). 
 
Figure 6. Determination of intracellular manganese concentration and expression of 
major ion regulatory transporters in the cells. (A) Cells were treated with 300 μM 
manganese for 24 h, and then intracellular manganese concentrations were measured 
using ICP-MS assays. Each group represented as mean ± SEM from at least three ICP-
MS measurements. (B-C) Representative images of Western blot analysis of divalent 
metal ion transporter (DMT1) and Transferrin (Tf) protein expression. 
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Figure 7. Prolonged manganese exposure induces α-synuclein aggregation. 
(A) Immunocytochemical analysis of α-Syn immunoreactive aggregates after exposure to 
300 μM manganese for 36 h or more. Magnification, 60 X. Scale bar, 20 μm. (B) 
Representative slot blot analysis with the oligomeric protein specific antibody (A11), 
indicating a time-dependent accumulation of the misfolded protein after manganese 
exposure. (C) Quantification of slot blot band intensities reveals a time-dependent 
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accumulation of aggregated protein in α-Syn-expressing cells. Each group represented by 
the mean ± SEM from at least four separate measurements (*p < 0.05 vs control, **p < 
0.01 vs control). (D) Representative fluorescence images of aggresome dye after 
exposing α-Syn cells to manganese. (E) Quantification of fluorescence intensities after 
manganese exposure in α-Syn and Vec cells. Magnification, 60 X. Scale bar, 20 μm. Data 
obtained from the ProteoStat inclusion assay kit. Each group represented as mean ± SEM 
from at least eight measurements. 
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Abstract  
The aggregation of α-synuclein (αSyn) is considered a key pathophysiological feature of 
a group of neurodegenerative disorders such as Parkinson’s disease (PD), multiple system 
atrophy (MSA), and diffuse Lewy body disease, which collectively are termed 
synucleinopathies. Recent studies also suggest that a prion-like cell-to-cell transfer of 
misfolded αSyn contributes to the spreading of αSyn pathology in MSA. The biological 
mechanisms underlying the propagation of the disease with respect to environmental 
neurotoxic chemical exposures, however, are not well understood. Considering the role of 
the divalent metal manganese (Mn) in synucleinopathy-related neurological disorders, we 
characterized its effect on αSyn misfolding and transmission in experimental 
parkinsonian models. Using dopaminergic cell line stably expressing wild-type human 
αSyn, we have shown that αSyn secreted into extracellular media following Mn exposure 
through exosomes. In functional studies, we demonstrated that exosomes released during 
Mn treatment can endocytosis via caveolae to microglial cells and induce 
neuroinflammatory responses microglial cultures and neurodegeneration in differentiated 
human dopaminergic cells (LUHMES) through the activation of caspase-3 signaling. 
Furthermore, using the BiFC assay we have shown that Mn elevates α-syn cell-to-cell 
transmission and results in dopaminergic neurotoxicity in a mouse model of Mn 
neurotoxicity. Interestingly, we also reported that welders exposed to Mn have higher 
misfolded αSyn content in their serum exosomes and showed for the first time that 
stereotaxic delivery of αSyn-containing exosomes isolated from Mn-treated αSyn-
expressing cells into the striatum can initiate parkinsonian-like pathological features in 
mice. Collectively, these results demonstrate that Mn exposure promotes αSyn secretion 
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via exosomal vesicles, which subsequently evoke pro-inflammatory and 
neurodegenerative responses in both cell culture and animal models.  
Keywords: Manganese (Mn), α-synuclein, exosome, protein aggregation, prion-like 
Introduction  
There are a number of neurodegenerative diseases marked by the presence of cytoplasmic 
inclusions called Lewy bodies and neurites composed of α-synuclein (αSyn) and 
ubiquitin. Together, they constitute synucleinopathy-related disorders. Among them, 
Parkinson’s disease is the most common, marked by motor dysfunction and progressive 
degeneration of dopaminergic neurons projecting from the substantia nigra pars compacta 
(SNpc) to the striatum and the presence of Lewy bodies in dopaminergic neurons. 
Multiple system atrophy (MSA) and diffuse Lewy body disease (DLB) also belong to this 
group of disorders, with Lewy bodies found primarily in glial cells of the basal ganglia in 
MSA and in more diffuse areas of the cortex in DLB.   While the physiological functions 
of αSyn are poorly understood, evidence suggests that the accumulation of aberrant αSyn 
species exerts intracellular toxic effects in the central nervous system (CNS). The idea 
that αSyn can pathologically propagate throughout the CNS recently gained much 
attention with the finding of αSyn species in human plasma and CSF (El-Agnaf et al., 
2003; Kordower et al., 2008) and host-to-graft propagation of αSyn-positive Lewy bodies 
in fetal ventral mesencephalic and embryonic nigral neurons transplanted in human PD 
patients (Kordower et al., 2008; Li et al., 2008). In agreement to this, recent studies have 
suggested that transcellular transmission of αSyn aggregates is associated with the 
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progression of PD (Bae et al., 2014; Danzer et al., 2012; Lee et al., 2010) and MSA 
(Prusiner et al., 2015). 
 
Growing evidence indicates that extracellular αSyn induces pathogenic actions by 
activating neuroinflammatory and neurodegenerative responses in vitro(Emmanouilidou 
et al., 2010; Su et al., 2008). The nature of the secretory mechanisms of αSyn remains 
elusive; however, recent studies have shown that neurons can secrete αSyn into the 
extracellular milieu via a brefeldin A-insensitive pathway involving exosome vesicles 
(Danzer et al., 2012; Lee et al., 2005). Exosomes are nano-scale vesicles generated within 
the endosomal system and secreted upon fusion of multivesicular bodies with the plasma 
membrane. Originally exosomes were thought to be molecular “trash bags”. However, it 
was recently discovered that exosomes contain miRNAs and proteins and mediate cell-to-
cell communications, which could potentially lead to therapeutic and biomarker 
discoveries. 
  
Moreover, emerging evidence from many neurodegenerative disorders including 
synucleinopathy-related disorders  now has expanded the notion of cell-to-cell 
transmission of misfolded proteins as a common mechanism for the onset and 
progression of the disease (Luk et al., 2012a; Luk et al., 2009; Volpicelli-Daley et al., 
2014; Volpicelli-Daley et al., 2011). Although the exact mechanisms for protein 
aggregate spreading in the CNS still largely remain unknown, several models including 
exocytosis, cell injury, receptor-mediated endocytosis, tunneling nanotubes, and 
exosomal transmission have been proposed(Lee et al., 2010). Although genetic 
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predisposition is an important risk factor in many familial cases of parkinsonian 
syndromes, environmental exposure to certain metals, herbicides, or insecticides 
augments the susceptibility to mitochondrial dysfunction and the progressive nature of 
these diseases. Specifically, divalent metal Mn is used widely in consumer and 
agricultural products. In trace amounts, Mn is essential for human health, but 
environmental exposure to high doses of Mn results in manganism, a neurodegenerative 
movement disorder sharing many parkinsonian features although it may not represent 
clinical PD because of the lack of the classic response to levodopa (Koller et al., 2004) . 
Yet, despite its prevalence and thus potential risk to human health and the development 
of neurodegenerative disorders, the mechanisms by which Mn exerts its neurotoxic 
effects and its role in the prion-like propagation of αSyn aggregates are not well studied 
thus far.  
 
Hence, in this study we assess the effects of Mn as an environmental factor on αSyn 
aggregation, secretion, and cell-to-cell transmission. To elucidate the mechanism of Mn-
induced αSyn release, we followed a systematic approach from in vitro to ex vivo to in 
vivo experimental models to better understand the role of exosomes in cell-to-cell 
transmission of misfolded αSyn protein. We show that Mn exposure promotes the 
extracellular secretion of αSyn via exosomal vesicles, which subsequently evoke pro-
inflammatory and neurodegenerative responses in both cell culture and animal models.   
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Materials and Methods 
Chemicals and Reagents 
All chemicals were purchased from Sigma-Aldrich and reagents related to cell cultures 
were obtained from Invitrogen unless otherwise specified. 
Cell cultures and stable expression of αSyn 
For αSyn release and exosome isolation experiments, we created a GFP-tagged αSyn 
stably-expressing MN9D dopaminergic cell line. Expression plasmids encoding human 
full-length αSyn-pMAXGFP and control pMAXGFP (Lonza) were transfected into 
MN9D cells using Lipofectamine 2000 reagent and grown in DMEM (D5648; Sigma) 
supplemented with 50 IU/ml penicillin, 50 μg/ml streptomycin, and 10% fetal bovine 
serum (FBS). For stable transfection, MN9D cells were selected after culturing in 400 
μg/ml of geneticin for one week post-transfection and then maintained in media 
supplemented with 200 μg/ml of geneticin. GFP-positive αSyn-expressing 
(MN9D_SynGFP) and vector control (MN9D_EVGFP) cells were selected further by 
FACSAria III (BD Bioscience) high-speed sorting flow cytometer to obtain 
homogeneously transgene-expressing cell populations.  
Primary murine microglial cells were isolated from primary mixed cultures prepared 
from C57BL/6 mouse pups, postnatal days P0 to P1, using a column-free magnetic 
separation method as previously described (Gordon et al., 2011). Exosome-induced 
neurodegeneration experiments were carried out with primary mesencephalic cultures 
and differentiated Lund human mesencephalic (LUHMES) cells. Primary mesencephalic 
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neuronal cultures and LUHMES cells were grown and differentiated as previously 
described (Ay et al., 2015; Jin et al., 2014; Scholz et al., 2011).  
The immortalized wild-type (C57BL/6) murine microglial cell (WTMC) line with 
morphology and surface marker expression highly similar to primary murine microglia 
was a kind gift from Dr. Douglas Golenbock at the University of Massachusetts Medical 
School, Worcester, MA (Halle et al., 2008). These cells were grown in DMEM medium 
supplemented with 50 IU/ml penicillin, 50 μg/ml streptomycin, and 10% fetal bovine 
serum (FBS) and exosome stimulation done in 2% DMEM. WTMC used for exosome-
induced neuroinflammation experiments and generation of Caveolin-1 and Clathrin 
knockdown cells using the CRISPR/Cas9 nuclease RNA-guided genome editing system. 
The lentivirus-based CRISPR/Cas9 KO plasmids, pLV-U6g-EPCG-Cav1 and pLV-U6g-
EPCG-Cltc with the Caveolin-1 and Clathrin gRNA target sequences 
GTTGAGATGCTTGGGGTCGCGG and TACTGAAGCCAATGTTTGCTGG, 
respectively, were purchased from Sigma-Aldrich. To make lentivirus, the lenti-
CRISPR/Cas9 Cav1 and C1tc KO plasmids and control plasmid were transfected into 
293FT cells using the Mission Lentiviral Packaging Mix from Sigma-Aldrich according 
to manufacturer’s instructions. The lentivirus was harvested 48 h post-transfection and 
added to the microglial cell line at an MOI of 100 to knockdown Caveolin-1 and Clathrin 
expression.  
MTT assays 
The 3-(4,5-dimethylthiazol-3-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay has 
been widely used to assess the median lethal dose (LC50) and cell viability by measuring 
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mitochondrial dehydrogenase enzymes that cleave the tetrazolium ring to produce 
formazan (Latchoumycandane et al., 2005). In this study, we used the MTT assay to 
determine the LC50 of Mn for MN9D cells. Briefly, 20,000 MN9D cells were seeded on a 
96-well microplate, allowed to adhere for 16 h, and then treated for 24 h with Mn (0 to 10 
mM) in serum-free DMEM media. Following the treatment, the cells were washed with 
warm PBS and then incubated with 200 μl 0.25% (w/v) MTT in serum-free DMEM for 2 
h at 37 °C. The supernatant was removed and MTT crystals were solubilized in 200 μl 
dimethyl sulfoxide (DMSO). Mitochondrial activity was measured with the SpectraMax 
spectrophotometer (Molecular Devices Corporation) at 570 nm with the reference 
wavelength at 630 nm. 
Western and Slot blotting  
Whole cell lysates or exosome lysates were prepared using modified RIPA buffer 
containing protease and phosphatase inhibitor cocktail (Thermo Scientific, Waltham, 
MA), as described previously (Harischandra et al., 2015; Harischandra et al., 2014). For 
αSyn release experiments, MN9D_SynGFP and MN9D_EVGFP cells were treated in serum-
free medium and spiked with 10μg/ml BSA, and then the media was collected and 
centrifuged for 5 min at 3000 x g to remove any dislodged cells or cell debris. The 
conditioned media were concentrated using 5000 MWCO Vivaspin-20 spin columns (GE 
Lifescience), and then protein concentrations were determined with the Bradford protein 
assay kit (Bio-Rad). Cell lysates containing equal amounts of protein were separated on a 
12-15% SDS-polyacrylamide gel. After separation, proteins were electro-blotted onto a 
nitrocellulose membrane and nonspecific binding sites were blocked by treating with LI-
134 
 
COR blocking buffer. Primary antibodies for Syn-1 (BD Bioscience), Flotillin-1 (BD 
Bioscience), BSA (Invitrogen), LDHA (Cell Signalling), Aip1/Alix (Millipore), IBA-1 
(Wako), iNOS (Santa Cruz), and β-actin (Sigma) were used to blot the membranes.  
The formation of oligomeric proteins following Mn exposure was analyzed with a slot 
blot apparatus (Bio-Dot, Bio-Rad) using the antibody against protein Oligomers (A11) 
(Invitrogen). Following protein adsorption, membranes were blocked with 5% BSA and 
incubated overnight with the A11 antibody. Membranes then were developed with 
IR800-conjugated anti-rabbit or Alexa Fluor 680-conjugated anti-mouse secondary 
antibody for 1 h at room temperature. Western and slot blot images were captured with 
the Odyssey IR Imaging system (LI-COR) and data were analyzed using Odyssey 2.0 
software. 
Immunocytochemistry and Immunohistochemistry 
For immunocytochemistry, MN9D cells and microglia cells were plated on 50 μg/mL 
poly-D-lysine-coated 12-mm glass coverslips and treatments were done as described. 
LUHMES cells were plated on coverslips pre-coated with 50 μg/mL poly-l-ornithine 
(Sigma-Aldrich) overnight, washed twice with cell culture grade water (Invitrogen) and 
then incubated with 1 μg/mL fibronectin (Sigma-Aldrich) overnight. After treatments, 
cells were washed with PBS and incubated in 4% paraformaldehyde for 30 min at room 
temperature. After fixing, the cells were washed with PBS and incubated in blocking 
agent (2% BSA, 0.05% Tween-20, and 0.5% Triton X-100 in PBS) for 45 min. Cells then 
were incubated with antibodies against human αSyn (Syn 211; Santa Cruz, 1:500), GFP 
(Abcam 1:2000), and IBA-1 (Wako, 1:500) overnight at 4°C or the cytoskeleton marker 
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Phalloidin (Alexa Fluor 647 phalloidin, Invitrogen) for 30 min at room temperature. After 
primary incubation, the cells were washed and incubated in the dark for 90 min with 
Alexa-488 and -555 dye-conjugated secondary antibodies (Invitrogen, 1:1000). Hoechst 
44432 was used as a nuclear stain and the coverslips were then mounted on glass slides 
and viewed with 63× and 43× oil objectives using a Leica DMIRE2 confocal microscope. 
Photomicrographs were further processed using Imaris software to analyze the Z-stack 
images for exosome internalization. Using 3D surface reconstruction, we generated 
surface topology images using the maximum intensity projection (MIP) image. 
For immunohistochemistry studies, fixed brains embedded in optimal cutting temperature 
(OCT) compound were sectioned at 30 μm using a Cryostat (CryoStar NX70, Thermo 
Scientific). Free-floating sections were processed for immunohistochemical analysis as 
described in our previous publications (Ghosh et al., 2013; Panicker et al., 2015) using 
antibodies against tyrosine hydroxylase (TH) (clone LNC1; Millipore, 1:1200). 
Diaminobenzidine (DAB) immunostaining was performed on substantia nigra sections as 
described previously (Ghosh et al., 2010; Ghosh et al., 2013; Panicker et al., 2015) for 
stereologically counting of TH+ neurons. Briefly, 30-μm sections were incubated with 
anti-TH antibody (clone LNC1; Millipore, 1:1200) overnight at 4°C. Then sections were 
incubated with biotinylated anti-rabbit secondary antibody (1:300, Vector Labs) for 1 h at 
room temperature followed by incubation with avidin peroxidase (Vectastain ABC Elite 
kit, Burlingame, CA). Immunolabeling was visualized by exposure to 0.5 mg/ml 3,3′ 
diaminobenzidine (DAB), 2.5 mg/ml nickel ammonium sulfate and 0.03% H2O2 followed 
by incubation with hematoxylin nuclear counterstain (Vector Hematoxylin QS, H-3404). 
Sections were mounted on charged glass slides, dehydrated to xylene and coverslipped 
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with DPX mounting medium (Sigma, Cat# 44581). Total numbers of TH-stained neurons 
in the SN were counted stereologically with Stereo Investigator software 
(MicroBrightField, Inc., Williston, VT) using an optical fractionator. For pS129 αSyn 
studies, 7-μm thick paraffin-embedded sections of mouse tissues were deparaffinized and 
subjected to antigen retrieval using formic acid treatment followed by 0.05% trypsin 
treatment. Sections were then incubated with blocking reagent (10% normal goat serum, 
2% BSA, and 0.5% Triton X-100 in PBS) for 60 min before being incubated with mouse 
monoclonal antibody against S129-phosphorylated human αSyn (Clone No. pSyn #64, 
Wako, 1:2000).  
Exosome isolation 
Cell-produced exosomes were isolated using the ExoQuickTC (System Biosciences) 
exosome precipitation reagent or were purified by differential ultracentrifugation via 
slight modification of a process described by Emmanouilidou and collegues 
{Emmanouilidou, 2010 #7} . Briefly, MN9D_SynGFP and MN9D_EVGFP cells at 70-80% 
confluency were treated with or without 300 µM Mn in exosome-depleted medium 
containing 10% FBS for 24 h. After treatment, cell culture supernatant was collected and 
spun at 300 x g for 10 min to remove cells and 10,000 x g for 15 min to exclude cell 
debris from the supernatant. The resulting media then was passed through a 0.2-µm 
syringe filter (Millipore) to remove any remaining particles or cell debris, and the filtrate 
was centrifuged at 100,000 x g for 90 min using a Beckman Optima L-100 XP 
ultracentrifuge. The pellet containing exosomes was washed once with cold PBS and 
centrifuged again at 100,000 x g for 90 min using a Beckman optima MAX 
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ultracentrifuge. Exosome pellets were resuspended in 50 μl of RIPA buffer for Western 
blot analysis, or when treating primary microglia cells, they were resuspended in 150 μl 
of DMEM-F12. Total serum exosomes from control and welder subjects were isolated 
using ExoQuick (System Biosciences) reagent following the manufactures’ 
recommended protocol.  
Nitric oxide and cytokine detection in microglia 
Quantification of nitric oxide production by microglia cells upon exosome treatment was 
measured indirectly by quantification of nitrite in the supernatant using the Griess reagent 
(Sigma Aldrich). Microglia plated at 70,000 cells/well were treated for 24 h with 
exosomes (1:100) or pretreated with endocytosis inhibitors for one hour and co-treated 
with exosomes for 24 h. At the end of the treatment, equal volumes of cell media and 
Griess reagent were added to a 96-well plate along with a sodium nitrite standard curve, 
and absorbance at 540nm was measured on SpectraMax microplate reader. The 
supernatant was used to determine extracellular cytokine levels using the Luminex bead-
based immunoassay system and recombinant standards for IL-6, IL-12, IL-10, TNF-α, 
and IL-1β (Gordon et al., 2011). 
Nanoparticle tracking analysis (NTA) 
Ultracentrifuged or ExoQuick/TC-precipitated exosome samples were used for NTA, as 
previously described (Soo et al., 2012). Briefly, isolated exosomes were resuspended in 
500-1000 µL PBS, from which approximately 300 μL was loaded into the sample 
chamber of an LM10 unit (Nanosight, Amesbury, UK) using a disposable syringe. 
Sample durations of 30-60 sec per sample were analyzed with NTA 2.3 software 
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(Nanosight). Samples containing higher numbers of exosomes were diluted before the 
analysis and their relative concentrations then were calculated according to the dilution 
factor. 
Transmission electron microscopy (TEM)  
Purified exosomes were resuspended in 200 µl PBS, 20 µL of each sample was mixed 
with uranyl acetate 2% (w/v) and incubated for 5 min, and then 5 µl were applied to 
carbon-coated copper grids. Images were taken using a JEOL 2100 200 kV scanning and 
transmission electron microscope (STEM) with a Thermo Fisher Noran System 6 
elemental analysis system. TEM was operated at 80 kV and images were obtained at 
18000-20000 x magnification.  
Quantification of αSyn in exosomes 
Concentrations of αSyn in cell-derived exosomes and human exosomes isolated from 
serum were determined by using human αSyn ELISA kits (Invitrogen, Cat# KHB0061 
and Covance, Cat# SIG-38974), as previously described (Wennstrom et al., 2012). 
Briefly, exosomes were isolated using ultracentrifugation or by ExoQuick reagent and 
lysed using RIPA buffer following manufacturer’s instructions.    
Small RNA isolation and characterization 
For detection of RNA species in exosome samples isolated from Mn- and vehicle- 
stimulated MN9D_SynGFP and MN9D_EVGFP cells, we used the mirVana (Invitrogen, 
Cat# KHB0061) miRNA and small RNA isolation kit according to the manufacturer’s 
protocol. The quality, yield, and size of exosomal small RNAs were analyzed using the 
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Agilent 2100 Bioanalyzer (Agilent Technologies, Foster City, CA) with the Agilent RNA 
6000 Nano kit as described previously (Zamanian et al., 2015).   
Alpha-synuclein fibril formation assays  
For the αSyn amyloid fibrillization assay, purified recombinant non-aggregated human 
αSyn was used as a substrate and exosomes isolated from welder and control serum 
samples were used as a seed. The assay also consisted of blank (PBS) wells as a negative 
control and exogenously produced recombinant αSyn fibrils as a positive control. Each 
sample was run in 4 replicates and the representative graph shown for welders and 
controls consists of average fluorescence from all the welders and controls with 4 
replicates for each sample. The αSyn fibrillization assay was performed in a 100 μl 
reaction mixture consisting of 5 µl of 100-fold diluted serum exosomes in 0.05% SDS in 
PBS, 0.2 mg/ml recombinant αSyn, 300 mM NaCl, 10 µM EDTA, and 20 µM 
Thioflavin-T in a BMG Clariostar plate reader using Nunc™ MicroWell™ 96-well 
optical-bottom plates. The reaction was carried out at 37
o
C with alternate cycles of shake 
and rest every other minute and readings were taken every 30 minutes for a 60-hour 
period.  
Animal studies 
Male C57BL/6 mice (8- to 12-week-old) were purchased from Charles River 
Laboratories and used for all mouse experiments. Human αSyn A53T overexpressing rats 
(model number 10680) and non-carrier littermate control Sprague Dawley rats were 
obtained from Taconic Biosciences (Germantown, NY). Rodents were housed on a 12-h 
light/dark cycle with ad libitum access to food and water. Iowa State University’s (ISU) 
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laboratory animal facility is fully accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC), and all procedures involving 
animal handling were approved by the Institutional Animal Care and Use Committee 
(IACUC) at ISU. For unilateral viral transduction experiments, we injected a total volume 
of 2 μl of virus at a rate of 0.2 μl/min using a 10-μl Hamilton syringe with a 30-gauge 
needle, which was guided using the Angle 2 stereotaxic apparatus (Leica Biosystems, St. 
Louis, MO) to target the SN with the use of the following coordinates: AP -3.30, ML -
1.20 and DV -4.60 (mm from bregma). For co-transduction of AAV_V1S  and AAV_
SV2 viruses, 1 μl of pAAV-CBA-Venus1-Synuclein-WPRE (AAV_V1S) virus (titer 8.3 
x 10
12
 viral genome/ml) and 1 μl of pAAV-CBA-Synuclein-Venus2-WPRE 
(AAV_SV2) virus  (titer 8.7 x 10
12
 viral genome/ml) were injected. For the venusYFP 
transduction group, 2 μl of pAAV-CBA-Venus virus (titer 1 x 1012 viral genome/ml) was 
injected. Four weeks post-injection, the AAV_V1S/AAV_SV2 co-transduction group 
received either 15 mg/kg body weight/day Mn (as MnCl2) for 30 days or an equal volume 
of vehicle (water) via oral gavage to assess the impact of environmental Mn exposure on 
αSyn cell-to-cell transmission. To control for the unintended effect of stereotaxic 
injections on animals, we also included a group of animals receiving 15 mg/kg Mn or an 
equal volume of vehicle similar to the AAV co-transduction group but without 
stereotaxic injection. To evaluate the effect of Mn on serum exosomes numbers, human 
αSyn A53T overexpressing and non-transgenic rats were exposed to a similar Mn 
treatment paradigm as in mice studies. This Mn dose regimen was chosen based on 
previous studies in humans and animals (Crossgrove and Zheng, 2004; Li et al., 2006; 
Zheng et al., 2000). 
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For stereotaxic delivery of exosomes to the striatum, we injected a total volume of 3 μl of 
exosomes (3.6 x 10
5
 particle numbers) isolated from Mn- or vehicle-stimulated 
MN9D_SynGFP and MN9D_EVGFP cells. Twelve weeks post-injection, animals were 
subjected to a battery of behavior tests, including an open-field test and the amphetamine-
induced rotational test. Mice then were sacrificed and their tissues collected for 
biochemical and neurochemical analyses, or they were transcardially perfused for 
histological procedures. 
Behavioral measurements 
The exploratory locomotor activity was measured using the VersaMax open-field 
apparatus (Accuscan Instruments, Columbus, OH) as described previously (Ghosh et al., 
2010) and the following indices were monitored for 10 min: rearing activity (labeled as 
vertical activity), horizontal activity, total distance traveled and total movement time. 
Motor coordination and motor learning were tested by measuring the latency to fall from 
a 3-cm diameter rod rotating at a constant 20 rpm for 20 min (Rota-rod, 
Accuscan Instruments). Each mouse was subjected to 5 trials separated by 5- to 7-min 
intervals to eliminate stress and fatigue. The rotameter test was used to assess the effects 
of unilateral exosome injection-induced lesions. At 90 days post-exosome injection, mice 
received 5 mg/kg amphetamine (D-amphetamine sulphate, Sigma) intraperitoneally. Then 
after 20 min, each mouse was placed in a cylindrical bowl within which amphetamine-
induced ipsilateral rotation was recorded via a video-camera coupled to automated 
tracking software (ANY-maze, Stoelting).  Rotational scores were used as an estimate of 
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the extent of lesions with data expressed as the average numbers of ipsilateral rotation per 
20-min period.  
Human studies  
Eighty-one subjects were recruited initially from unions in central PA, USA, and local 
communities. Welders were defined as subjects who had welded at any point in their 
lifetime, and controls as those without history of welding. All subjects were male, 
answered negatively for past Parkinson’s diagnosis or other neurological disorders, and 
were free of any obvious neurological or movement deficits using the Unified 
Parkinson’s Disease Rating Scale-motor scores (UPDRS-III) with a threshold score of 
<15 (Lee et al., 2015). Written informed consent was obtained in accordance with 
guidelines approved by the Penn State Hershey Internal Review Board.  Welders 
represented several different trades and industry groups (e.g., boilermakers, pipefitters, 
railroad welders, and a variety of different manufacturing jobs). Controls were age-
matched volunteers from the same regional community with various occupations. Seven 
subjects either failed to complete the DTI acquisition (3 welders and 1 control) or had 
poor image co-registration (2 welders and 1 control). Thus, their data were excluded from 
the analysis resulting in 31 controls and 43 welders (Table 1). 
Exposure Assessment and Blood analysis  
Exposure first was assessed by the work history (WH; Lee et al., 2015) questionnaire that 
collected job information over the individual’s working lifetime, emphasizing welding 
and other jobs associated with welding exposure. Responses to the WH questionnaire 
enabled a cumulative lifetime years welding (YrsW = years spent welding during the 
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subjects’ life) estimate (Lee et al., 2015). An additional supplementary exposure 
questionnaire (SEQ; Lee et al., 2015) focused on the 90-day period prior to the MRI and 
determined the time spent welding, type of metal welded, and various types of welding 
performed. The exposure metrics derived from the SEQ were: hours welding, brazing, or 
soldering [HrsW = (weeks worked) * (h/week) * (fraction of time worked related directly 
to welding)](Lee et al., 2015) in the 90 day period preceding the MRI.  
Whole blood samples were obtained by venipuncture, Samples were allowed to sit at 
room temperature for ~15 min, after which they were centrifuged at 4° for 20 min. The 
serum supernatant then was pipetted in 1 mL aliquots into 2.5 mL cryovials 
(manufacturer) and stored at -80° C. When preparing samples for shipment to Iowa State, 
samples were thawed and 200 µL of serum was pipetted into another 2.5 mL cryovial. 
The samples then were frozen in a -80° C freezer and packaged with a sufficient supply 
of dry ice to maintain their frozen status during overnight shipment. 
Statistical analysis: 
Data analysis was performed using Prism 4.0 software (GraphPad). Normally distributed 
raw data were first analyzed using one-way ANOVA, and then Tukey’s post-test was 
performed to compare all treatment groups. Raw data not follow Gaussian distribution 
were analyzed with Kruskal-Wallis test followed by Dunn's multiple comparison test to 
compare all treatment groups. Statistically significant differences were denoted as 
*p<0.05, **p<0.01, and ***p<0.001. 
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Results 
Manganese exposure upregulates the release of αSyn into the extracellular milieu.  
Growing evidence indicates that misfolded αSyn is a transmissible pathological agent 
responsible for the initiation and spread of parkinsonian pathology(Desplats et al., 2009; 
Gallegos et al., 2015; Hansen et al., 2011; Jucker and Walker, 2013; Oueslati et al., 2014; 
Recasens and Dehay, 2014; Visanji et al., 2013). To further investigate the effect of 
exposure to the neurotoxic metal Mn on αSyn transmission and the underlying molecular 
mechanisms, we established a human αSyn expressing dopaminergic cell line 
(MN9D_SynGFP) by stably transfecting MN9D mouse dopaminergic cells with a 
construct encoding amino-terminal GFP-tagged human wild-type αSyn. A control cell 
line (MN9D_EVGFP) also was generated by stably transfecting a pmaxFP-Green-N 
control vector. As shown in Fig. 1A, immunocytochemical analyses indicate that >90% 
of the MN9D_SynGFP cells were positive for GFP-tagged human αSyn, and that all 
MN9D_EVGFP cells were positive for GFP. Further analysis through Western blot 
indicates a low-level expression of endogenous αSyn in both stable cells and a strong 
expression of the higher molecular weight GFP-tagged αSyn in MN9D_SynGFP cells (Fig. 
1B).  
Next, we performed MTT assays to determine the sensitivity of naïve MN9D cells to Mn. 
As shown in Fig. 1C, an LC50 value of 1129 µM for Mn was obtained when exposing 
MN9D cells to Mn for 24 h under serum-free conditions. Based on this LC50 and 
previously published doses for Mn in dopaminergic neuronal cell lines (Cai et al., 2010; 
Latchoumycandane et al., 2005), we chose to use a non-toxic dose of 300 µM Mn for our 
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subsequent studies. To evaluate whether αSyn was released from the cells, we analyzed 
the amount of secreted αSyn in the conditioned media following Mn treatment in serum-
free DMEM. The medium was collected and concentrated using centrifugal 
concentrators together with 10ug/ml (final concentration) BSA as a loading control. Mn 
treatment at 300 µM markedly upregulated the release of GFP-tagged αSyn into the 
extracellular milieu when compared to time-matched untreated cells (Fig. 1D-F). We also 
immunoblotted the same membranes with an antibody against LDHA, a cytosolic enzyme 
indicative of cellular toxicity. Our results show that the cytotoxicity following 300 µM 
Mn exposure was minimal in both MN9D_SynGFP and MN9D_EVGFP cell groups, further 
confirming that the αSyn protein detected in the culture media resulted from the actual 
release of αSyn and was not due to cytotoxicity.   
Manganese induces oligomeric αSyn secretion via exosomes.  
To further investigate the underlying molecular mechanisms of αSyn secretion and its 
relevance in the progression of neurodegenerative disorders, we looked into the possible 
mechanisms of cargo used in αSyn secretion. For this, we analyzed the conditioned media 
collected from Mn- or vehicle-treated cells through TEM followed by differential 
ultracentrifugation. Our results indicate the presence of nanoscale exosomal vesicles 
morphologically similar to previously reported exosomes (Emmanouilidou et al., 2010) in 
both vehicle- and Mn-treated samples (Fig. 2A). Since exosomes reportedly contain a 
unique RNA profile distinct from that of host cells(Valadi et al., 2007), we further 
analyzed the exosomes for small non-coding RNAs, such as microRNAs (Mongabadi et 
al.). Exosomal RNA was isolated using the mirVana
TM
 miRNA isolation kit, and small 
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RNAs were analyzed with the Agilent 2100 Bioanalyzer Lab-on-a-Chip instrument 
system (Agilent Technologies). Our data show that the isolated exosomes do indeed 
contain small RNAs with sizes ranging from 4-150 nucleotides, of which about 86% are 
positive for miRNAs (Fig. 2B), suggesting that these exosomes not only play an 
important role in cell signaling, but also impact biological processes in the recipient cells 
upon fusion.  
 
In parallel experiments, we used the NanoSight LM10 instrument to visualize, count, and 
measure the size of exosomes isolated from MN9D_SynGFP cells in the presence or 
absence of Mn. The average diameter of exosomes isolated from control cells, 150.8 ± 
7.05 nm, was comparable to that of Mn-treated exosomes, 148.6 ± 12.42 nm (Fig. 2B) , 
indicating that Mn exposure does not alter the size distribution of exosomes. These 
calculated sizes are consistent with previously published observations(Danzer et al., 
2012; Emmanouilidou et al., 2010). Interestingly, we were able to detect significantly 
more exosomes in the Mn-treated cells than in the vehicle-treated cells, indicating that 
Mn significantly upregulates the release of exosomes (Fig. 2C). To further characterize 
these cell-derived exosomes, we examined the presence of αSyn and exosomal surface 
proteins. Western blot analysis readily detected the exosomal surface membrane protein 
markers Alix and Flotillin-1 in all exosome samples (Fig. 2E). Surprisingly, we observed 
more GFP-tagged αSyn fusion protein in the exosomes isolated from Mn-exposed cells 
than from untreated cells (Fig. 2E), indicating Mn exposure increases the αSyn payload 
carried by exosomal cargos. Similar results were obtained by using quantitative ELISA 
analysis (Fig. 2F).  
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The existence of αSyn oligomers in biological fluids and exosomal fractions isolated 
from cultured cells(Danzer et al., 2012; Lee et al., 2005) has been well characterized. 
Therefore, using confirmation specific antibodies against peptide-independent prefibrillar 
oligomers(Glabe, 2008; Kordower et al., 2008) and prefibriller αSyn species, we sought 
to determine whether misfolded  αSyn proteins are accumulated in exosomes isolated 
from Mn stimulated cells. As shown in Fig. 2G (upper panel), we have observed 
noticeably increased levels of prefibrillar oligomer accumulation in Mn-stimulated 
MN9D_EVSyn exosomes and to lesser extent in MN9D_EVGFP exosomes compare to 
exosomes isolated from vehicle treated cells. To further evaluate whether the observed 
differences in oligomeric protein accumulation due to Mn induced αSyn protein 
misfolding, we have extended our slot blot analysis with newly developed αSyn antibody 
against filament confirmation to evaluate prefibriller αSyn species accumulation in Mn 
stimulated exosomes isolated from MN9D_SynGFP cells Fig. 2G (lower panel). 
Collectively, our data suggest that Mn exposure increases the amount of αSyn-containing 
exosomes released and also upregulates the aggregated protein cargos packaged into 
these exosomes.  
  Manganese-stimulated exosomes promote neuroinflammatory responses.  
Although exosomes play an important role in many physiological and pathological 
processes, the exosome-cell interaction mode and the intracellular trafficking pathway of 
exosomes in their recipient cells remain unclear. Recently, Feng and colleagues have 
shown that exosomes are taken up more efficiently by phagocytic cells than non-
phagocytic cells, which suggests that phagocytic capability is essential for exosome 
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uptake (Feng et al., 2010). This is particularly important in microglia, which are the brain 
and spinal cord’s resident macrophages and whose phagocytic capability makes them the 
first and main form of active immune defense. Moreover, aberrant activation of glial cells 
and associated proinflammatory cytokines becomes elevated in neurodegenerative (Amor 
et al., 2010; Heppner et al., 2015; Kordower et al., 2008; Lindqvist et al., 2013; Wyss-
Coray and Mucke, 2002) and in experimental models of PD(Gao et al., 2011). Therefore, 
we exposed primary murine microglia to either vehicle- or Mn-stimulated exosomes to 
study whether Mn-stimulated exosomes have any role in neuroinflammatory processes. 
We added purified exosomes to primary microglia and allowed their cellular 
internalization to occur for 24 h at 37°C. Immunocytochemical analysis with an anti-
IBA-1 antibody revealed that microglia exposed to Mn-stimulated αSyn-containing 
exosomes exhibited an amoeboid morphology as a result of activation and formation of 
diverse forms of surface protrusions, such as blebs and filopodia, similar to that observed 
in other phagocytic cells (Fig. 3A). Furthermore, GFP-positive punctate structures were 
observed inside the microglia cells, indicating potent exosomal internalization in 
microglial cells. The expression of IBA-1 and iNOS, as revealed by Western blot 
analysis, increased significantly in cells treated with Mn-induced αSyn-containing 
exosomes in contrast to cells receiving vehicle-stimulated αSyn-containing exosomes, 
further confirming a pronounced activation of microglia and subsequent oxidative stress 
(Fig. 3B-D). Supporting these observations, we found a significantly elevated release of 
proinflammatory cytokines, such as TNFα, IL-12, IL-1β and IL-6, from microglia upon 
exposure to Mn-stimulated αSyn-containing exosomes, compared to vehicle-stimulated 
αSyn-containing exosomes or GFP control exosomes (Fig. 3E-H). We also measured the 
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anti-inflammatory cytokines IL-10 and IL-5 in our Luminex bead-based cytokine assays. 
Neither IL-5 nor IL-10 levels, however, were changed significantly in any treatment 
group (Supplementary Fig. 1A-B).  These data collectively indicate that Mn-stimulated 
αSyn-containing exosomes are biologically active and capable of activating microglial 
cells and inducing the release of proinflammatory cytokines, which may further 
potentiate inflammatory process.  
 
Microglia internalize manganese-stimulated αSyn exosomes through caveolin-1-
mediated endocytosis 
The process of endocytosis in mammalian cells involves multiple mechanisms depending 
on the host cell type as well as cargo type and fate. So far, different modes of endocytosis 
seem to be responsible for the uptake of exosomes by both phagocytic and non-
phagocytic cells (Feng et al., 2010; Mulcahy et al., 2014; Tian et al., 2014). The 
previously described mechanisms of classical endocytosis include clathrin-dependent 
endocytosis, macropinocytosis and clathrin-independent endocytic pathways (e.g. 
caveolae-mediated uptake that is associated with lipid rafts in the plasma membrane). 
However, the mechanisms by which exosomes interact with recipient cells and how 
exosomes are sorted after entry into these cells remain unclear. Therefore, using 
immortalized microglial cells (WTMC) with morphology and surface marker expression 
highly similar to primary microglia (Halle et al., 2008) we have attempted to determine 
which endocytic pathway microglia use to take up exosomes. We treated WTMC with 
various pharmacological inhibitors of endocytosis, including dynasore, which binds 
dynamin to inhibit both caveolae- and clathrin-dependent endocytosis; (N-ethyl-N-
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isopropyl)-amiloride (EIPA), an inhibitor of macropinocytosis; and chlorpromazine and 
genistein, which inhibit clathrin- and caveolin-mediated endocytosis, respectively 
(Mulcahy et al., 2014; Rejman et al., 2005). To better visualize exosomal vesicles, the 
cell-derived exosomes were pre-labeled with the green fluorescent dye PKH67, which is 
stably incorporated into lipid regions of the vesicle membrane, and then incubated with 
WTMC cells. Confocal microscopy revealed efficient internalization of the vehicle- and 
Mn-stimulated αSyn-containing exosomes by the WTMC cell line (Supplementary Fig. 
2A). The 3D surface reconstruction images generated by Imaris software clearly indicate 
the homogeneous internalization of exosomes by the microglial cells and the activated 
microglial morphology upon internalization of Mn-stimulated, but not vehicle-stimulated, 
αSyn-containing exosomes (Supplementary Fig. 2A). Next, we pre-treated the WTMC 
with the endocytosis inhibitors, either chlorpromazine (5 μM) or genistein (50 μM) or 
EIPA (10 μM) or dynasore (50 μM), for 60 min at 37°C. Subsequently, Mn-stimulated 
PKH67-labeled αSyn-containing exosomes were added and incubation was continued for 
24 h. Confocal microscopy indicated (Fig 4A) successful inhibition (80-90%) of exosome 
uptake by dynasore and genistein, whereas EIPA and chlorpromazine were unable to 
effectively inhibit (40-50%) exosome uptake. Therefore, given its clathrin independence 
and dynamin dependence during the internalization, exosome uptake in our microglial 
cell cultures were controlled through caveolae-dependent endocytosis. In a parallel 
experiment, we co-treated the microglial cells with Mn-stimulated αSyn-containing 
exosomes and the aforementioned inhibitors to further analyze the production of 
proinflammatory cytokines and nitrite. Similarly, treatment with dynasore and genistein 
significantly attenuated the production of the proinflammatory cytokines TNFα, IL-1β 
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and IL-6 in response to Mn-stimulated αSyn exosomes, whereas chlorpromazine and 
EIPA did so only marginally or not at all (Fig. 4B-D). Furthermore, we detected 
significantly reduced nitrite production upon treating cells with dynasore, genistein, and 
EIPA, but not with chlorpromazine (Fig. 4E). Therefore, these data indicate that the high 
capacity uptake of Mn-stimulated αSyn-containing exosomes by microglia involves 
multiple mechanisms, with the caveolae-dependent endocytosis playing a central role in 
regulating this process.  
 
Next, using primary murine microglial cultures we confirmed the prominent role of 
caveolin-1-mediated endocytosis in microglial uptake of αSyn-containing exosomes. For 
this, we employed fluorescently labeled transferrin and the cholera toxin B subunit 
(ctxB), which are widely recognized as ligands exclusively internalized via clathrin-
mediated endocytosis and caveolae-mediated endocytosis, respectively, in several cell 
types(Hansen et al., 1993; Orlandi and Fishman, 1998; Rejman et al., 2005; Singh et al., 
2003). Primary microglia cells were pre-treated with chlorpromazine or genistein as 
described above for 60 min at 37°C. At the end of the incubation, cells were co-treated 
with either Alaxa-555-labeled transferrin and PKH67-labeled exosomes (Fig 4F) or 
Alaxa-555-labeled ctxB and PKH67-labeled exosomes (Fig 4G) for 24h at 37°C. As 
depicted in Fig. 4F-G, chlorpromazine treatment led to a significant inhibition of 
Alexa555-conjugated transferrin uptake, whereas only a moderate inhibition of the 
uptake of PKH67-labeled exosomes or Alexa555-conjugated ctxB was observed.  
Furthermore, cells treated with genistein exhibited 90-100% inhibition of both Alexa555-
conjugated ctxB and PKH67-labeled exosome uptake. Genistein, however, did not inhibit 
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transferrin uptake by the microglial cells. Therefore, our data suggest that caveolin-
mediated endocytosis primarily facilitate for the recognition and internalization of 
neuronal exosomes by microglia. 
In an effort to rule out the possible non-specific effects of pharmacological/chemical 
inhibitors, we next employed the CRISPR/Cas9 nuclease RNA-guided genome editing 
technique to individually knockdown (KD) caveolin-1 or clathrin in the murine wide-type 
microglial cell line to validate our experimental results involving chemical inhibition of 
endocytosis. The inhibition of αSyn-containing exosome uptake in caveolin-1-KD cells 
was significantly greater than in clathrin-KD microglial cells as seen by confocal 
microscopy (FIGURE). In parallel experiments involving Luminex magnetic bead-based 
cytokine analysis, the release of the proinflammatory cytokines IL-6, IL-12, TNFα,  and 
IL-1β was reduced significantly by exposing clathrin--KD cells to Mn-stimulated αSyn 
exosomes in contrast to control microglial cells (Fig. 4I-K). A further reduction in αSyn 
exosome-stimulated proinflammatory cytokine release occurred in caveolin-1-KD cells. 
Therefore, we report that microglial internalization of exosomes derived from αSyn-
overexpressing dopaminergic cells depends on multiple mechanisms, in particular the 
involvement of caveolin-1-dependent endocytosis. 
Manganese-stimulated αSyn exosomes induce neurodegeneration in vitro. 
After establishing the role of Mn-stimulated αSyn exosomes in promoting 
neuroinflammation, we further extended our experiments to evaluate whether these 
exosomes mediate neurodegeneration. For this purpose, we established a neuron-glia 
mixed culture system using primary microglial cells and differentiated Lund human 
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mesencephalic (LUHMES) cells (Fig. 5A). By using a transwell cell culture system, we 
were able to mimic the biological environment where microglia and neurons reside in 
close proximity and to evaluate the extent of αSyn exosome-mediated neurodegeneration. 
Since LUHMES cells can be differentiated into morphologically and biochemically 
mature post-mitotic dopamine-like neurons, they are widely used as an in vitro model 
system for dopaminergic neurotoxicity. As shown in Fig. 5B, Mn-stimulated αSyn 
exosomes evoked apoptosis as indicated by increased caspase-3 activity in differentiated 
LUHMES cells. In contrast, we did not observe significantly increased caspase-3 activity 
in cells that received either GFP exosomes or vehicle-stimulated αSyn exosomes, 
indicating that this observed cell death may result from the combined effects of increased 
inflammation and prefibrillar oligomers packaged in Mn-stimulated αSyn exosomes. 
 
Immunocytochemical analysis of the exosome-treated LUHMES cells readily detected 
exosome uptake as evidenced by GFP-immunoreactive punctate structures inside the 
neuronal cells (Fig. 5C). Immunolabeling of the LUHMES cells with neuron-specific 
class II β-tubulin (Tuj1) confirmed the fully differentiated post-mitotic nature of the 
LUHMES cells, as described previously (Scholz et al., 2011). Collectively, our data 
indicate that Mn-stimulated αSyn exosomes could initiate neuronal apoptosis in vitro.  
 
Live cell model for αSyn oligomer transmission  
To further clarify the role of Mn in cell-to-cell transmission of αSyn aggregates, we 
adopted an assay based on bimolecular fluorescence complementation (BiFC), which has 
been successfully applied to assess protein oligomerization, protein-protein interaction, 
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and cell-to-cell transmission in in vitro and in vivo models (Bae et al., 2014; Danzer et al., 
2012; Dimant et al., 2013). For this assay, human wild type αSyn is fused to either the 
amino terminus (V1S) or carboxy terminus (SV2) fragment of the Venus protein, which 
is an improved variant of GFP (Fig. 6A). When V1S or SV2 constructs were individually 
transfected into MN9D cells, neither cells fluoresced (Fig. 6D). Once cells were co-
transfected with V1S and SV2, however, αSyn-αSyn interactions brought together 
(Danzer et al., 2012) and reconstituted the Venus fluorescent protein as a result of cell-to-
cell transmission of αSyn as visualized using BiFC (Fig. 6D). Utilizing this assay system, 
we have shown that Mn exposure increases αSyn-αSyn interactions in living cells and 
reconstitutes the Venus fluorophore which only occurs when each fragment is brought 
together and covalently linked.  
To study the nature of αSyn species visualized by the BiFC assay, in parallel Western 
blot experiments we immunoblotted with anti-Ubiquitin, αSyn and GFP antibodies. As 
expected, cells transfected with V1S+SV2 followed by Mn treatment accumulated high 
molecular weight poly-ubiquitinated proteins and mono-ubiquitinated proteins, indicating 
that Mn enhanced protein oligomerization when compared with vehicle-treated cells (Fig. 
6E). Under these experimental conditions, we also detected discrete bands corresponding 
to Venus-link-αSyn (V1S) and αSyn-Venus (SV2) protein expression and their N-
terminal Venus fluorescent tag (Fig. 6E).   
To ensure αSyn oligomerization and transmission were not driven by the Venus 
fluorescent moieties, we adopted another protein complementation assay based on a 
luciferase assay system consisting of the two fusion constructs αSyn-hGLuc1 (S1) and 
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αSyn-hGLuc2 (S2) as described elsewhere (Danzer et al., 2012; Outeiro et al., 2008). 
This assay works on the same principle as the BiFC assay, and Gaussia princeps 
luciferase only reconstitutes with S1 and S2 protein interaction, allowing direct 
monitoring of these protein interactions in their normal cellular environment. Transient 
transfection of S1 and S2 constructs showed about 5 times higher luciferase activity 
relative to the background signal from cells transfected with either S1 or S2 plasmids. 
Furthermore, cells transfected with S1+S2 followed by Mn exposure showed about 8 
times higher luciferase activity relative to background and about 160% higher activity 
than vehicle-treated S1+S2 co-transfected cells (Fig. 6F). These data are consistent with 
our fluorescent-based BiFC assay results and support our finding that Mn exposure 
induces cell-to-cell transmission of misfolded αSyn species. Interestingly, the luciferase 
signal in cells co-transfected with S1+S2 and treated with magnesium (Mg), another 
divalent metal commonly found in biological systems, did not differ from that of vehicle-
treated cells (Supplementary fig). These results suggest some specificity to Mn in 
misfolded αSyn formation and transmission.   
We used flow cytometry to further confirm that Mn promotes cell-to-cell transmission of 
oligomeric αSyn. Since the Venus fluorescent protein in our plasmid constructs (V1S and 
SV2) used in the BiFC experiment matures at 37°C as a strong fluorescent signal, we 
used fluorescent-activated cell sorting (FACS) to contrast GFP-positive cell populations 
exposed to Mn or vehicle treatments (Fig. 6G). Cells co-transfected with V1S and SV2 
and treated with either Mn or vehicle for 24 h were fixed and processed for flow 
cytometry analysis. Our FACS analysis shows significantly more GFP-positive cells in 
Mn-exposed cells than in the vehicle-treated control group (Fig. 6H). Consistent with our 
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BiFC assay, we did not detect GFP-positive cells when they were transfected with either 
V1S or SV2.  Thus, using multiple experimental approaches, we have shown that Mn 
exposure promotes cell-to-cell transmission of oligomeric αSyn in our cell culture 
system.  
    
Direct detection of manganese-induced cell-to-cell transmission of α-synuclein 
oligomers and associated neurotoxicity in vivo. 
Once we established the effect of Mn in cell-to-cell transmission of oligomeric αSyn in 
vitro, we shifted to in vivo models of Mn toxicity. Using a novel in vivo protein 
complementation approach consisting of co-injecting AAVs encoding αSyn fused to the 
N- or C-terminal half of VenusYFP(Dimant et al., 2013), we showed elevated levels of 
αSyn oligomers in vivo in Mn-exposed animals. Thirty days after stereotaxically co-
injecting AAV-V1S and AAV-SV2 into the SNpc of C57BL6 (Fig. 7A), animals were 
exposed to either vehicle or Mn (15 mg/kg/day) via oral gavage once daily for another 30 
days (Fig. 7B). Two additional control groups were injected with either AAV-V1S or 
AAV-SV2 virus to exclude the possibility of non-specific fluorescence from one half of 
the VenusYFP protein, and another group was injected with AAV-CBA-VenusYFP as a 
positive control for the experiment. At 60 days post-viral injection, VenusYFP 
fluorescence was clearly visible in the substantia nigra pars compacta (SNpc) of animals 
injected with AAV-CBA-VenusYFP, confirming our injection target and the expression 
of VenusYFP epifluorescence (Fig. 7C). 
To determine whether Mn exposure promotes αSyn oligomerization and pathogenesis in 
vivo, we used Kodak Image Station In-Vivo FX to image VenusYFP expression in 
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vehicle-treated and Mn-exposed mice. Whole brain images were captured using its 
fluorescence imaging capability and converted into heat-maps using MATLAB and 
superimposed on white-light reference images to show anatomical localization of 
VenusYFP fluorescence (Fig. 7D). Imaging clearly indicates that Mn exposure promotes 
αSyn oligomerization, which increased about 350% in Mn-exposed animals compared to 
vehicle-treated animals, based on ImageJ quantification of fluorescent intensities (Fig. 7D 
and E). Notably, control animals injected with either AAV-V1S or AAV-SV2 alone did 
not express any VenusYFP fluorescence on the injected side (data not shown), 
demonstrating that the fragmented Venus protein lacks background fluorescence. 
To further characterize the effect of Mn in αSyn-mediated neurotoxicity, we compared 
the behavior deficits of viral-transduced and non-transduced mice exposed to Mn via oral 
gavage. Non-transduced and transduced mice were age-matched littermates and the Mn 
or vehicle exposures were conducted simultaneously. To assess Mn-induced motor 
deficits in mice after the 30-day Mn treatment paradigm, we measured various motor 
performance parameters using a computerized infrared activity monitoring system 
(VersaMax, Accuscan). Representative maps of the locomotor movements of vehicle-
treated and Mn treated non-transduced (No injection) and transduced (AAV-
V1S+AAV_SV2) mice suggest that Mn decreased movements in both experimental 
groups, and viral-transduced mice exhibited greater movement deficits upon Mn 
exposure (Fig. 7F). Quantitative analysis of infrared beam breaks confirmed that Mn 
exposure markedly decreased the total number of movements (Fig. 7I) , total distance 
travelled (Fig. 7J), and the horizontal activity (Fig. 7K) in transduced mice compared to 
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vehicle-treated animals, further indicating that Mn exposure augments αSyn-mediated 
neurotoxicity in animals by enhancing αSyn oligomerization and pathogenesis.  
To determine whether Mn-induced αSyn oligomerization promotes dopaminergic 
neurodegeneration in SN, we examined neuronal viability in vivo after a 30-day Mn 
exposure period in both AAV-V1S+AAV_SV2 virus-transduced and non-transduced 
animals. Coronal sections through the SN were immunostained for tyrosine hydroxylase 
(TH) and immunopositive cells visualized by DAB (Fig. 7G). Dopaminergic neuronal 
loss was evaluated using unbiased stereology of TH-immunoreactive neurons on both the 
ipsilateral and contralateral sides. TH DAB staining and stereological counts revealed 
severe loss of nigral dopaminergic neurons, especially TH-positive neurons in the SNpc 
and substantia nigra pars reticulata SNpr of Mn-treated AAV_V1S+AAV_SV2 virus-
transduced animals relative to vehicle controls (Fig. 7H). These observations further 
support Mn-induced cell-to-cell transmission of αSyn promoting dopaminergic 
neurodegeneration in vivo. In contrast, Mn-exposed non-transduced animals showed no 
significant loss of TH+ neurons when compared to their age-matched vehicle control 
animals. Overall these results, together with the abovementioned whole brain imaging of 
the cell-to-cell transmission of αSyn, strongly demonstrate that exposure to 
environmental neurotoxicants such as Mn can augment the progression of αSyn 
misfolding in vivo, resulting in dopaminergic cell death.  
Manganese exposure promotes exosome release in transgenic animals and αSyn 
oligomer transmission in humans 
Having shown that exposing viral transduced mice to Mn induces αSyn oligomerization 
and dopaminergic neurodegeneration, we then evaluated total serum exosome release in 
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rats expressing the human αSyn-A53T mutation. Rats were dosed with Mn as described 
above and their blood was collected through cardiac puncture at study termination. Serum 
separation and exosome isolation were carried out as described above and total serum 
exosome numbers were counted using the Nanosight particle analyzer. Mn challenged 
αSyn-A53T transgenic rats produced significantly higher concentrations of exosome than 
did either vehicle-treated transgenic rats (p=0.0035) or non-transgenic rats (p value 
0.0082) (Fig. 8A).  Manganese exposure did not alter exosome size and it only increased 
the number of exosomes released during a neurotoxic insult (Fig. 8B).  Therefore, 
exosomes may act as a means of cell-to-cell communication during increased 
intracellular stress conditions and use as a cargo for secretion and cell-to-cell 
transmission of harmful or unwanted cellular proteins.  
 
It has been proposed that exogenously added misfolded αSyn serves as nucleation seeds 
for propagating aggregate-initiated polymerization of αSyn in in vitro and in vivo models 
of PD (Luk et al., 2012a; Luk et al., 2012b; Luk et al., 2009; Nonaka et al., 2010; 
Volpicelli-Daley et al., 2014). Since exosomes are well recognized as one of the potential 
mechanisms mediating cell-to-cell transmission of cytosolic protein aggregates (Guo and Lee, 
2014), and given the strong interaction between heavy metals and neurodegenerative disease or 
parkinsonian syndromes (Fored et al., 2006; Racette et al., 2012; Willis et al., 2012; Wright Willis 
et al., 2010), we undertook an exploratory study to compare the αSyn content in 21 serum 
exosome samples from welders (aged 26-65 years; 46 ± 11.2 years) recently (within 90 
days) exposed to Mn fumes to 27 healthy controls (aged 28-73 years; 49 ± 11.0 years 
with no history of welding (see details in Lee et, al 2015 for the first description of the 
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subjects, also see Lee 2016) . Serum exosomes were isolated as described above and total 
exosome numbers were counted using Nanosight particle analysis. Contrary to our 
previous observations with transgenic cells and rats, the exosome counts in welders and 
controls did not differ significantly (p=0.0993) (Fig. 8C). We also analyzed the total 
αSyn concentration in these exosomes using a commercially available, highly sensitive 
luciferase-based αSyn ELISA assay (BioLegend; 844101). Total αSyn cargo in the serum 
exosomes did not differ between welders and controls (p=0.6848; Fig. 8D), indicating 
that the level of Mn exposure experienced by the welders in this sample was not 
sufficient to alter exosome numbers or total αSyn cargo in humans.  
 
Though the outcome we observed in humans did not directly support changes observed in 
transgenic cells and rats, it has been reported that varying αSyn expression levels in 
peripheral blood and CSF in PD patients and healthy controls (El-Agnaf et al., 2003; El-
Agnaf et al., 2006; Foulds et al., 2011; Mollenhauer et al., 2013; Tinsley et al., 2010).  
Importantly, in the αSyn model of neuron injury, β-sheet-rich soluble oligomers are 
considered more toxic than monomers(Lashuel et al., 2013; Sharon et al., 2003; Winner 
et al., 2011). Therefore, we measured the αSyn oligomer levels in these exosomes using 
the highly sensitive, Thioflavin T (ThT)-based αSyn fibril formation assay. In this 
microplate-based cell-free seeding assay, exosomes isolated from welders and controls, 
serving as the seeds presumably with trace amounts of αSyn fibrils, are added to a 
recombinant human αSyn substrate (Supplementary Fig 4A) and repeatedly agitated. First 
we optimized the assay using different concentrations of synthetically aggregated αSyn as 
a seed, and we showed that the onset of fibril formation, which increases fluorescence 
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intensity when ThT binds to aggregates, directly correlates to αSyn fibril seed density 
(Supplementary Fig 4B). This correlation is predicted by theory and has been used 
previously to quantify the aggregation kinetics of two major forms of amyloid-beta 
peptides and TSE-associated forms of prion protein(Henderson et al., 2015; Meisl et al., 
2014; Orru et al., 2015; Pedersen and Heegaard, 2013). Blank and baseline-corrected 
average kinetic traces for seeded fibrillar formation assays revealed a significant 
difference in the lag-phase of the averaged traces of welders and control exosome 
samples. The lag phase duration was determined from the point where the ThT 
fluorescence intensity first reached the threshold value for detecting the presence of 
amyloid (Fig. 8E). This threshold was defined as five standard deviations of the 
fluorescence intensity of the first 10 h from the blank (3.66) sample. Standard error of the 
mean lag phase was calculated via bootstrap with replacement protocol in MATLAB. 
The calculated lag phases for control and welders’ exosomes were 23.5±1.2 h and 
16.2±5.1 h, respectively. Furthermore, we calculated final fluorescence intensity for 
comparing two kinetic traces by averaging the raw ThT fluorescence of the last 10 data 
points of each trace (Fig. 8F). By averaging intensity values for controls (270 data points) 
and welders (210 data points), we observed a statistically significant difference in their 
final ThT fluorescence intensities, indicating that exosomes isolated from welders have 
higher seeding capacity and misfolded αSyn protein content compared to exosomes 
isolated from healthy controls.      
Manganese-stimulated exosomes induce motor deficits in mouse models of PD 
The accumulation of misfolded proteins and associated behavioral deficits are 
fundamental pathogenic processes in the progression of PD and number of other 
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synuclopathy-related disorders(Luk et al., 2012b). Furthermore, evidence from recent in 
vitro and in vivo studies suggests that misfolded proteins play a central role in a variety of 
neurodegenerative disorders by functioning as a “seed” for the protein misfolding and 
aggregation processes; much like prions (Sacino et al., 2013; Ubeda-Banon et al., 2013; 
Watts et al., 2013). Thus far, we have shown that Mn-stimulated exosomes contain 
prefibrillar αSyn oligomers could potentiate neuroinflammatory and degenerative 
response in vitro. Therefore, we further extended our study to evaluate the effects of these 
exosomes in mouse models, that mimic of the neurodegenerative process. 
 
To investigate whether exosomes carry disease-associated prefibrillar αSyn oligomers 
that can seed and propagate pathology in vivo, we injected 2 to 3-month old wild-type 
C57BL/6 mice with exosomes isolated from Mn or vehicle-treated pMAXGFP and 
pMAXGFP_αSyn cells. Roughly 4-5 x 108 exosomal particles ( 5 µg total exosome 
proteins) from each treatment group were stereotaxically injected into one side of the 
striatum (Fig. 9A) and neurological behavioral deficits were monitored over time. 
Interestingly, we observed attenuated behavioral performance in animals injected with 
αSyn exosomes at 90 days post-inoculation (dpi). Specifically, mice receiving Mn-
stimulated αSyn exosomes showed reduced exploratory locomotor activity as measured 
by stereotypy counts, movement time (Fig. 9 C-D) in an open field test. Some of these 
observed behavioral deficits, however, are not statistically significant, which may be 
attributable to the fact that the exosome injections were done unilaterally, lesioning only 
one side of the brain. Also, the amphetamine-induced rotation test indicates increased 
ipsilateral movements in the Mn-stimulated αSyn exosome injected mice, indicating 
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unilateral CNS damage in in these animals compared to mice receiving vehicle-
stimulated αSyn exosomes or vehicle- and Mn-stimulated GFP exosomes (Fig 9B).  
 
Lewy bodies and Lewy neurites are pathological hallmarks of synucleinopathy-related 
disorders. As a final step, we performed histological evaluations of brain sections to 
check for the presence of these proteinaceous inclusions. Interestingly, we detected 
αSyn(Ser(p)129)-immunoreactive cytoplasmic inclusions in mice injected with Mn-
stimulated αSyn exosomes compared to vehicle-stimulated αSyn exosomes or vehicle- 
and Mn-stimulated GFP exosomes injected mice. These data suggest that αSyn exosomes 
are able to initiate synucleinopathy pathologies in experimental models of PD. Mice 
receiving GFP exosomes did not appear to have any protein inclusions or GFP immune-
positive structures, suggesting that the GFP protein may have been cleaved-off and 
degraded. Collectively, our results clearly indicate that αSyn-containing exosomes could 
initiate parkinsonian symptoms and propagate αSyn misfolding and aggregation in vivo. 
These observations also may help further the understanding of prion-like, cell-to-cell 
transmission of aggregated proteins in progressive neurodegenerative disorders.  
Discussion 
The role of extracellular αSyn in the progression of PD gained much interest recently 
with the discovery of αSyn in human cerebrospinal fluid (CSF) and blood plasma (El-
Agnaf et al., 2003). Recent reports support a pathogenic role for extracellular αSyn, 
showing that αSyn aggregates released from neurons unleash toxic effects in recipient 
neurons by forming Lewy body-like inclusions (Desplats et al., 2009; Emmanouilidou et 
al., 2010) or by activating inflammatory responses in microglia (Kim et al., 2013). Also, 
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adding exogenous fibrillar αSyn into αSyn-overexpressing cells and primary neurons 
actively recruits soluble endogenous αSyn, converting it into a detergent-insoluble 
misfolded state (Luk et al., 2009; Volpicelli-Daley et al., 2014; Volpicelli-Daley et al., 
2011) much like the mechanism observed in prion disease (Aguzzi and Falsig, 2012). 
Furthermore, inoculation of pathological αSyn and recombinant αSyn amyloid (Luk et 
al., 2012b) were sufficient to transmit and initiate parkinsonian symptoms in animal 
models of neurodegenerative disorders, providing evidence that misfolded αSyn serves as 
a seed and template for endogenous αSyn to propagate αSyn aggregation in a prionic 
manner. However, given the strong synergistic environmental influence and 
multifactorial etiology in synucleinopathy-related pathogenesis, it is important to 
understand the role of environmental neurotoxicants and their interaction with genetic 
risk factors to further our understanding of neurodegenerative processes. Chronic 
exposure to heavy metals in occupational settings, especially exposure to Mn through 
mining, welding and smelting, has been reported as a putative risk factor for 
environmentally-linked neurodegenerative disorders (Fored et al., 2006; Gorell et al., 
1997; Racette et al., 2012). However, despite the strong association with exposure to 
agro-chemicals and heavy metals, little is known about environmental influences on the 
cell-to-cell transmission of pathogenic proteins.  
 
Though previous studies have shown that Mn neurotoxicity leads to neuronal apoptosis 
and the upregulation and aggregation of αSyn in experimental models of PD (Cai et al., 
2010; Hirata, 2002; Kordower et al., 2008), its role in the release and transmission of 
pathogenic αSyn has not been studied. Therefore, to further understand the role of Mn in 
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the cellular release of αSyn, we systematically carried out experiments to show that Mn 
increases the release of αSyn amyloid containing exosomes, which could increase 
neuroinflammatory and neurodegenerative responses in experimental models of 
neurodegenerative disorders. We also show that low-dose chronic exposure to Mn 
increases the exosomal release of αSyn cargo resulting in αSyn oligomerization in vitro 
and in vivo. We show further that humans exposed to Mn through welding fumes contain 
higher misfolded αSyn in their serum exosomes than control subjects. These findings 
could improve our understanding of exosome-mediated cell-to-cell propagation of αSyn 
and its role in the progression of neurological disorders.  
Our wild-type human αSyn-overexpressing cell culture model clearly demonstrates that 
Mn exposure significantly enhances the release and accumulation of extracellular αSyn 
(Fig 1D and E) providing direct evidence of an environmental influence of αSyn release. 
Since αSyn protein structure doesn’t contain a signal recognition sequence, which would 
be required for the conventional ER/Golgi secretion pathway (Emmanouilidou et al., 
2011; Vekrellis et al., 2011), several unconventional excretion mechanisms have been 
implicated in αSyn release, including an endosomal pathway, direct transfer across the 
membrane, and release through exosomes (Emmanouilidou et al., 2010; Lee et al., 2005). 
Therefore, to characterize the mode of αSyn release induced by Mn, we analyzed the 
conditioned media through TEM and Western blotting followed by differential 
ultracentrifugation. We readily detected micro-vesicles similar in size and morphology to 
exosomes (Fig. 2A).  Our exosomes also contained Alix and Flotillin, which are common 
to these vesicles and serve as “markers” along with tetraspanin (CD63, CD81) and heat 
shock proteins (HSP70, 90) (Schneider and Simons, 2013). Mn exposure in αSyn cells 
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resulted in significantly higher αSyn amyloid-containing exosome release. This is 
particularly interesting because the regulation of exosome release previously was thought 
to be controlled by lysosomal dysfunction (Alvarez-Erviti et al., 2011) and a calcium-
dependent mechanism (Emmanouilidou et al., 2010) but the role of environmental 
neurotoxicants remained ill-studied.   
Extracellular αSyn reportedly interacts with CD36 (Su et al., 2008), toll-like receptor 4 
(TLR4), (Fellner et al., 2013) and TLR2, (Kim et al., 2013) and thus activates microglial 
inflammatory processes and enhances ROS production. In this regard, we further 
characterized the capability of exosomal amyloid αSyn content to trigger 
neuroinflammatory responses by activating primary microglial cells and releasing pro-
inflammatory cytokines. In line with recent observations indicating that 
neuroinflammation is a pivotal step in neurodegenerative disorders (Rocha et al., 2015), 
our experiments show that Mn-stimulated exosome treatments in primary microglial cells 
significantly elevated the release of IL1-β, IL-6, IL-12 and TNF-α (Fig. 3E-H). Our 
results further provide evidence that exosomes are biologically active entities that interact 
with recipient cells. The membrane transport mechanisms and the downstream signaling 
events involved in the uptake of these exosome vesicles, however, are inconclusive. Fate 
of the exosome cargo in recipient cells is often determined by which endocytic pathway 
is used to gain entry and often distinguished on the basis of their differential sensitivity to 
pharmacological/chemical inhibitors. The possibility of nonspecific effects of such 
inhibitors, however, frequently is overlooked. For example, the potent GTPase inhibitor 
dynasore, which prevents endocytosis by rapidly and reversibly inhibiting dynamin 
activity, was shown to reduce labile cholesterol in the plasma membrane and to disrupt 
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lipid raft organization in a dynamin-independent manner (Preta et al., 2015).Moreover, 
genistein is reported to be a general Src tyrosine protein kinase inhibitor (Kaul et al., 
2005), a competitive inhibitor of ATP, (Versantvoort et al., 1994) and inhibits cancer 
metastasis, and these actions may or may not directly influence its inhibition of caveolin-
mediated endocytosis. Therefore, in this study, using both selective inhibitors and 
CRISPR/Cas gene editing molecular tools, we shown that caveola-mediated endocytosis 
was primarily involved in the microglial uptake of neuronal cell-derived exosomes. These 
findings add insights into the endocytic pathway and the biological significance of 
exosome-mediated neuroinflammation. Having shown the capability of αSyn amyloid-
containing exosomes to increase inflammation, we further characterized their ability to 
exert a neurodegenerative effect by using a neuron-glia mixed culture system. In 
concordance with previous observations by Emmanouilidou and colleagues 
(Emmanouilidou et al., 2010), we also have seen increased caspase-3 activity upon αSyn 
containing exosomes leading to neuronal apoptosis upon exposure to differentiated 
LUHMES cells (Fig. 4C); differentiated LUHMES cells show morphological and 
biochemical characteristics similar to mature post-mitotic dopamine-like neurons and 
primary neuronal cultures (Scholz et al., 2011).  
The current study also provided direct evidence for enhanced αSyn transmission from Mn 
by increasing BiFC-positive cells in Mn exposed cells and greatly increasing extracellular 
V1S/SV2 exsosomal protein content. Thus, we have shown for the first time that Mn not 
only causes αSyn oligomerization but also cell-to-cell transmission. We extended these in 
vitro findings to animals, showing a significantly elevated BiFC-positive signal in 
animals exposed to Mn, supporting the notion that environmental neurotoxicants can 
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cause αSyn misfolding and cell-to-cell transmission. Previously, we showed that 
physiological levels of human wild-type αSyn protein attenuate acute Mn-induced 
dopaminergic neuronal degeneration in cell culture models, but prolonged Mn exposure 
promotes αSyn aggregation and neurotoxicity (Harischandra et al., 2015). Except for 
studies showing accumulation in the globus pallidus and striatum causing GABAergic 
and dopaminergic toxicity (Crossgrove and Zheng, 2004; Li et al., 2006; Zheng et al., 
2000), few have addressed Mn’s long-term effects in animal models or in humans. 
Moreover, the findings from neuroimaging and neurobehavior studies of humans exposed 
to Mn through mining or welding are inconclusive due to conflicting outcomes on the 
possibility of nigrostriatal dopamine neuron degeneration (Fored et al., 2006; Guilarte, 
2010; Racette et al., 2012; Willis et al., 2012). In fact, it has been reported that Mn 
decreases dopamine turnover in the striatum of transgenic mice expressing human wild-
type αSyn, but didn’t result nigrostriatal degeneration (Peneder et al., 2011). Despite the 
discrepancies in the published literature on Mn-induced dopaminergic neurodegeneration, 
we clearly observed TH
+
-neuron loss and related behavior deficits in animals transduced 
with V1S/SV2 AAV and exposed to Mn. This may result from Mn-induced cell-to-cell 
transmission causing αSyn oligomerization in vivo, which in turn causes toxicity to 
dopaminergic cells. Therefore, these findings have important implications on our current 
understanding of gene-environment interactions in neurodegenerative disorders.    
 
In this study, Mn also significantly elevated concentrations of serum exosomes in rats 
expressing the human A53T-αSyn mutation, a genetic risk factor for PD. A strong 
correlation existed between the effects of genetic risk factors and environmental 
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neurotoxicants on exosome release. Although, we did not see higher exosome numbers 
nor larger αSyn concentrations in exosomes isolated from humans exposed to Mn via 
welding fumes, our study of active welders was constrained by our inability to measure 
actual brain Mn levels and it was not a randomized controlled experiment. Nevertheless, 
we have reported that these welders do have higher misfolded αSyn content in their 
serum exosomes that may explain previous epidemiological studies on welding as a 
putative risk factor for developing parkinsonian neurological symptoms in later life 
(Gorell et al., 1997; Racette et al., 2012; Racette et al., 2005; Willis et al., 2012).  Given 
the fact that these welder cohorts may have the potential for multiple etiologies and 
confounding variables (e.g., ergonomics, disease states, other exposures, age), however, 
clinical significance is uncertain and yet to be determined. Yet, the ability to detect 
amyloid αSyn species in serum exosomes can be studied further as a potential 
noninvasive biomarker, taking diagnosis of familial and sporadic PD to the next level. 
We also evaluated whether exosomes function as a “seed” for the protein misfolding and 
aggregation process in experimental models of PD. Having shown that αSyn-
overexpressing cells produce exosomes rich in αSyn amyloid upon Mn exposure, we 
unilaterally injected these Mn-stimulated exosomes into the mouse striatum to evaluate 
possible nucleation-dependent protein polymerization. Behaviorally, these mice 
displayed compromised locomotor activity, as measured by attenuated vertical activity, 
horizontal activity, and total distance travelled, whereas amphetamine-induced ipsilateral 
rotations were increased. Interestingly, we also detected αSyn(Ser(p)129) immuno-positive 
inclusion bodies, indicating that exosomal αSyn propagates in vivo, resulting in 
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inclusions similar to Lewy bodies and Lewy neurites, as reported elsewhere (Luk et al., 
2012b; Luk et al., 2009; Watts et al., 2013). 
In conclusion, we identified a possible mechanism for how the environmental 
neurotoxicant Mn contributes to exosome-mediated cell-to-cell transmission of αSyn and 
thus to the progression of neurodegenerative processes. Importantly, we showed that Mn 
exposure upregulates the release of αSyn-packed exosomes capable of propagating and 
accumulating in animal models of neurodegeneration. We also report that humans 
exposed to Mn through welding fumes contain higher αSyn amyloid content in their 
circulating exosomes. More well-designed, epidemiology studies, however, are needed 
that combine detailed histories of occupational exposure in welders with both behavioral 
and biochemical endpoints of neurotoxicity. Moreover, our findings might be relevant to 
other environmental toxicants implicated in protein misfolding disorders and possibly to 
the development of pharmacological interventions to block exosome-mediated disease 
progression.  
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Supplementary section  
 Alpha-Synuclein purification and aggregation: Expression and purification of 
recombinant human wild-type αSyn Expression protein was performed in E.coli 
Bl21(DE3) in a pT7-7 based expression system. After IPTG induction bacterial cell 
pellets were harvested by centrifugation and resuspended in 10 mM Tris-HCl, pH 8.0, 1 
mM EDTA, and 1 mM PMSF, lysates were sonicated and centrifuged at 10,000 x g for 
30 min. at 4°C.  Streptomycin sulfate precipitated DNA was removed and ammonium 
sulfate precipitation step was performed to selectively precipitate the αSyn protein. 
Resulting lysates were filtered through 0.22-μm membranes and loaded onto a Bio-Rad 
UNO Q6 ion exchange column on BioLogic DuoFlow (Bio-Rad) chromatography 
system. Fractions collected during elution with a salt gradient were assayed for the 
presence of α-synuclein protein by SDS-PAGE followed by Coomassie staining. 
Fractions containing α-synuclein were pooled, dialyzed against 10 mM HEPES, 50 mM 
NaCl, pH 7.4, and protein concentration determined by Bradford assay.  
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Figure 1: Generation of GFP-tagged stable α-synuclein expressing MN9D cells and 
manganese-induced α-synuclein secretion. 
(A) Immunocytochemical analysis depicting stably expressed GFP-tagged wild-type 
αSyn protein in MN9D dopaminergic cells. αSyn-expressing cells exhibited strong 
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ubiquitous expression of αSyn, whereas vector cells showed no detectable αSyn 
immunoreactivity. (B) Stable expression of αSyn was determined by Western blot 
analysis. A 45-kDa band corresponding to the molecular mass of GFP-fused αSyn was 
detected in α-syn expressing cells, whereas no GFP-fused αSyn expression appeared in 
vector cells. However, both αSyn-expressing and control cells showed low levels of 
endogenous αSyn expression. (C) Manganese dose-dependent toxicity measured by MTS 
assay. (D) Increased -syn release in extracellular media as measured by Western blot. 
(E-F) Densitometric analysis of a-syn and LDH respectively released in extracellular 
media normalized to BSA. 
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Figure 2:  Manganese induces exosomes release from neuronal cells.    
(A) Electron micrograph of isolated exosomes revealing that transmission electron 
microscopy of ultracentrifuged conditioned medium readily detected exosomes. (B) 
Nanosight-generated histogram of particle size and abundance of isolated exosomes. (C) 
Exosome concentrations showing that manganese exposure upregulated the release of 
exosomes into the extracellular micro-environment. (E) Western blot analysis shows 
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exosomal surface membrane protein markers alix and flotillin-1 in all exosomes samples 
and elevated αSyn in manganese stimulated αSyn-pmaxGFP exosomes. 
(G) Slot blot analysis showing higher oligomeric protein accumulation in exosomes 
isolated from manganese-stimulated exosomes from both αSyn-pmaxGFP and control 
pmaxGFP cells relative to vehicle-treated αSyn-pmaxGFP and control pmaxGFP cells. 
However, exosomes from manganese-stimulated αSyn-pmaxGFP indicate greater 
accumulation of prefibrillar oligomeric protein.   
 
Figure 3: (A) Immunocytochemical analysis depicting activation of microglia upon Mn 
stimulation only in the presence of Syn exosomes. (B-D) Increased protein expression 
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of IBA-1 and iNOS in Mn-stimulated MN9D_SynGFP cells compared to 
MN9D_EVGFP and control treated MN9D_SynGFP cells. (E-H) Increased cytokine 
release from Mn-stimulated MN9D_SynGFP cells compared to vehicle stimulated 
MN9D_SynGFP cells.  
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Figure 4: Exosome extry into neurons is primarily mediated by caveolin-mediated 
endocytotis. (A) Micorglia cell treatment with different endocytosis inhibitors. (B-E) 
Luminex cytokine analysis upon exosome treatment. (F-G) Selective inhibiton of 
Clathrin and caveolin1 endocytosis. (I-M) Decreased cytokine release from Clathirin and 
especially Caveolin knock-out MN9D cells exposed to exosomes collected from Syn 
expressing MN9D cells exposed to Mn. 
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Figure 5: (A) Schematic representation of co-culture of LUHMES and primary microglia. 
(B) Increased caspase-3 activity in Mn-stimulated co-culture system pre-treated with 
Syn exosomes. (C) Immunocytochemical analysis of LUHMES treated with GFP 
tagged exosomes. 
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Figure 6: Increased cell to cell transmission of Syn occurs upon Mn-stimulation  
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 Figure 7: Direct detection of manganese-induced cell-to-cell transmission of α-
synuclein oligomers and associated neurotoxicity in vivo. (A-B) Schematic 
representation of stereotaxic injection site and Mn-expoosure timeline. (C-D) 60 days 
post-viral injection, VenusYFP fluorescence is visible in the substantia nigra pars 
compacta (SNpc) of animals injected with AAV-CBA-VenusYFP. (F) Open-field test 
showing decreased locomotor activity of aSyn treated and Mn-exposed mice compared to 
vehicle exposed controls. (G-H) Loss of TH positive neurons in the substantia nigra 
assessed by DAB staining and stereological counts respectively. (I-K) Open field 
behavior of aSyn injected mice exposed to Mn shows decreased movement and motor 
behavior upon exposure to manganese. 
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 Figure 8: Manganese exposure promotes exosome release in transgenic animals and 
αSyn oligomer transmission in humans: (A-B) Higher exosomes counts seen in Mn 
challenged αSyn-A53T transgenic rats compared to either vehicle-treated transgenic rats 
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or non-transgenic rats. (C) Exosome counts of welders and age-matched controls by 
nanoparticle tracking analysis. No difference between either groups is seen. (D) No 
significant increase in the packaging of aSyn is seen between welders and controls. (E-F) 
ThT fluorescence measured by RTQuik of exosomes isolated from welders showing 
higher seeding capacity and misfolded αSyn protein content compared to exosomes 
isolated from healthy controls  
 
Figure 9: Manganese-stimulated exosomes induce motor deficits in mouse models of 
PD. (A) Pictoral representation of stereotaxy injection site in mice. (B) Rotameter 
readings showing greater ipsilateral rotations in amphetamine exposed mice denoting 
greater unilateral lesions in the brains of Mn-stimulated Syn mice.(C-D) Reduced 
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exploratory locomotor activity seen in mice receiving Mn-stimulated αSyn exosomes as 
measured by stereotypy counts, movement time. (E) αSyn(Ser(p)129)-immunoreactive 
cytoplasmic inclusions detected in mice injected with Mn-stimulated αSyn exosomes 
compared to vehicle-stimulated αSyn exosomes or vehicle- and Mn-stimulated GFP 
exosomes injected mice.  
 
Supplementary figure 1: No change seen in serum IL-10 and IL-5 levels in vehicle or 
Mn-stimulated GFP/Syn mice. 
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Supplementary figure 2: Confocal microscopy revealed efficient internalization of the 
vehicle- and Mn-stimulated αSyn-containing exosomes by the WTMC cell line.   
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Abstract 
Many age-related neurodegenerative disorders share a common pathogenic mechanism 
involving the aggregation and deposition of misfolded proteins. In Parkinson’s disease 
(PD), the accumulation of misfolded and aggregated α-synuclein (αSyn) is considered a 
key pathophysiological feature. Generally, these misfolded proteins can be degraded by 
autophagy via the lysosomal pathway. However, the lysosomal degradation pathway is 
impaired in the disease state, leading to a significant accumulation of autophagic vesicles 
in the neuronal body. Considering the role of the divalent metal manganese (Mn) in PD-
like neurological disorders, we characterized the effect of Mn on misfolding as well as its 
role in autophagic/lysosomal dysfunction using a MN9D dopaminergic cell model of PD, 
which stably expresses wild-type human αSyn. Western blot analysis revealed that Mn 
increased the expression of the autophagosomal markers LC3-II and Beclin-1, whereas 
the lysosomal marker LAMP2 was downregulated in αSyn-expressing cells relative to 
vector control cells, suggesting that Mn treatment impairs the autophagic/lysosomal 
degradation pathway. Interestingly, Mn treatment also induced the release of αSyn-
containing exosomes into the extracellular media, as determined by NanoSight particle 
analysis and electron microscopy. Furthermore, we found these αSyn-containing 
exosomes are bioactive and able to induce neuroinflammatory response and 
neurodegeneration in cell culture models of PD. To further elucidate the molecular 
mechanisms underlying Mn-induced autophagic/lysosomal dysregulation, we performed 
next-generation miRNA sequence analysis of manganese- and vehicle-stimulated 
exosomes. We identified 43 miRNAs differentially expressed in Mn-stimulated αSyn 
exosomes as compared to control exosomes. Among them, 12 mRNAs were associated 
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with regulation of autophagic/lysosomal degradation pathway. Three miRNAs 
(miRNAs124, 320a and 325) were previously reported to control autophagic regulation 
by targeting Bim, Hsc70 and E2F1 in experimental models of PD. Collectively, our 
results suggest a novel paradigm in which dysregulation of exosomal miRNA pertaining 
to autophagic degradative machinery may play a role in cell to cell transmission of 
misfolded αSyn protein.(NIH ES19267 ES10586, and NS088206, Lloyd Chair) 
Introduction 
Chronic exposure to high concentrations of metal manganese (Mn) can cause 
neurotoxicity and manganism, neurological syndrome consists of movement 
abnormalities that shares many parkinsonian features although it may not represent 
clinical Parkinson's disease (PD) because lack of nigrostriatal dopaminergic neuron 
damage and classic response to levedopa. Current evidence also indicate that primates 
exposed to manganese do not release dopamine, a key neurotransmitter necessary for 
normal motor function, when stimulated suggesting the dysfunctional dopamine system 
even though the neurons do not show the damage present with PD (El-Agnaf et al., 
2003). Therefore, manganese-induced Parkinsonism predilection to accumulate in and 
damage the globus pallidus and striatum rather than the sunstancia nigra (SN) as does in 
PD. Therefore, given the Mn deposition in the globus pallidus and associated increased 
T1-weighted MRI signal in the extra-pallidal basal ganglia (caudate and putamen) has 
been studied as potential marker of neurotoxicity associated with manganese exposure. 
However, in clinical settings, differential diagnosis of manganese-induced Parkinsonism 
is primarily based on the Unified Parkinson Disease Rating Scale, motor subsection 3 
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(UPDRS3), a clinical rating scale associated with motor functions. Nevertheless, due to 
the fact UPDRS3 scale can only be applied when motor symptoms are present and MRI 
is expensive method yet not accessible throughout the world, and effectiveness of the 
current biomarker to detect Parkinsonism as early diagnosis criteria is not feasible.  
Since there are no reliable quantitative diagnostic tests for these neurological disorders, 
molecular biomarker discoveries are important and potentially could be used to diagnose 
Parkinsonism in early stages. However, current candidate biomarkers are heavily based 
on individual proteins related to pathogenesis of PD in CSF and brain tissues, which 
often involve invasive techniques and surgeries.  Therefore, the development and 
validation of noninvasive screening tests capable of detecting neurodegenerative diseases 
during early, presumably asymptomatic stage is important.  Thus, blood based assays for 
diagnoses of neurodegenerative diseases are particularly interesting and informative to 
assay biomarkers such as proteins, antibodies and circulating miRNAs.  
miRNA is a class of non-coding RNA, whose final product is an approximately 18-22 
nucleotides long functional RNA molecule. miRNA repress translation and regulate 
degradation of their target mRNA by binding complementary regions of messenger 
transcripts. Research in various disease processes from cancer to cardiovascular disease 
has found that miRNAs play a role in disease pathogenesis and have potential as 
biomarkers and therapeutic agents. Recently, number of miRNA expression changes 
reported in different brain areas involved in AD development (Kordower et al., 2008) and 
comprehensive review by Tan et al 2013 (Kordower et al., 2008) identify the 
involvement of miRNA in the development of AD such as accumulation of amyloid-β, 
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tau toxicity, neuroinflammation and cell death. Identification of miRNA involvement in 
PD has been focused on miRNA expression in the midbrain and the role of miRNA for 
the functioning of doperminergic neurons. In late 2007 Kim and colleagues identified 
miR-133b that is specifically expressed in the midbrain doperminergic neurons in healthy 
adults were deficient in midbrain tissues isolated from PD patients (Li et al., 2008). Since 
then, several miRNAs controlling autophagy regulation (miR-124, miR-320a and miR-
325) and α–synuclein synthesis (miR-7 and miR153) in experimental models of PD have 
been identified. Furthermore, a recent miRNA research looked at global miRNA 
expression patterns in circulating miRNAs in PD patients and age matched healthy 
individuals  resulting in the identification of PD-predictive biomarkers k-TSP1 (miR-
1826/miR-450b-3p), miR-626, and miR-505, with highest predictive power of 91% 
sensitivity and 100% specificity, bringing forth the ossiblity of diagnostic approach based 
on analysis of miRNAs in plasma (Bae et al., 2014). Importantly, studies have shown that 
circulating miRNA signatures discriminate PD from Multiple System Atrophy (MSA), 
patients and healthy controls providing further strengthening the idea of using miRNA 
differential diagnosis in diseases that have similar clinical and pathological resemblance 
(Danzer et al., 2012). Therefore, peripheral blood is important as a source of non-invasive 
biological sample to facilitate miRNA biomarker discoveires in humans, as well their 
future clinical applicability. 
miRNAs are also found in blood,(Chen et al., 2008; Lawrie et al., 2008; Mitchell et al., 
2008) and such circulating miRNAs are remarkably stable even under harsh 
conditions,(Chen et al., 2008; Mitchell et al., 2008) suggesting possible novel diagnostic 
potential of circulating miRNAs. Circulating miRNAs have been detected in plasma, 
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serum, urine, and saliva where they are protected from degradation by membranes of the 
exosomes and other microvesicles that contain them. Exosomes are nano-sized vesicles 
(50-250 nm) that are released from many cell types into the extracellular space. These 
vesicles are widely distributed in various body fluids and can easily cross the blood–brain 
and other barriers. Tremendous interest has emerged in recent years on exosome research 
because of its potential role in disease pathogenesis and biomarker discovery.(Alderton, 
2015; Anastasiadou and Slack, 2014; Couzin, 2005; Minton, 2015; Thery et al., 2002) 
There are numerous examples of miRNA’s as putative biomarkers of occupational and 
environmental exposures to polycyclic aromatic hydrocarbons,(Deng et al., 2014) 
dioxin,(Feitelson and Lee, 2007) metal rich particulate matter,(Volinia et al., 2006)  
arsenic,(Dai et al., 2009) and many others.(Vrijens et al., 2015)  Growing evidence 
suggests that miRNAs play a significant role in the pathogenesis of many chronic 
diseases, including PD. For example, there are differences in miRNA expression in the 
midbrain and in circulating plasma miRNAs in PD patients compared to control 
subjects.(Cardo et al., 2013; Khoo et al., 2012; Kim et al., 2007) Circulating miRNA 
signatures can also discriminate PD patients from Multiple System Atrophy 
patients,(Vallelunga et al., 2014) demonstrating the feasibility of using circulating 
miRNAs as a biomarker to distinguish between diseases that share similar clinical and 
pathological features. Recently, several miRNAs regulating the synthesis of α-synuclein 
(αSyn), the hallmark protein of PD, as well as autophagy and apoptosis, were identified 
in experimental models of PD.(Alvarez-Erviti et al., 2013; Heman-Ackah et al., 2013; 
Kabaria et al., 2015; Wang et al., 2015) Yet, despite its prevalence, and thus potential risk 
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to human health, the mechanisms by which manganese exerts its neurotoxic factors 
effects by αSyn secretion and transmission is not well studied thus far.  
Hence, in this study, we use manganese as environmental neurotoxicant to induce αSyn 
aggregation, secretion and cell-to-cell transmission miRNAs to manipulate recepeant cell 
gene expression via exosomes. To elucidate the molecular mechanisms of manganese-
induced neurotoxicity, we used miRNA deep sequencing and custom miRNA PCR array 
technology to investigate role of exosomes in cell-to-cell transmission of miRNAs.  
 
Materials and Methods 
Chemical and Reagents 
All chemicals were purchased from Sigma-Aldrich and reagents related to cell cultures 
were obtained from Invitrogen unless otherwise specified. 
Cell culture and stable expression of αSyn 
For αSyn release and exosome isolation experiments, we created a GFP-tagged αSyn 
stably-expressing MN9D cell line. Expression plasmids for human full-length αSyn-
pMAXGFP and control pMAXGFP vectors (Lonza) were transfected into MN9D cells 
using Lipofectamine 2000 reagent (Invitrogen) and grown in DMEM (D5648; Sigma) 
supplemented with 50 IU/ml penicillin, 50 μg/ml streptomycin, and 10% FBS. For stable 
transfection, MN9D cells were selected after culturing in 400 μg/ml of geneticin for one 
week post-transfection, and then selected cells were cultured in media supplemented with 
200 μg/ml of geneticin to maintain the stable transfection. GFP-positive αSyn-expressing 
(MN9D_SynGFP) and vector control (MN9D_EVGFP) cells were further selected by 
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FACSAria III (BD Bioscience) high-speed sorting flow cytometer to obtain 
homogeneously transgene-expressing cell populations.  
Western and slot blotting  
Whole cell lysates or exosome lysates were prepared using modified RIPA buffer 
containing protease and phosphatase inhibitor cocktail (Thermo Scientific, Waltham, 
MA), as described previously (Emmanouilidou et al., 2010; Lee et al., 2010). For αSyn 
release experiments, cells were treated in serum-free medium spiked with 0.025 mg/ml 
BSA, and then at the end of their incubation, the media was collected and centrifuged for 
5 min at 3000 x g to remove any dislodged cells or cell debris. The conditioned media 
was concentrated using 5000 MWCO Vivaspin-20 spin columns (GE Lifescience), and 
then protein concentrations were determined with the Bradford protein assay kit (Bio-
Rad). Cell lysates containing equal amounts of protein were separated on a 12-15% SDS-
polyacrylamide gel. After separation, proteins were electro-blotted onto a nitrocellulose 
membrane, and nonspecific binding sites were blocked by treating with LI-COR blocking 
buffer. Syn-1 (BD Bioscience), Flotillin (BD Bioscience), BSA (Invitrogen), LDHA (Cell 
Signalling), Aip1/Alix (Millipore), IBA-1 (Wako), iNOS (Santa Cruz) and β-actin 
(Sigma) primary antibodies were used to blot the membranes.  
Oligomeric proteins treated with manganese were analyzed with a slot blot apparatus 
(Bio-Dot, Bio-Rad) using the antibody against protein Oligomers (A11) (Invitrogen). 
Following protein adsorption, membranes were blocked with 5% BSA and incubated 
overnight with the A11 antibody. Membranes were then developed with IR800-
conjugated anti-rabbit or Alexa Fluor 680-conjugated anti-mouse secondary antibody for 
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1 h at room temperature. Western and slot blot images were captured with the Odyssey 
IR Imaging system (LI-COR) and data were analyzed using Odyssey 2.0 software. 
Immunocytochemistry and Immunohistochemistry 
For immunocytochemistry, MN9D cells and microglia cells were plated on 50 μg/mL 
PDL-coated 12-mm glass coverslips and treatments were done as described. LUHMES 
cells were plated on coverslips pre-coated with 50 μg/mL poly-l-ornithine (Sigma-
Aldrich) overnight, washed twice with cell culture grade water (Invitrogen) at the end of 
the incubation and incubated with 1 μg/mL fibronectin (Sigma-Aldrich) overnight. After 
treatments, cells were washed with PBS and incubated in 4% paraformaldehyde for 30 
min at room temperature. After fixing, the cells were washed with PBS and incubated in 
blocking agent (2% BSA, 0.05% Tween-20, and 0.5% Triton X-100 in PBS) for 45 min. 
Cells were then incubated with antibodies against human α-synuclein (Syn211; Santa 
Cruz, 1:500), GFP (Abcam 1:2000), IBA-1 (Wako, 1:500) overnight at 4°C or the 
cytoskeleton marker Phalloidin (Alexa Fluor 647 phalloidin, Invitrogen) for 30 min at 
room temperature. After primary incubation, the cells were washed and incubated in the 
dark for 90 min with Alexa-488 and -555 dye-conjugated secondary antibodies 
(Invitrogen, 1:1000). Hoechst 44432 was used as a nuclear stain and the coverslips were 
then mounted on glass slides and viewed with 63× and 43× oil objectives using 
a Leica DMIRE2 confocal microscope. 
Exosome isolation 
Cell-produced exosomes were isolated using ExoQuickTC (System Biosciences) reagent 
or were purified by differential ultracentrifugation via slight modification of a process 
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described by Emmanouilidou et al. (2010). Briefly, MN9D_SynGFP and MN9D_EVGFP 
cells at 70-80% confluency were treated with or without 300 µM manganese in exosome-
depleted medium containing 10% FBS for 24 h. After treatment, cell culture supernatant 
was collected and spun at 300 x g for 10 min to remove cells and 10,000 x g for 15 min to 
exclude cell debris from the supernatant. The resulting media was then passed through a 
0.2-µm syringe filter (Millipore) to remove any remaining particles or cell debris, and the 
filtrate was centrifuged at 100,000 x g for 90 min using a Beckman Optima L-100 XP 
ultracentrifuge. The pellet containing exosomes was washed once with cold PBS and 
centrifuged again at 100,000 x g for 90 min using a Beckman optima MAX 
ultracentrifuge. Exosome pellets were resuspended in 50 μl of Radioimmunoprecipitation 
assay (RIPA) buffer for Western blot analysis, or when treating primary microglia cells, 
they were resuspended in 150 μl of DMEM-F12. Total serum exosomes were isolated 
using ExoQuick (System Biosciences) reagent following the manufactures’ 
recommended protocol.  
 
Nanoparticle tracking analysis (NTA) 
Ultracentrifuged or ExoQuick/TC-precipitated exosome samples were used for NTA, as 
previously described (Su et al., 2008). Briefly, isolated exosomes were resuspended in 
500-1000 µL PBS, from which approximately 300 μL was loaded into the sample 
chamber of an LM10 unit (Nanosight, Amesbury, UK) using a disposable syringe. 
Sample durations of 30-60 sec per sample were analyzed with NTA 2.3 software 
(Nanosight). Samples containing higher numbers of exosomes were diluted before the 
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analysis and their relative concentrations were then calculated according to the dilution 
factor. 
Transmission electron microscopy (TEM)  
Purified exosomes were resuspended in 200 µl PBS.  We mixed 20 µl of each sample 
with uranyl acetate 2% (w/v), incubated them for 5 min, and then 5 µl were applied to 
carbon-coated copper grids. Images were taken using a JEOL 2100 200 kV scanning and 
transmission electron microscope (STEM) with a Thermo Fisher Noran System 6 
elemental analysis system. TEM was operated at 80 kV and images were obtained at 
18000-20000 x magnification.  
Exosomal RNA extraction and characterization 
For detection of RNA species in exosome samples isolated from manganese-stimulated 
αSyn-pMAXGFP and control pMAXGFP cells or vehicle-treated αSyn-pMAXGFP and 
control pMAXGFP cells, we used the miRCURY RNA isolation kit (Exiqon; 30010) 
according to the manufacturer’s protocols. After extraction, a Nanodrop 
spectrophotometer used initially to determine the concentration and quality of the RNA 
preparation. Then RNA quality, yield, and size of exosomal small RNA were analyzed 
using the Agilent 2100 Bioanalyzer (Agilent Technologies, Foster City, CA) with the 
Agilent RNA 6000 Nano Kit as described previously (Danzer et al., 2012).  Next 
generation sequencing of exosomal RNA 
Upon manganese stimulation, whole conditioned media sent to SBI bioscience for 
exosome isolation, preparation of exoRNA libraries compatible with sequencing on 
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Illumina NGS platform. The amplified indexed libraries are then resolved in a 
polyacrylamide gel from which the desired bands are excised in a streamlined gel 
purification method. The recovered amplified libraries are then ready for analysis on the 
Illumina sequencing platforms (HiSeq, MiSeq, and Genome Analyzer II) with about 
300M reads per sample in order to generate substantial sequencing depth. After 
sequencing, reads can be de-multiplexed based upon their unique index sequence and 
then assigned to their appropriate input samples identities. Using Maverix exoRNA 
analysis pipeline (Maverix Biomics; San Mateo, CA), sequences are mapped to a 
reference genome of choice to determine sequence identities and relative abundances of 
various RNA types such as ncRNAs, antisense transcripts, and miRNAs.  
MicroRNA (miRNA) profiling and data validation 
Total RNA that includes small non-coding miRNA was purified from exosomes isolated 
from untreated and manganese stimulated αSyn-pMAXGFP cells using miRCURY RNA 
isolation kit (Exiqon; 30010) following manufacturer's instructions. Post-isolation, RNA 
quality was determined using a Nanodrop 2000 instrument. For miRNA validation 
studies, SYBR green based custom miScript miRNA PCR Array (Qiagen, MD) was used. 
The custom miScript miRNA PCR Array allows the simultaneous detection of 
41miRNAs previously identified in through our exosome miRNA NGS studies, as well as 
appropriate housekeeping assays and RNA quality controls. Diluted cDNA was mixed 
with universal primer and SYBR Green dye and added to the wells of 96-well plates 
containing lyophilized primer. The plates were run on a Stratagene Mx3005P instrument 
(Agilent technologies) and the expression of individual miRNAs was analyzed using the 
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obtained Ct values. As a normalizer, SNORD61 was used as a housekeeping miRNA. 
The plate assay was performed according to the manufacturer's protocol and fold changes 
in miRNA expression were calculated using the Ct value of the normalizer control 
Statistical analysis 
Prism 4.0 software was used to analyze data from two or more independent experiments, 
each with n ≥ 6.  Bonferroni’s multiple comparison testing was used to find significant 
differences between treatment and control groups. Differences with p < 0.05 were 
considered significantly different 
Results 
Manganese exposure upregulates the release of αSyn into the extracellular milieu. 
A transgenic cell line constitutively expressing GFP-tagged human wild-type αSyn was 
established by stably transfecting MN9D mouse dopaminergic cells with either plasmid 
pMAXGFP_αSyn or pMAXGFP_EV (empty vector). MN9D cell line is a widely used 
cell model in the area of PD research. Immunocytochemical analyses indicate that >90% 
of the pMAXGFP_αSyn cells were positive for the transgene human αSyn, and that all 
pMAXGFP cells were positive for GFP (Fig. 1A). Further analysis through Western blot 
indicates a low level expression of endogenous αSyn in both cell types and a strong 
expression of higher molecular weight GFP-tagged αSyn in pMAXGFP_αSyn (Fig. 1B). 
Manganese induces exosomes release from neuronal cells.    
To further investigate the underlying molecular mechanisms of αSyn secretion and its 
relevance in the progression of PD, we looked in to the possible mechanisms of cargo 
used in αSyn secretion. For this, we analyzed the conditioned media collected from 
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manganese-or vehicle treated cells through TEM followed by differential 
ultracentrifugation. Our results indicate the presence of nano-scale exosome vesicles 
morphologically similar to previously reported exosomes in both vehicle and manganese 
treated samples (Fig. 3A, Supplementary Fig 1A) (Emmanouilidou et al., 2010). Since 
exosomes reportedly contain a unique RNA profile distinct from that of host cells (Valadi 
et al., 2007), we further analyzed the exosomes for small noncoding RNAs, such as 
microRNAs (miRNA). Exosomal RNA was isolated using the mirVanaTM miRNA 
isolation kit and small RNAs were analyzed with the Agilent 2100 Bioanalyzer Lab-ona-
Chip instrument system (Agilent Technologies). Our data show that the isolated 
exosomes do indeed contain small RNAs, of which about 86% are positive for miRNAs 
(Supplementary FigB), suggesting that these exosomes not only play an important role in 
cell signaling, but also impact biological processes in the recipient cells upon fusion. 
 
In parallel experiments, we carried out NanoSight analyses to visualize, count and 
measure the size of exosomes isolated from pMAXGFP_αSyn cells after manganese 
treatment. As illustrated in Fig 2B, the diameter of exosomes isolated from control cells, 
150.8 ± 7.05 nm, was comparable to that of manganese-treated exosomes (148.6 ± 12.42 
nm, data not shown), indicating that manganese exposure does not alter the average size 
of exosomes. These calculated sizes are consistent with previously published 
observations (Danzer et al., 2012; Emmanouilidou et al., 2010). However, we were able 
to detect significantly more exosomes in the manganese-treated cells compared to the 
vehicle-treated cells, indicating that manganese highly upregulates the release of 
exosomes (Fig 2C). 
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Manganese induces oligomeric αSyn secretion via exosomes. 
To further characterize these cell-derived exosomes, we examined the presence of αSyn 
and exosomal surface proteins. Western blot analysis readily detected the exosomal 
surface membrane protein markers alix and flotillin-1 in all exosomes samples (Fig. 3A). 
Surprisingly, we observed more GFP-tagged αSyn fusion protein in exosomes isolated 
from manganese-exposed cells than from untreated cells (Fig. 3A), indicating manganese 
exposure increases the αSyn payload carried by exosomal cargos.  
Existence of αSyn oligomers in biological fluids and exosomal fractions isolated from 
cultured cells (Danzer et al., 2012; Lee et al., 2005) has been well characterized. 
Therefore, we sought to determine whether oligomeric αSyn proteins are present in the 
isolated exosomes by using slot blot analysis with the anti-oligomer antibody A11. This 
conformational-specific antibody detects peptide-independent prefibrillar oligomers 
(Glabe, 2008; Kordower et al., 2008). As shown in Fig.2F, the exosomes isolated from 
manganese-stimulated pMAXGFP-αSyn cells show a greater accumulation of the 
prefibrillar oligomers compared to manganese-treated pMAXGFP or untreated cells. 
Collectively, our data suggest that manganese exposure increases the amount of 
exosomes released and also upregulates the aggregated protein cargos packaged into 
these exosomes.  
 
Manganese exposure leads to differential expression of small RNAs 
To identity and abundance of small RNA changes upon manganese exposure, we have 
performed next-generation exosome RNA sequencing in exosomes. We isolate the 
exosomes from pMAXGFP-αSyn cells treated with manganese or vehicle, purify the 
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exoRNA and build the Illumina NGS libraries. These libraries are then sequenced using a 
1x 50bp single end Illumina HiSeq NGS runs to provide enough depth of RNA sequence 
identification. Our small RNA subtype profiles (Fig 4.A) indicated gross changes in 
miRNA, rRNA, tRNA and ncRNAs expression indicating manganese exposure cause 
changes in small RNA profiles in exosomes. Then we have further analyzed the miRNA 
changes in manganese stimulated exosomes compare to vehicle treated exosomes. After 
filter out those with 0 expression in either sample, our analysis indicates (Fig 4.B) 
substantial changes in miRNA expression in manganese stimulated exosomes.  The figure 
4C shows log2 fold changes in normalized expression (positive/control) with green = 
miRNAs that are > 4-fold unregulated and red = miRNAs that are > 4-fold upregulated in 
the manganese stimulated sample.  
 
Validation of miRNA targets through custom miScript PCR array technology.  
After identification of differentially express miRNAs through RNA-sequencing, we have 
performed miRNA qPCR to validate out RNA Seq results. Our custom miRNA PCR 
array consist of 48 miRNA including 43 previously identified miRNAs and five internal 
controls for expression normalization. Our data indicated 12 miRNAs significantly 
increased in manganese stimulated exosomes compares to vehicle stimulated exosomes.  
 
Discussion 
In this study, we report that the environmental neurotoxicant manganese can enhance the 
release of miRNA containing exosomes into the extracellular milieu, inducing which may 
in-turn modulate host cell gene expression. Our results also identified 43 differentially 
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express miRNAs in manganese stimulated exosomes in manganese stimulated exosomes 
compare to vehicle treated exosomes. To the best of our knowledge, we are the first to 
demonstrate the ability of environmental neurotoxicants modulate miRNA expression in 
cell culture- derived exosomes in cell culture models of PD. These findings could 
improve our understanding of exosome-mediated cell-to-cell propagation of αSyn in the 
progression of neurological disorders.  
 
Cell-to-cell transmission of αSyn and the role of extracellular αSyn in the progression of 
PD gained much interest recently with the discovery of αSyn in human cerebrospinal 
fluid (CSF) and blood plasma (El-Agnaf et al., 2003). In support of a pathogenic role for 
extracellular αSyn, recent reports showed that αSyn aggregates released from neurons 
unleash toxic effects in recipient neurons by forming Lewy body-like inclusions 
(Desplats et al., 2009; Emmanouilidou et al., 2010) or by activating inflammatory 
responses in microglia (Kim et al., 2013). Furthermore, recent studies have shown that 
adding exogenous fibrillar αSyn into αSyn-overexpressing cells actively recruits soluble 
endogenous αSyn, converting it into a detergent-insoluble misfolded state (Luk et al., 
2009). Thus, much like the mechanism observed in prion disease (Aguzzi and Falsig, 
2012), extracellular αSyn serves as a seed and template for endogenous αSyn to 
propagate αSyn aggregation.  
 
In this study, we are evaluating the effect of the environmental neurotoxin manganese in 
modulating miRNA expression in exosomes. Although environmental toxicants accounts 
for most sporadic PD cases, its role in the release and regulation of gene expression is 
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poorly studied. Chronic occupational exposure to high levels of manganese by welding, 
mining, dry cell battery manufacturing and manganese rich agro-chemicals is known to 
cause manganism, a condition closely related to PD, as characterized by tremors, rigidity 
and psychosis (Gerber et al., 2002; Kordower et al.). Previous studies have shown that 
manganese neurotoxicity leads to neuronal apoptosis, αSyn upregulation and aggregation 
in experimental models of PD (Cai et al., 2010; Hirata, 2002; Kordower et al., 2008). To 
further understand the role of manganese in the cellular release of αSyn, we have created 
GFP-fused wild-type human αSyn constitutively expressing dopaminergic cells which we 
exposed to inorganic manganese. We subsequently collected and concentrated 
conditioned culture media to analyze possible αSyn release, and as our Western blot 
results indicate, we readily detected αSyn in the culture medium obtained from 
pMAXGFP-αSyn cells.  
 
The αSyn protein structure doesn’t contain a signal recognition sequence, hence the 
observed secretion could be independent of the ER/golgi secretion pathway 
(Emmanouilidou et al., 2011; Vekrellis et al., 2011). Moreover, several unconventional 
excretion mechanisms have been implicated in αSyn release, including an endosomal 
pathway, direct transfer across the membrane and release through exosomes 
(Emmanouilidou et al., 2010; Lee et al., 2005). Therefore, to understand the mode of the 
αSyn release induced by manganese, we analyzed the conditioned media through TEM 
followed by differential ultracentrifugation. As our results indicated, we readily detected 
exosomes (Fig. 2A).  Further analysis through Western blot indicates significantly more 
αSyn in exosomes derived from manganese-exposed cells. Surprisingly, Nanosight 
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particle analysis showed a higher exosomal release upon manganese treatment (Fig. 2C), 
indicating that manganese increases the total exosome release and the αSyn cargo 
residing in the exosomes are higher too.  
Furthermore, we have analyzed exosomal small RNA content through miRNA Seq 
analysis and identified 43 differentially express miRNA which among them, 12 miRNAs 
were previously reported to regulate cellular autophaic/lysosomal degradation pathway.  
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 Figure 1. Generation of GFP-tagged stable human -α-synuclein expressing MN9D 
cells and manganese-induced α-synuclein secretion. 
(A) Immunocytochemical analysis depicting stably expressed GFP-tagged wild-type 
human αSyn protein in MN9D dopaminergic cells. αSyn-expressing cells exhibited 
strong ubiquitous expression of αSyn, whereas vector cells showed no detectable αSyn 
immunoreactivity. (B) Stable expression of αSyn was determined by Western blot 
analysis. A 45-kDa band corresponding to the molecular mass of GFP-fused human αSyn 
was detected in α-synexpressing cells, whereas no human-specific αSyn expression 
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appeared in vector cells. However, both human αSyn-expressing and control cells showed 
low levels of endogenous αSyn expression. 
 
 
 Figure 2.  Manganese induces exosomes release from neuronal cells.    
(A) Electron micrograph of isolated exosomes revealing that transmission electron 
microscopy of ultracentrifuged conditioned medium readily detected exosomes. (B) 
Nanosight-generated histogram of particle size and abundance of isolated exosomes. (C) 
Exosome concentrations showing that manganese exposure upregulated the release of 
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exosomes into the extracellular micro-environment. 
 
 
Figure 3.  Manganese induces oligomeric αSyn secretion via exosomes. 
Western blot analysis shows exosomal surface membrane protein markers alix and 
flotillin-1 in all exosomes samples and elevated αSyn in manganese stimulated αSyn-
pmaxGFP exosomes. 
Slot blot analysis showing higher oligomeric protein accumulation in exosomes isolated 
from manganese-stimulated exosomes from both αSyn-pmaxGFP and control pmaxGFP 
cells relative to vehicle-treated αSyn-pmaxGFP and control pmaxGFP cells. However, 
exosomes from manganese stimulated αSyn-pmaxGFP indicate greater accumulation of 
prefibrillar oligomeric protein 
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 Figure 4: Top: Comparison of RNA profiles between Control (Left) and Positive (Right) 
samples reveals different abundances of small RNA subtypes. 
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Bottom: Differentially expressed miRNAs are highlighted in red (> 4-fold upregulation) 
and green (> 4-fold downregulation) (Left). The expression log-normalized expression 
profiles of specific upregulated (Middle) and downregulated (Right) miRNAs are plotted.  
 
Figure 5: Validation of miRNA targets through custom miScript PCR array 
technology (A) Heat-map of miRNA expression between control and Mn-stimulated 
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exosomes. (B) Increased expression of miRNA’s isolated from manganese stimulated 
exosomes compares to vehicle stimulated exosomes (C) Volcano-plot showing fold 
change and p-values of validated miRNA’s. Data above p=0.05 show miRNA’s with 
significantly different expression in Mn-stimulated exosomes compared to vehicle 
stimulated exosomes. 
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CHAPTER V: GENERAL CONCLUSIONS 
This section presents an overview of the results and findings of this dissertation, 
with a special emphasis on overall implications of these findings for the roll of 
environmental neurotoxicants on cell-to-cell transmission of α-synuclein in Parkinson’s 
disease. The major findings of each research chapter included in this dissertation are 
covered in the discussion section of the relevant chapter.  
 
α-Synuclein Protects against Manganese Neurotoxic Insult during the Early Stages 
of Exposure in a Dopaminergic Cell Model of Parkinson’s Disease 
The primary finding from the chapter 2 of the thesis is that the human wild-type 
α-Syn plays a neuroprotective role against manganese neurotoxicity in its early stages, 
but the protein becomes increasingly susceptible to aggregation during prolonged metal 
exposure. In this study, we sought to understand possible the role of α-Syn’s multiple 
metal binding sites and possible physiological function of wild-type α-Syn in manganese 
induce neurotoxicity. To this end, we developed an α-Syn-expressing dopaminergic 
neuronal cell model for examining the role of α-Syn in both acute and prolonged 
manganese neurotoxicity. Using this in vitro model, we provided direct evidence for the 
neuroprotective effect of human α-Syn in dopaminergic neurons during acute manganese 
toxicity. We observed this effect at 300 µM manganese, a dose consistent with previously 
published work (Exil et al., 2014; Latchoumycandane et al., 2005; Martin et al., 2011) 
and concentration within the toxicologically relevant range as its has been shown that 
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depending upon the dose, duration, and route of exposure, manganese concentrations can 
reach up to 350 µM in certain brain regions (Ingersoll et al., 1999).  
In our current study, dopaminergic cells expressing human wild-type α-Syn exhibited 
significantly lower apoptotic cell death compared to vector control N27 cells upon acute 
manganese toxicity. Interestingly, α-Syn does not hamper the cells’ ability to produce 
ROS when exposed to manganese. To further characterize the mechanism underlying the 
neuroprotective effect of α-Syn against manganese-induced apoptotic cell death, and 
because manganese is known to impair mitochondrial function (Gunter et al., 2009; 
Latchoumycandane et al., 2005), we systematically examined the mitochondria-
dependent apoptotic signaling events. We found a significant attenuation of cytochrome c 
release to cytosol from the mitochondrial inner-membrane in α-Syn-expressing cells, 
suggesting that α-Syn interferes with the process of cytochrome c release during early 
phases of manganese neurotoxicity. However, our immunocytochemistry and slot blot 
analysis data indicate intracellular protein aggregate accumulation during prolonged 
manganese exposure in dopaminergic neuronal cells. These observations were validated 
using the ProteoStat aggresome detection kit (Enzo) and the ProteoStat inclusion body kit 
(Enzo) to indicate the accumulation of aggregated proteins in α-Syn cells compared to 
Vec cells after prolonged manganese exposure. Overall, our results support the idea that 
α-Syn initially protects against manganese-induced neurotoxicity by reducing 
mitochondria-dependent apoptotic signaling, whereas prolonged exposure to manganese 
significantly alters the stability of α-Syn protein, increasing the amount of aggregated α-
Syn protein.  
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The Environmental Neurotoxicant Manganese Promotes Prion-like Cell-to-Cell 
Transmission of α-Synuclein via Exosomes in Cell Culture and Animal Models of 
Parkinson’s Disease 
Recent studies suggest that a prion-like cell-to-cell transfer of misfolded αSyn contributes 
to the spreading of αSyn pathology. However, the biological mechanisms underlying the 
propagation of the disease with respect to environmental neurotoxic chemical exposures 
are not well understood. Therefore, in chapter 3, we sought to understand possible 
manganese induced αSyn protein aggregation and extracellular secretion of αSyn via 
exosomal vesicles, which subsequently evokes pro-inflammatory and neurodegenerative 
responses in both cell culture and animal models. To elucidate the mechanism of 
manganese-induced release, we followed a systematic approach form in vitro to ex vivo to 
in vivo experimental models to better understand the role of exosomes in cell-to-cell 
transmission of misfolded αSyn protein. First, using wild-type human αSyn-
overexpressing cell culture model, we provided direct evidence that manganese exposure 
significantly enhances the release and accumulation of extracellular αSyn providing 
direct evidence of an environmental influence of αSyn release. 
Neuroinflammation is key to the pathogenesis of PD and other related α-
synucleinopathies. To study whether manganese-stimulated exosomes have any role in 
neuroinflammatory processes, we exposed primary murine microglia to either vehicle or 
manganese-stimulated exosomes and quantified the neuroinflammatory effects. Our 
immunocytochemistry data and Luminex cytokine analysis indicate microglia cells 
treated with manganese-induced αSyn exosomes show enhanced levels of oxidative stress 
and proinflammatory cytokines, such as TNFα, IL12, IL1β and IL6, indicating that 
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exosomes can evoke inflammatory responses. Further characterization of exosomes 
through slot blot analysis with protein oligomer-specific antibodies indicated a greater 
accumulation of prefibrillar oligomers in manganese-stimulated αSyn exosomes. To 
further investigate whether exosomes carry disease-associated prefibrillar αSyn 
oligomers, which can seed and propagate pathology in vivo, we injected 2- to 3-month 
old wild-type C57BL/6 mice with exosomes isolated from manganese or vehicle-treated 
EV cells and αSyn cells. Interestingly, we detected human αSyn-immunoreactive 
cytoplasmic inclusions at 90 dpi in mice stereotaxically injected with either vehicle-
stimulated or manganese-stimulated αSyn exosomes. However, mice injected with 
manganese-stimulated αSyn exosomes had more Lewy body/Lewy neurite structures 
compared to vehicle-stimulated αSyn exosome-injected mice. These data suggest that 
αSyn exosomes can initiate Parkinsonian neuro-pathologies in experimental models of 
PD. 
Finally, we show further that humans exposed to manganese through welding fumes 
contain higher misfolded αSyn in their serum exosomes than control subjects. In 
conclusion, we identified a possible mechanism for how the environmental neurotoxicant 
manganese contributes to exosome-mediated cell-to-cell propagation of αSyn and its role 
in the progression of neurological disorders. 
Environmental Neurotoxicant Manganese Increases Exosome-Mediated miRNA 
Delivery and Autophagic Regulation in Cell Culture Model of Parkinson’s Disease.   
miRNA is a class of small non-coding RNA, whose final product is an approximately 18-
22 nucleotides long functional RNA molecule. miRNA repress translation and regulate 
degradation of their target mRNA by binding complementary regions of messenger 
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transcripts. Research in various disease processes from cancer to cardiovascular disease 
has found that miRNAs play a role in disease pathogenesis and have potential as 
biomarkers and therapeutic agents. Recently, number of miRNA expression changes 
reported in different brain areas involved in AD development (Kordower et al., 2008) and 
comprehensive review by Tan et al 2013 (Kordower et al., 2008) identify the 
involvement of miRNA in the development of AD such as accumulation of amyloid-β, 
tau toxicity, neuroinflammation and cell death. These miRNAs circulate through the body 
either by binding to certain proteins or as cargo packaged in exosomes, whereby it can 
modulate the recipient cell’s gene expression upon endocytosis. Despites its importance, 
dysregulation of circulating miRNAs upon environmental neurotoxicant insults have 
rarely been studied. In chapter 4, we hypothesize that exposure to the environmental 
neurotoxicant manganese impairs the cellular protein degradation mechanism, causing a 
misfolded αSyn protein payload to accumulate in cells, and then induces secretion and 
transmission of aggregated αSyn via exosomes to its microenvironment.  
In this study, we also analyzed and validated miRNA changes in exosomes collected 
from cells expressing human  -synuclein, a genetic risk factor for Parkinson’s disease, 
upon manganese neurotoxic insult. Our study identified 43 differentially expressed 
miRNAs in manganese-stimulated αSyn exosomes as compared to control exosomes. 
Among them, majority of miRNAs were associated with regulation of 
autophagic/lysosomal degradation pathway by targeting important autophagic regulates 
such as Bim, Hsc70, E2F1 and etc in experimental models of PD. Our custom miRNA 
PCR array confirmed our NGS miRNA sequencing results and further validates and 
identified 12 miRNAs which significantly changes among control and manganese treated 
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group. In future studies, we will be validating the possible gene regulation by miRNA by 
feeding exosomes and synthetic miRNAs back to naïve differentiated dopaminergic cells 
and investigates its biological relevance. Hence, our in vitro assays demonstrate the 
exosome’s capacity to deliver miRNAs and act as a cargo vessel that invades recipient 
cells much like a “Trojan horse mechanism,” thereby exacerbating neuropathology.  
With the recent clinical advancements with therapeutic siRNAs using liposomal and 
polymerbased delivery technologies, natural vesicular lipid transporters such as exosomes 
with the abundance of adhesive proteins that readily interact with cellular membranes, 
exosome-based drug delivery systems may have advantages in the treatment of 
neurodegenerative disorders. Therefore, we can further develop miRNA antagonists as 
novel therapeutics to inhibit endogenous miRNAs that show a gain-of-function in 
diseased state and fused in exosomes for effective delivery. Importantly, our research 
identified multiple miRNA targets potentially use as drug targets and address rather 
essential research questions related to protein misfolding and accumulation in 
neurodegenerative disorders.  
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Abstract 
Prion diseases are a class of fatal neurodegenerative diseases caused by 
misfolding of the endogenous prion protein (PrP
C
) induced by exposure to the pathogenic 
conformational isomer of PrP (PrP
Sc
) or by heritable mutation of PrP
C
. Although the 
exact role of the protein has yet to be solved, considerable evidence reveals prion protein 
to be a metalloprotein harboring divalent metal-binding sites for various cations such as 
copper, manganese, zinc, and nickel. Despite low-affinity binding to prion protein, when 
manganese interacts with prion, it can alter the development and transmission of prion 
disease. In this chapter, the role of metals in the pathogenesis of prion disease will be 
discussed. Particular emphasis will be placed on the link between manganese and PrP
C
.    
 
Keywords: metals, manganese, copper, conformational change, protein aggregation and 
prion disease. 
 
1. Introduction 
Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), 
describe a group of fatal neurodegenerative disorders affecting both humans and animals 
(Prusiner, 1991). Although the prevalence of prion disease is relatively low with about 
300 cases reported annually in the United States, the potential for the disease to be 
transmitted between humans and animals raises strong concerns over its control. Prion 
disease occurs in many forms due to differences in pathology as well as modes of 
pathogenesis (Head, 2013). Their etiologies are also multi-fold in dimension with the 
possibility of iatrogenic routes from infected surgical materials, human grafts, and even 
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blood transfusions; or hereditary in nature. Typical clinical symptoms of prion diseases 
include rapidly developing dementia, difficulty walking, changes in gait, hallucinations, 
confusion, fatigue, muscle stiffness and difficulty speaking. Historically, prion diseases 
have been characterized neuropathologically by vacuolation of neutrophils, neuronal loss, 
gliosis, and by the deposition of amyloid plaques in the brain of diseased animals and 
humans (Belay and Schonberger, 2005; Wadsworth and Collinge, 2011). The 
neurodegeneration in prion disease primarily occurs in the brain regions that coordinate 
motor functions, such as the basal ganglia, cerebral cortex, thalamus and cerebellum 
(Jang et al., 2013; Mallucci, 2009). Reactive astrocytic gliosis, microglial activation and 
the deposition of amyloid plaques have been associated with the accumulation of the 
abnormal prion protein PrP
Sc
 (scrapie isoform) derived from the normal prion protein 
PrP
C
 (cellular isoform) (DeArmond et al., 1987). Thus far, neither effective treatment nor 
prevention methods have been developed for prion disease (Roettger et al., 2013; 
Wisniewski and Goni, 2012). Most confirmed cases have been identified post-mortem, so 
the development of ante-mortem tests are essential for effective detection. There are 
different methods of dealing with the prion disease (Forloni et al., 2013; Sim and 
Caughey, 2009). Since total eradication of the disease has not been possible, reducing its 
infectivity, reducing the substrate, and developing vaccinations have been explored.  
Despite extensive research, the precise cause of prion disease remains unknown. 
However, it is generally believed that the diseased state of an organism occurs when the 
soluble α-helix-rich form of PrPC has been converted to the insoluble β-sheet-rich 
pathogenic form of PrP
Sc
 (Collinge, 2005). The conversion steps required for the protein 
to become pathogenic remain unclear. Interestingly, different conformational isomers 
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with identical primary sequences can display widely varying pathology, indicating that 
the secondary and tertiary structures of PrP
Sc
 can encode different strains of TSE 
(Gambetti et al., 2011; Parchi et al., 2010; Weissmann et al., 2011). Though the absolute 
pathogenesis of prion disease remains obscure, several pathogenic mechanisms have been 
proposed, including synaptic damage, dendritic atrophy, autophagy, microglial activation, 
oxidative stress, protein misfolding, ER stress and apoptosis. Further complicating the 
effort to uncover the disease’s etiology, a combination of multiple interlinking pathways, 
rather than a unifying mechanism, could contribute to the pathology of prion diseases.  
Substantial evidence also highlights the prion protein to be a metalloprotein, and 
to have affinity to various cations such as copper, zinc, manganese, and nickel (Brown, 
2004; Di Natale et al., 2005; Hornshaw et al., 1995). Many studies have reported 
significant differences in metal content in diseased humans and animals (Hesketh et al., 
2007b; Wong et al., 2001a), suggesting the involvement of metal homeostasis in prion 
disease pathogenesis. The redox metals are essential trace element metals normally 
required for physiological process, and are precisely regulated by the cells. Interactions of 
these metal ions with prion protein may have a role in protein misfolding and the 
neurodegenerative progression of prion diseases. Therefore, a detailed understanding of 
metal-prion interactions would not only expand our understanding of the 
pathophysiological mechanisms of prion diseases, but may also enable the development 
of effective treatment strategies for these debilitating diseases. 
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2. Prion diseases  
Although the biochemical process that converts PrP
C 
to PrP
Sc
 is not completely 
understood, according to a seeding-nucleation model, the pre-existing or acquired 
PrP
Sc 
oligomers catalyze the conversion of PrP
C 
molecules into PrP
Sc 
fibrils. The breakage 
of these fibrils provides more PrP
Sc 
templates for further seeding of the conversion 
process (Prusiner, 1982). This process results in more aberrant PrP
Sc
 proteins, which are 
extremely resistant to proteolysis or degradation by conventional means, thereby 
initiating the classical prion disease state. 
The earliest description of TSE, dating back to the mid-18
th
 century, was 
identified as scrapie, the prototypic prion disease affecting sheep and goat (Aguzzi, 
2006). In the early 19
th
 century, a critical experiment performed by Cuille and Chelle 
confirmed the transmissibility of scrapie to goats, turning a new page in prion biology 
(Cuille J., 1939).  In 1920, the first human case of TSE, Creutzfeldt-Jakob disease (CJD), 
was reported (Aguzzi et al., 2008) and it remains the most common form of human prion 
disease. The number of identified human and animal prion diseases has increased steadily 
ever since and over fifteen different diseases have been described so far (Aguzzi, 2006; 
Imran and Mahmood, 2011). In the following section, we will review some of the 
prevalent human prion disease. 
 
2.1 Creutzfeldt-Jakob disease 
Initially CJD was described as a sporadic disease (sCJD) caused by the 
spontaneous transformation of PrP
C 
into PrP
Sc
, resulting in rapid cognitive decline, 
involuntary movements, blindness, weakness of extremities and coma. Disease onset for 
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sCJD occurs at about age 60 and 90% of patients die within 1 year. Sporadic CJD 
accounts for 85% of all CJD cases with an annual incidence rate of approximately 0.6-1.2 
cases/million worldwide (Ladogana et al., 2005). Epidemiologically, there are three other 
distinct types of CJD in addition to sCJD: familial (fCJD), iatrogenic (iCJD), and variant 
(vCJD). Familial CJD develops from a heritable mutation in the Prnp gene, which 
accounts for 5-10% of all CJD cases.  Several point mutations have been identified as risk 
factors for fCJD, including E200K and V210I (Prusiner and DeArmond, 1994). A rather 
smaller number of cases (<5%) have been classified as acquired forms accounting for 
both iCJD and vCJD. These acquired CJD cases are mostly transmitted iatrogenically by 
accidental exposure to PrP
Sc
-infected brain or nervous system tissues during medical 
procedures. The first reported iCJD case occurred in 1974 by corneal transplantation 
from a deceased patient with undiagnosed sCJD (Duffy et al., 1974). Pituitary growth 
hormones and dura matter graft-transplants obtained from CJD-infected individuals 
account for most iCJD cases (Gay et al., 1988), where the current worldwide total of 
growth hormone-associated cases of CJD is up to 226 (Gibbs et al., 1985). Variant CJD is 
a new subset of acquired CJD with its own distinct pathological and clinical phenotypes. 
The first confirmed case of vCJD was reported in 1996 in the United Kingdom (UK) 
(Will et al., 1996) and is suggested to be causally linked to the bovine spongiform 
encephalopathy (BSE) outbreak in Europe. By the end of 2013, 177 deaths in UK 
(http://www.cjd.ed.ac.uk/) have been attributed to vCJD.  Unlike sCJD cases, vCJD 
patients are relatively young (median age of 28) and have relatively long incubation 
periods. Interestingly, unlike other CJD patients, vCJD patients lack the classic CJD 
electroencephalogram and they develop extensive fluoride plaques in the brain (Will et 
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al., 1996). Also, whereas epidemiological and experimental data suggest that sCJD 
doesn’t transmit from person to person via blood transfusion, this might not apply to 
vCJD. For example, there is an incidence of one recipient developing symptoms of vCJD 
6.5 years after receiving a transfusion of red blood cells donated by an individual later 
identified as a vCJD patient (Llewelyn et al., 2004). Such evidence continues to mount as 
there have been four more identified cases of vCJD resulting from blood transfusions in 
the UK. To prevent further transmission, since April 2004, anyone having received a 
blood transfusion in the UK after 1980 became ineligible to donate blood 
(http://www.hpa.org.uk/).  
 
2.2 Kuru 
Kuru is another acquired human prion disease seen exclusively in the Fore 
linguistic groups and neighboring tribes in the Okapa area of the Eastern Highlands of 
Papua New Guinea. The disease resulted from the practice of ritualistic cannibalism 
among the Fore, in which relatives prepared and consumed the tissues, including brain, of 
deceased family members. Kuru affected predominantly women and young children as 
they were exposed most to infectious brain and visceral tissues, while adult men 
primarily consumed muscles (Imran and Mahmood, 2011). Although the first case was 
observed ~1920, Kuru was not thoroughly documented until 1957, and since then over 
2700 cases have been reported (Will, 2003).  Dr. Gajdusek and colleagues have shown 
disease transmission in nonhuman primates by intracerebral introduction of brain 
homogenates from Kuru patients, proving that Kuru was caused by a transmissible agent 
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(Gajdusek et al., 1966), thus indicating for the first time the infectious nature of prion 
diseases.   
Clinically, the prodrome stage of Kuru consists of headaches and joint pain in the 
legs followed by three clinical stages: an ambulatory stage, a sedentary stage and a 
tertiary stage (Kaufman et al., 1985). The symptoms seen in these clinical stages are 
characteristic of the term “Kuru”, which means “to shiver from fever and cold” in Fore 
language. Additionally, Kuru is considered largely a cerebellar syndrome with ataxia, 
tremors, and choreiform and athetoid movements being the prominent clinical signs of 
the disease (Alpers, 1987); dementia is a late and less prominent symptom. Interestingly, 
recent genome‑wide studies of Kuru confirmed a strong association with a single 
nucleotide polymorphism (SNP) localized within the codon 129 and also with two other 
SNPs localized within the genes retinoic acid receptor beta (RARB) and stathmin like 2 
(STMN2; the gene encoding SCG10) (Lockwood, 1989; Thomson et al., 2012). 
Importantly, studies have shown that individuals with 129
Val/Val 
and 129
Met/Met 
genotypes 
are susceptible to Kuru (Cervenakova et al., 1998), whereas heterozygosity at codon 129 
confers relative resistance to prion diseases (Mead et al., 2003). An evolutionarily strong 
balancing selection for these alleles had been imposed at this locus, not only in Fore, but 
also in those human populations practicing cannibalism (Liberski, 2013).  
 
2.3 Gerstmann-Sträussler-Scheinker Syndrome 
Gerstmann-Straussler-Scheinker disease (GSS) is a genetically determined adult 
prion disease associated with the autosomal dominant inheritance of Prnp mutations. 
GSS is also considered one of the rarest forms of prion disease with an incidence of 2-5 
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per 100 million people. However, this disorder may be underdiagnosed. Many of its key 
clinical symptoms, such as cerebellar ataxia, dysdiadochokinesia, speech disturbance, 
personality changes, and dementia, are also characteristic of other neurodegenerative 
diseases like Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS or Lou 
Gherig’s disease), Huntington’s disease (HD), Alzheimer’s disease (AD) and etc.  
Neuropathologically, GSS is primarily characterized by prominent amyloid 
plaques and diffuse deposits resulting from the accumulation of PrP degradation products 
in the cerebellum (Masters et al., 1981). However, GSS shows great pathological 
heterogeneity, which often partly overlaps those found in AD, PD and Dementia with 
Lewy bodies (DLB). These phenotypic differences correlate to the haplotype-specific 
pattern. For instance, immunohistochemical analysis of the neocortex of GSS patients 
associates with F198S (Ghetti et al., 1989), Q227X (Liberski et al., 1998), D202N 
(Piccardo et al., 1998), etc, indicating the presence of neurofibrillary tangles normally 
found in AD. Patients with the F198S mutation have also been found with α-synuclein 
immunopositive Lewy bodies typical of PD (Piccardo P, 1998). Currently, at least 16 
point mutations in the Prnp gene have been implicated as risk factors for GSS including 
P102L, P105L, A117V, Y145X, H187R, D178N, Q160X, Q217R, Y218N, Y226X, 
G131V, Q212P and S132I (Doh-ura et al., 1989; Hsiao et al., 1992; Imran and Mahmood, 
2011; Jansen et al., 2010).  
Biochemically, GSS is characterized by the presence of proteinase K (PK) 
resistant N- and C-terminal truncated and non-glycosylated PrP peptides ranging from ~7 
to 15 kDa (Tagliavini et al., 1994). Interestingly, the transmissibility of GSS is widely 
studied and common GSS-associated mutations (P102L) seem to be more capable of 
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transmitting the disease than are less frequent GSS-associated mutations (Tateishi et al., 
1988).  
 
2.4 Fatal familial insomnia 
Fatal familial insomnia (FFI) is an extremely rare genetic disorder arguably 
considered the deadliest form of insomnia which steals one’s sleep, mind and eventually 
one’s life. Clinically FFI is characterized by untreatable alterations of the sleep-wake 
cycle (loss of sleep spindles, slow-wave sleep, non-rapid eye movement and enacted 
dreams) (Brown, 2002; Huber et al., 1999), autonomic hyperactivation, and cognitive and 
motor impairments such as dysarthria, myoclonus, ataxia, tremor, pyramidal and 
extrapyramidal signs (Montagna et al., 2003). Thalamic atrophy is recognized as the 
histopathological hallmark of FFI, while pathological lesions in the neocortex and the 
limbic cortex are also observed. Since the importance of the thalamus in sleep physiology 
has been well characterized (Brown et al., 2012), observed sleep disturbance well 
accordance with the physiological changes. These clinical manifestations also result in 
dysautonomia (hyperhidrosis, hyperthermia, tachycardia, and hypertension) and 
endocrine disturbances (decreased adrenocorticotropic hormone secretion, increased 
cortisol secretion), and disturbances in growth hormone, melatonin, and prolactin 
secretion. In addition, FFI is the only known prion disease exhibiting these secondary 
heath complications (Engleberg, 2012).  
Historically, FFI was first identified and characterized in 1986 by Lugaresi and 
colleagues, and to date, at least 40 unrelated kindred identified worldwide including 
families from Japan, China, Africa, as well as families with American and European 
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ancestry (Harder et al., 1999; Padovani et al., 1998; Zhang et al., 2010). Genetically, FFI 
is characterized as an autosomal dominant disease associated with a point mutation at 
codon 178 in the Prnp gene where asparagine has been substituted for aspartic acid 
(D178N) (Medori et al., 1992). However, the same D178N mutation is also linked to 
fCJD. What distinguishes the two diseases is the genotype at the polymorphic codon 129 
where FFI is associated with methionine (M) (D178N-129M haplotype) and fCJD is 
associated with valine (V) (D178N-129V haplotype) (Taniwaki et al., 2000). 
Additionally the polymorphic codon 129 in the non-mutated allele determines the 
severity of the disease. In FFI, methionine at polymorphic codon 129 (Fig. 1A) is 
associated with a more severe insomnia and dysautonomia at onset and with thalamic 
damage and fewer cortical alterations, whereas heterozygotes (methionine/valine) (Fig. 
1B) are associated with ataxia and dysarthria at onset, and after prolonged disease, with 
widespread neuropathological damage and cortical spongiosis (Medori and Tritschler, 
1993; Tabernero et al., 2000). 
Biochemically, FFI is quite distinct from other prion diseases. Where both fCJD 
and sCJD results in a ~21 kDa protein fragment after digestion with protease, in contrast, 
FFI results in a shorter ~19 kDa protein fragment (Prusiner, 1998). These results further 
confirm the “prion strain” hypothesis, allowing researchers to identify two different 
strains from their origin to their experimental transmission to laboratory animals. Further 
characterization of the glycosylation patterns helped to distinguish FFI from sporadic 
fatal insomnia (sFI), a rare sporadic form of the disease similar to FFI and its clinical 
symptoms. Biochemically, sFI is characterized by the predominant monoglycosylated 
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form, whereas FFI is characterized by an under-representation of the unglycosylated form 
(Broderick, 1977). 
3. Prion protein (PrP
C
) 
3.1 Structure of PrP
C
  
PrP
C
 is an N-linked glycoprotein tethered to extracellular membrane by a 
glycosylphosphatidylinositol (GPI) anchor and is ubiquitously expressed throughout the 
central nervous system, particularly in both neuronal and glial cells. In humans PrP
C
 is 
encoded by the PRNP gene located on the short arm of human chromosome 20 (20q13) 
as a 16-kb long single gene copy. The human PRNP gene encodes a 253-residue 
precursor prion protein, and upon translation, the first 22 N-terminal residues (signal 
peptide) post-translationally are cleaved during transport to the cell surface (Kretzschmar 
et al., 1986) (Fig. 2). The last 23 C-terminal amino acids are excised after the addition of 
the GPI anchor, resulting in mature PrP
C
 on the cell surface consisting of 208 amino acid 
residues (Stahl et al., 1987). Properly folded and GPI-anchored PrP
C 
becomes localized in 
detergent-resistant membranes, also known as lipid rafts (Aguzzi et al., 2008). This PrP
C 
is rapidly internalized from the cell membrane via caveolae-like (Marella et al., 2002; 
Peters et al., 2003) or clathrin-dependent (Prado et al., 2004; Taylor et al., 2005) 
endocytosis. Internalization is considered to be crucial for PrP
C 
function in regulating 
signal transduction pathways, neurite outgrowth, etc (Di Guglielmo et al., 2003; York et 
al., 2000). Experimentally this surface bound PrP
C 
can be removed in vitro by incubating 
with bacterial phosphatidylinositol-specific phospholipase C (PI-PLC), which liberates 
PrP
C 
from the cell membrane by cleaving the GPI anchor (Stahl et al., 1987; Weissmann, 
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2004). Structural modeling through nuclear magnetic resonance (NMR) studies on 
recombinant human PrP
C
 reveals the C-terminal globular domain to have three α helices 
(α1, α2 and α3) and a short anti-parallel β-sheet (β1 and β2) (Zahn et al., 2000). The C-
terminal domain of PrP
C
 also contains a single disulfide-bonded bridge linking the Cys 
residues of α2 and α3 at positions 179 and 214. This disulfide bridge is important for 
conformational stability of PrP
C
 and removal greatly destabilizes the native PrP
C
 
structure, which could reversibly switch between α-helical conformation and a 
monomeric form rich in β-sheet structure (Maiti and Surewicz, 2001). The N-terminal 
moiety of the prion protein is an unstructured region that characteristically interacts with 
a broad range of partners having contrasting capabilities, including neuroprotection and 
neurotoxicity. One hallmark of this region is the highly conserved tandem repeats of an 
eight-residue sequence (PHGGSWGQ) referred to as an octapeptide repeat domain. The 
number of repeats differs from species to species (see Fig. 3 for PrP
C
 homology among 
mammalian species). For example, humans, mice, sheep, and deer each have five 
octapeptide repeats in the wild-type cellular protein while bovine PrP has six repeats 
(Mastrangelo and Westaway, 2001). 
 
3.2 Physiological function of prion protein 
Interestingly, octapeptide repeat regions have a high affinity for binding to 
divalent metals; their highest affinity is for copper, followed by nickel, zinc and 
manganese (Jackson et al., 2001). Metal binding has been suggested to play an important 
role in the biological function of prion protein and their pathogenesis. This protein also 
has been speculated to act as an antioxidant. Its role in antioxidant defense was 
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demonstrated by blocking toxic effect by treating cells with synthetic PrP
C 
59-91 peptide 
in cells exposed to high levels of copper (Brown et al., 1998). Transmembrane signaling 
is another physiological function of prion proteins, which is regulated by different 
binding partners. Since most  PrP
C
s are localized on plasma membranes, specifically on 
cholesterol- and glycosphingolipid-rich lipid raft domains serving as scaffolds for signal 
transduction (Taylor and Hooper, 2006), numerous studies have identified binding 
ligands of prion proteins. Indeed, PrP
C
 interacts with various macromolecules at the cell 
membrane to activate transmembrane signaling pathways involved in several different 
phenomena, including neuronal survival, neurite outgrowth and neurotoxicity. It has been 
demonstrated that both the laminin precursor protein (LRP), via the yeast two hybrid 
system (Rieger et al., 1997), and the neuronal cell adhesion molecule (N-CAM), via 
formaldehyde cross-linking studies (Schmitt-Ulms et al., 2001), interact with PrP
C
 on cell 
surfaces, promoting diverse transduction pathways involved in differentiation and neurite 
outgrowth (Colognato and Yurchenco, 2000; Maness and Schachner, 2007). Moreover, 
Santuccione and colleagues have shown that heterophilic cis and trans interactions 
between N-CAM and PrP at the neuronal surface promote N-CAM recruitment to lipid 
rafts for activation of p59
Fyn
, a member of the Src family of non-receptor tyrosine protein 
kinases (Santuccione et al., 2005). Furthermore, studies carried out with the 1C11 
neuronal differentiation model with antibody-mediated cross-linking have shown p59
Fyn
 
activation in a caveolin-1-dependent manner (Mouillet-Richard et al., 2000). In 
subsequent studies, as a downstream event, they also report NADPH oxidase-dependent 
ROS production and extracellularly regulated kinase 1/2 (ERK1/2) phosphorylation in 
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fully differentiated progenies, identifying NADPH oxidase and ERK1/2 as targets of 
PrP
C
-mediated signaling in neuronal and non-neuronal cells (Schneider et al., 2003). 
 
4. Metals and prion diseases  
Our understanding of the role of metals in key neurobiological processes as well 
as in the pathogenesis of various neurodegenerative diseases has continued to expand 
over the last two decades. Although it is well known that elemental metals are required 
for cells to function normally, the degree to which the central nervous system (CNS) uses 
metals in synaptic signaling and the loss of metal homeostasis during neurodegenerative 
diseases was, until recently, unknown. Dyshomeostasis of transition metals such as 
manganese, iron, copper, and zinc have been implicated in major neurodegenerative 
conditions such as PD, AD, ALS, HD, and prion disease (Brown, 2009; Bush and 
Curtain, 2008; Kanthasamy et al., 2012; Molina-Holgado et al., 2007). Another common 
pathological feature of neurodegenerative diseases is the aggregation of proteins rich in 
β-sheets associated with each specific disease (Tyedmers et al., 2010). Alarmingly, 
exposing amyloidogenic proteins or their cleavage products to metals impacts the protein 
misfolding and progression of neurodegenerative processes (Brown, 2009). Specially, 
manganese has been shown to bind to the cellular form of prion protein, and this 
interaction has been implicated in the aggregation and misfolding of PrP
C
. In this section, 
we will summarize the current evidence of manganese and prion interaction and its 
functional consequences in prion disease.  
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4.1 Manganese 
Manganese (Mn) is one of the most abundant transitional metals on earth, 
comprising approximately 0.1% of the earth’s crust. It may exist in both inorganic and 
organic forms, and has been heavily used in welding, mining, the manufacturing of 
batteries, glass, fireworks, chemicals, pesticides and fertilizers and in other industrial 
settings (Meeker et al., 2007). In nature, Mn exhibits 11 oxidation states ranging from -3 
to +7, while in biological systems it occurs primarily as Mn
2+
, Mn
3+
, and Mn
4+
 (Su et al., 
2013). In the human body, Mn is an essential trace element that functions as a key 
cofactor for numerous metalloenzymes, such as manganese superoxide dismutase, 
pyruvate carboxylase, arginase, and phosphoenolpyruvate decarboxylase and glutamine 
synthetase (Aschner and Aschner, 2005). As such, Mn is involved in various biochemical 
and cellular functions, including blood clotting, ATP production, immune 
responsiveness, digestion, and reproduction (Erikson et al., 2007). It also plays a key role 
in the development and normal functioning of the brain. Transport of Mn ions into the 
brain can be mediated through both the blood-brain and the blood-cerebrospinal fluid 
barriers (Crossgrove and Yokel, 2004; Yokel, 2002), and studies have documented 
various transporting mechanisms in this process (Aschner and Gannon, 1994; Aschner et 
al., 1999; Martinez-Finley et al., 2013). Recommended intake levels of Mn for men and 
women have been established at 2.3 mg/day and 1.8 mg/day, respectively (Trumbo et al., 
2001). Although dietary Mn deficiencies are exceedingly rare in humans, diets low in Mn 
may cause many developmental defects. On the other hand, excess exposure to Mn 
results in a severe and degenerative neurologic condition, known as manganism or Mn-
induced Parkinsonism. Early signs of manganism include a variety of psychiatric 
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disturbances, such as emotional liability, mania, and hallucinations, while motor 
symptoms including bradykinesia, rigidity, and dystonia are late manifestations of this 
disorder (Dobson et al., 2004). Unlike PD, manganism is pathologically characterized by 
the loss of neurons in the globus pallidus, cortex and hypothalamus and without the 
formation of Lewy bodies (Aschner et al., 2009; Verina et al., 2013). Although the 
pathogenic mechanisms underlying manganism are poorly understood, several lines of 
evidence suggest that Mn-induced neurotoxicity is associated with increased oxidative 
stress, impairment of energy metabolism and antioxidant systems, attenuation of 
astrocytic glutamate uptake, upregulation of binding sites for peripheral benzodiazepine 
receptor ligands, and alterations in various cell signaling pathways (Erikson and Aschner, 
2003; Kitazawa et al., 2002; Roth and Garrick, 2003). We have previously reported that 
the proapoptotic kinase PKCδ plays a crucial role in mediating Mn-induced dopaminergic 
neurodegeneration (Anantharam et al., 2002; Kanthasamy et al., 2010; Kitazawa et al., 
2005; Latchoumycandane et al., 2005). Interestingly, a role for Mn in the pathogenesis of 
prion disease has been emerging in recent years. Particularly, evidence has indicated that 
Mn-bound PrP
Sc
 can be isolated from both human and animal prion diseases (Wong et al., 
2001b).  
4.2 Manganese binding to PrP
C
 
As aforementioned, PrP
C
 is a putative metalloprotein since the octapeptide repeat 
sequences at the N-terminus of the protein have a high affinity for divalent cations 
including copper (Cu), Mn, and zinc (Zn). The possible complexation of Mn by PrP
C
 first 
came to light in 2000 when total reflection x-ray fluorescence spectrometry (TXRF) was 
applied (Brown et al., 2000). In this study, recombinant full-length PrP
C
 was discovered 
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to bind Mn in vitro followed by the refolding of this protein in the presence of high 
concentrations of Mn. However, deletion of the octapeptide repeat sequences completely 
abolished this Mn binding. The authors also documented that Mn can equivalently 
substitute for Cu in the octameric repeat region. These facts highlight the importance of 
the octameric repeat domain in mediating Mn and prion interactions. Later on, a few 
other studies on the affinity of Mn for prion were carried out using different amino acid 
sequences of recombinant prion protein; however, the results varied. Although evidence 
has indicated that Mn does have a binding affinity to the octameric repeat region, a 
spectroscopic study by Garnett and Viles showed that Mn does not bind to the PrP 
octameric repeat region (Garnett and Viles, 2003). Similarly, Treiber et al., using the 
surface plasmon resonance (SPR) technique, found that peptides covering the octameric 
repeat sequences of prion were not able to bind Mn and, on the contrary, full-length PrP 
and the mutant PrP lacking the octameric repeat region bound to Mn with a nanomolar 
dissociation constant (Treiber et al., 2007b). They concluded that the octameric repeat 
region is not involved in Mn binding and proposed a conformational binding site for Mn 
involving the PrP residues 91-230. In contrast, analysis involving NMR and circular 
dichroism (CD) spectroscopy in the presence of glycine, has confirmed the binding of Mn 
to the octameric repeat region despite an affinity at least three orders of magnitude less 
than Cu (Jackson et al., 2001). These divergent results might be due to variations in 
detection techniques and the use of different peptide sequences of PrP. Additional Mn-
binding sites were identified at His 95 and 110 in the so-called “fifth site” (Jackson et al., 
2001; Jones et al., 2004). However, a subsequent report from Dr. David Brown’s 
laboratory revealed that His 95 is the preferential binding site for Mn in this region, and 
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His 110 plays no role in Mn binding (Brown, 2009). Interestingly, further work by the 
same group suggests that the higher-affinity Mn binding site is not the octapeptide repeat 
motif, but the His 95 in the 5
th
 site (Brazier et al., 2008). Using isothermal titration 
calorimetry, they identified two Mn binding sites for prion protein. The principle one is 
located at histidine residue 95 and the second low-affinity site is associated with the 
octameric repeat region, with dissociation constants of 63 µM and 200 μM, respectively 
(Brazier et al., 2008). This study also revealed an optimum pH of 5.5 for Mn binding at 
both sites. Additionally, the authors determined that PrP
C
 binds two molecules of Mn at 
these sites, while it was originally thought to bind up to four molecules of Mn at the 
octapeptide repeat region (Brown et al., 2000). This study went on to show that Mn is 
able to replace Cu in Cu-saturated prion, even though PrP has a higher affinity for Cu at 
both binding sites. It should be noted that the micromolar range of affinity values for Mn 
binding to prion is in the range of other known Mn-binding proteins (Brown, 2011). 
Although the research relating to PrP and Mn interaction has mostly been conducted in 
vitro, prion clearly is a Mn-binding protein. Given the important roles Mn and prion 
protein play in normal and disease states, it is logical to assume that the binding of Mn to 
prion protein has significant structural and functional consequences.  
 
4.3 Role of manganese in the pathogenesis of prion disease 
Over the past dozen or so years, evidence has been mounting suggesting a 
possible role for Mn binding to PrP in the pathogenesis of prion diseases. Limited 
proteolytic digestion experiments using proteinase K and recombinant prion protein have 
revealed that Mn-loaded PrP gains partial protease resistance in vitro (Brown et al., 
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2000). Further cell-free studies involving the protein misfolding cyclic amplification 
(PMCA) technique supported the idea that Mn acts as a cofactor in the conversion of 
PrP
C
 into the protease-resistant PrP
Sc
-like form PrP
res
, and determined that this 
conversion ability was similar to but less profound than the diagnostic proteolytic 
resistance characteristic of PrP
Sc
 (Kim et al., 2005). Using a PrP-expressing yeast cell 
system, PrP
res
 formation was induced in vivo after the supplementation of Mn-containing 
media, suggesting that environmental Mn could be a risk factor for prion disease (Treiber 
et al., 2006). Similarly, in vivo PrP
res
 formation was detected in rat astrocytes when 
incubated with Mn for a prolonged period of time (Brown et al., 2000). These changes in 
protease resistance of PrP
C
 have been suggested to be related to an altered conformation 
of PrP when Mn is bound. Indeed, analysis of full-length recombinant PrP using CD 
indicated that Mn-bound PrP has increased β-sheet content (Brown et al., 2000; Giese et 
al., 2004). A near-infrared spectroscopy (NIRS) study on metal binding of prion protein 
in aqueous solutions documented that Mn-bound PrP undergoes highly different 
structural changes leading to fibril formation (Tsenkova et al., 2004). Interestingly, 
experiments using a method combining Raman optical activity (ROA) and ultraviolet 
circular dichroism (UV CD) demonstrated a very different impact of Cu and Mn on prion 
protein structure. Cu binding to prion protein destroyed its folded α-helical structure in 
the N-terminus; however, upon binding to Mn, the secondary structure became more 
organized, gaining more α-helices (Zhu et al., 2008). Another study with recombinant 
PrP further showed that Mn can replace Cu bound to PrP, resulting in an altered protein 
conformation with fewer helices (Brazier et al., 2008). In this study, cyclic voltammetric 
measurements indicated that the oxidation of Mn bound to PrP
C
 rendered the PrP
C
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binding irreversible, which is not seen with Cu-bound PrP
C
. In addition to the resulting 
conformational changes in prion structure, Mn-bound PrP
C
 has been shown to initiate PrP 
aggregation and seed polymerization of soluble PrP
C
. The protease-resistant PrP
res
 with 
Mn was shown to propagate and form more PrP
res
 in the presence of normal hamster 
brain homogenate by standard PMCA technique, whereas a treatment with the Mn 
chelator EDTA inhibited this process, indicating a reversible intermolecular Mn binding 
with PrP (Kim et al., 2005). Other studies confirmed that once bound to Mn, the β-sheet-
rich PrP was able to seed polymerization of soluble metal-free PrP (Brazier et al., 2008; 
Lekishvili et al., 2004). Additionally, Hesketh et al. characterized the Mn-bound PrP seed 
in a non-denature polymerization assay (Hesketh et al., 2012). In this assay, a ~200 kDa 
oligomeric form of PrP seed capable of catalyzing PrP aggregation was generated by 
exposing recombinant prion protein to Mn. Using mutant recombinant PrP molecules, 
they further showed that Mn binding to PrP is essential for seed formation but not for 
polymerization. Another interesting finding from this report is that prion protein from 
chickens, in which no known prion disease is found, was able to generate PrP seed after 
treatment with Mn.  
Despite extensive in vitro studies on prion-Mn interaction and its subsequent 
effects on prion aggregation, the in vivo consequences of Mn binding to prion in terms of 
neuronal loss have not yet been well studied. An earlier report showed that recombinant 
PrP refolding in the presence of Mn was toxic to PrP-expressing cell lines and primary 
neuronal cultures (Uppington and Brown, 2008). More recently, treatment with an 
effective and relatively selective chelator for Mn, cyclohexanediaminetetraacetic acid 
(Na2CaCDTA), significantly extended survival time in an animal model of prion disease 
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where mice were infected with a low dose of prion disease (Brazier et al., 2010). In 
agreement with these findings, Hortells et al. demonstrated that that a Mn-rich diet in 
Scrapie prion-inoculated mice increased neuronal loss and the levels of PrP-containing 
plaques (Hortells et al., 2010), although this has not been replicated by other workers 
(Legleiter et al., 2007). Interestingly, elevated Mn levels in the brain and blood of 
humans and animals afflicted with TSE have been observed. In particular, altered Mn 
content has been observed in the blood and brains of humans infected with CJD (Hesketh 
et al., 2008; Wong et al., 2001b), mice infected with scrapie (Kim et al., 2005; Thackray 
et al., 2002), in cattle infected with BSE (Hesketh et al., 2007a), and in elk infected with 
chronic wasting disease (CWD) (White et al., 2010). What is more interesting is that the 
elevated blood Mn levels in scrapie and BSE were detected prior to the onset of disease 
symptoms, suggesting that altered metal levels might be a biomarker for diagnosis in the 
early stages of prion disease. Thus far, whether alteration in Mn levels in prion disease is 
a primary cause leading to infection or a secondary effect due to the infection itself 
remains unclear. Indeed, we lack clear evidence as to why Mn levels were elevated in 
these prion disease cases. At the cellular level, these increases may be linked to altered 
Mn homeostasis and signaling. Several cell culture studies including ours have shown 
that prion protein expression and infection can modulate the expression of Mn 
transporting proteins and cause ensuing Mn cellular retention (Kralovicova et al., 2009; 
Martin et al., 2011). On the other hand, as we have reported (Choi et al., 2010), increased 
Mn may in turn result in more PrP due to its inhibitory effects on proteasome degradation 
(Cai et al., 2007; Zhou et al., 2004). Therefore, a feed-forward mechanism may be 
involved in this process. One of the other consequences of increased Mn in prion disease 
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is likely the abnormalities in iron metabolism since both Mn and iron ions are generally 
complexed and transported to the brain through a transferrin-transferrin receptor pathway 
(Heilig et al., 2006). In fact, iron abnormalities have been found in the brains of humans 
and animals with prion diseases (Singh et al., 2013; Singh et al., 2009). Additionally, 
PrP
Sc
-infected cells were more susceptible to oxidative stress (Fernaeus et al., 2005; 
Milhavet et al., 2000), suggesting that Mn toxicity might be responsible for TSE-related 
neuronal loss. 
To date, the vast majority of work done to elucidate the mechanisms of TSE 
pathogenesis has focused on the genetic determinants and biophysical kinetics of protein 
aggregation. Despite the fact that essential trace minerals are not manufactured by the 
body and that foreign (ingested) PrP
Sc
 can propagate, their environmental contribution to 
TSE etiology has not received the same kind of attention. However, the evidence 
continues to build for an environmental role in the initiation or development of the 
disease. In particular, the environmental distribution of metals correlates with the 
incidence of TSE (Polano et al., 2008; Purdey, 2000). Likewise, a correlation between 
soil clay content and the incidence of chronic wasting disease in elk further indicates that 
soil constituents may affect the persistence of PrP
Sc
 in the environment (Johnson et al., 
2007). A pair of monozygotic twins with a pathogenic hereditary mutation to PrP 
developed TSE pathology seven years apart from each other (Bowman et al., 2011), 
providing more evidence for an environmental trigger. The recurrence of TSE in 
livestock despite multiple governmental programs designed to eradicate the disease 
argues for the persistence of a pathogen or trigger in the environment. Interestingly, a 
recent study strongly argues in favor of the notion that environmental Mn levels could be 
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relevant to prion disease transmission. In this study, they found that infectious PrP
Sc
 can 
persist in soils for at least two years (Davies and Brown, 2009). Additionally, the 
presence of high levels of Mn in soils not only protects the protein from degradation, but 
may actually increase infectivity by up to 100-fold. These findings provide a route 
whereby PrP
Sc
 derived from carcasses or farm runoff can enter and persist in the 
environment. Thus, oral inoculation can occur in ruminants ingesting soil microparticles 
while grazing. The retention of infectivity in the environment seems to depend highly on 
the presence of Mn in the soil.  However, it should be noted that soil is a very complex 
matrix comprising many other components that could influence the incidence of prion 
disease. A greater understanding of environmental determinants would greatly help in 
assessing the risk factors of TSE.  
 
4.4 Role of manganese in the physiological function and expression of PrP
C
 
Current evidence suggests a role for prion protein in modulating metal 
homeostasis as well as antioxidant levels (Brown et al., 2002; Wong et al., 2001c). 
Previously, we examined the role of PrP
C
 in regulating Mn-induced neurotoxicity (Choi 
et al., 2007). Using mouse neuronal cell lines, we demonstrated that cells expressing 
prion protein (PrP
C
) were more protected against Mn-induced neurotoxicity than were 
prion-knockout cells (PrP
KO
). Inductively-coupled plasma mass spectrometry (ICP-MS) 
revealed that lacking prion protein expression caused significantly lower basal Mn levels 
in PrP
KO
 cells, and upon Mn treatment, PrP
C
 cells internalized significantly less Mn than 
did PrP
KO
 cells. Examination of reactive oxygen species (ROS) formation, caspase 
activation, and cell death all revealed that the mouse neuronal cell line lacking prion 
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protein expression was more susceptible to Mn neurotoxicity. This increased 
susceptibility likely resulted from the homeostatic imbalance of Mn, as evidenced by the 
significantly higher amount of cellular Mn in these cells following treatment. Similar 
findings were achieved with hydrogen peroxide, which also increased the susceptibility 
of PrP
KO
 cells (unpublished data). Our findings suggest that prion might act as a metal 
sink, thereby preventing Mn from entering the cells and exerting its neurotoxic effect. In 
another recent study (Choi et al., 2010), we further examined the fate of cellular prion 
protein in a Mn-treated PrP
C
-expressing mouse neuronal cell line. Interestingly, our 
results indicated that with Mn treatment, prion protein levels significantly increased over 
time. A previous study showed increased prion protein expression in a particular cell line 
treated with Cu, which elevated the activity of the reporter vector with Prnp (Varela-
Nallar et al., 2005). Surprisingly, this was not the case for the Mn-mediated upregulation 
of cellular prion protein. We eliminated the possibility that Mn increased the transcription 
or inhibition of the ubiquitin proteasomal system (UPS), and further verified that in our 
system, Mn treatment significantly altered the turnover of PrP
C
. Pulse chase experiments 
confirmed that the half-life of PrP
C
 in Mn-treated cells was significantly increased. 
Together, these findings suggest that prion-mediated alterations in cellular Mn uptake and 
Mn-induced upregulation of PrP
C
 levels through increasing global protein stability may 
contribute to neurodegeneration in prion and other neurodegenerative diseases.   
 
4.5 Role of other metals in prion disease 
Additional metals such as Cu, Zn, and nickel (Ni) may have the potential to bind 
to prion protein. A reduced Zn content in brains with prion disease has been revealed 
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(Wong et al., 2001a; Wong et al., 2001b) and a few other studies suggest that Zn binds to 
the octapeptide repeats in PrP
C
, albeit at an apparently lower affinity (Kenward et al., 
2007; Stellato et al., 2011; Walter et al., 2007). Evidence also exists showing that the 
interaction promotes the endocytosis of PrP
c
 (Pauly and Harris, 1998; Perera and Hooper, 
2001). Although Spevacek et al. showed that Zn binding changes the structure of murine 
PrP
c
 (Spevacek et al., 2013), the structural and functional consequences of Zn-prion 
interaction are still largely unknown. Interestingly, a recent study pointed out a role for 
cellular prion protein in facilitating the uptake of Zn into neurons, which was not 
observed in prion disease (Watt et al., 2013; Watt et al., 2012). The mechanism of prion-
mediated metal uptake seems to be metal-specific since our study showed that prion 
protein reduced Mn uptake in neurons (Choi et al., 2007). Ni has been used to isolate PrP 
in affinity columns (Choi et al., 2006), but its potential interaction with PrP has been 
neglected since Ni binds to PrP
c 
with quite low affinity (Brown et al., 2000). In contrast, 
it is widely accepted that PrP binds Cu. Many lines of in vitro evidence indicate that the 
interaction between Cu and PrP
C
 primarily occurs within the octapeptide repeat region or 
a second site at the His 95 and 110 residues in the fifth site with a dissociation constant in 
the nanomolar range (Aronoff-Spencer et al., 2000; Jackson et al., 2001; Jones et al., 
2004). Further studies on Cu coordination with the octapeptide repeat domain have 
shown that there are three distinct modes at physiological pH (Chattopadhyay et al., 
2005). Similar to Zn, Cu binding governs PrP
c
 endocytosis, and this requires the 
octapeptide repeat region (Haigh et al., 2005; Pauly and Harris, 1998; Perera and Hooper, 
2001). The binding of Cu to PrP
c
 appears to be crucial to the normal function of the 
protein. For instance, the antioxidant activity of PrP
C
 requires Cu bound within the 
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octapeptide repeat domain (Brown et al., 2001; Brown et al., 1999; Gaggelli et al., 2008; 
Treiber et al., 2007a). Cu bound by the octapeptide repeat domain of PrP
C
 undergoes full 
and reversible redox chemistry and can detoxify superoxide and reduce hydroxyl radicals 
(Nadal et al., 2007). However, the concept that Cu-PrP complex acts as an antioxidant is 
controversial based on conflicting results of several studies (Hutter et al., 2003; Jones et 
al., 2005). Loss of Cu accompanied with increased Mn levels has been described in 
prion-infected brains (Thackray et al., 2002; Wong et al., 2001a; Wong et al., 2001b), 
suggesting that a Cu deficiency or Cu displacement from the PrP
C
 might contribute to the 
pathology of prion disease. Unfortunately, experiments on the role of Cu in the pathology 
of prion disease have generated contradictory viewpoints. Some studies reported that Cu-
bound PrP
c
 undergoes conformational changes and increases protease resistance (Qin et 
al., 2000; Quaglio et al., 2001; Stockel et al., 1998), while others showed that when 
refolded in the presence of Cu, PrP
c
 decreases its protease resistance and its level of 
aggregation (Bocharova et al., 2005; Wong et al., 2000). In addition, reduced Cu levels in 
the brain and blood using a Cu chelator extended the incubation period of the diseases 
(Sigurdsson et al., 2003), whereas another report indicated that increased Cu in the diet 
delayed the onset of prion disease (Hijazi et al., 2003). Overall, these findings and those 
of others suggest the contributions of Cu in the pathogenesis of prion disease tend to be 
far more complex than originally expected.  
 
5. Conclusion 
  Prion protein readily binds Mn despite an apparent lower affinity. Once bound to 
Mn, it adopts a conformational change and converts into the protease-resistant PrP
Sc
-like 
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form that is essential for seed formation. Chelation of Mn in a prion animal model 
extended the incubation time for the disease, indicating that Mn could be a significant 
risk factor for prion disease. The discovery that Mn increased during the course of TSE in 
both humans and animals and that it could stabilize prions in the soil, thereby increasing 
PrP
Sc
 availability, further implicated Mn in the pathogenesis of the disease. However, 
many questions remain unanswered, like what’s the impact of Mn binding on the normal 
functioning of PrP
C? What’s the molecular basis behind the Mn-induced conformational 
conversion of prion protein? Furthermore, why are Mn levels altered in prion diseases? 
Although Mn could be an important component in the pathogenesis of the disease, 
by no means is it the only causative factor in prion disease development and progression. 
Most likely, developing a prion disease results from the culmination of various 
environmental, genetic, and even sporadic conditions. Therefore, approaching cures to 
prion disease may require multifaceted strategies to effectively combat its progression 
and even development. 
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Figure 1: The haplotypes in fatal familial insomnia (FFI). (A) Methionine at polymorphic 
codon 129 is associated with thalamic damage and fewer cortical alterations, whereas (B) 
Valine at polymorphic codon 129 is associated with prolonged disease and widespread 
neuropathological damage with cortical spongiosis. 
 
 
Figure 2: Structure of the prion protein. Mouse PrP
C molecule has 254 amino acids in 
length, with N-terminal signal peptide (SP) and C-terminal sequences that are cleaved 
shortly after translation. MA denotes the C-terminal membrane anchor region and HPR 
denotes the central hydrophobic domain (111-134) of the prion protein. Toward the N-
terminus is the octapeptide repeat region (OR), which is suggested to play a role in metal 
binding. S-S indicates the single disulfide bridge between residues 179-214. Approximate 
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cutting site of PK within PrP
Sc
 is indicated by lightening symbol and a PK resistant 
fragment is in between residue 90 and 231. 
 
Figure 3: Prion protein (PrP
C
) sequence homology among various mammalian species. 
Peptide sequence was obtained from NCBI Entrez protein database and aligned using 
CLC DNA workbench 6 software.     
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Abstract 
Prion diseases are infectious and inevitably fatal neurodegenerative diseases 
characterized by prion replication, widespread protein aggregation and spongiform 
degeneration of major brain regions controlling motor function. Oxidative stress has been 
implicated in prion-related neuronal degeneration but the molecular mechanisms 
underlying prion-induced oxidative damage are not well understood.  In this study, we 
evaluated the role of oxidative stress-sensitive, pro-apoptotic protein kinase Cδ (PKCδ) in 
prion-induced neuronal cell death using cerebellar organotypic slice cultures (COSC) and 
mouse models of prion diseases. We found a significant upregulation of PKCδ in RML 
scrapie infected COSC as evidenced by increased levels of both PKCδ protein and its 
mRNA. We also found an enhanced regulatory phosphorylation of PKCδ at its two 
regulatory sites, Thr505 in the activation loop and Tyr311 at the caspase-3 cleavage site. 
The prion infection also induced proteolytic activation of PKCδ in our COSC model. 
Immunohistochemical analysis of scrapie-infected COSC revealed loss of PKCδ positive 
Purkinje cells and enhanced astrocyte proliferation.  Further examination of PKCδ 
signaling in the RML scrapie adopted in vivo mouse model showed increased proteolytic 
cleavage and Tyr 311 phosphorylation of the kinase.  Notably, we observed a delayed 
onset of scrapie-induced motor symptoms in PKCδ knockout (PKCδ-/-) mice as 
compared to wild type (PKCδ+/+) mice, further substantiating the role of PKCδ in prion 
disease.  Collectively, these data suggest that PKCδ signaling likely plays a role in the 
neurodegenerative processes associated with prion diseases.  
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Introduction  
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are a group of fatal 
neurodegenerative diseases of humans and animals. Human prion diseases include 
Creutzfeldt-Jakob disease (CJD), Kuru, Gerstmann-Sträussler-Scheinker disease (GSS) 
and Fatal familial insomnia. Examples of TSEs found in animals include bovine 
spongiform encephalopathy (BSE), scrapie in sheep, chronic wasting disease (CWD) in 
deer and elk, and transmissible mink encephalopathy (TME)(Aguzzi et al., 2008; Martin 
et al., 2011; Prusiner, 1996). All these diseases share common neuropathological and 
clinical signs. Prion diseases are mainly characterized by misfolding of the normal 
cellular prion protein (PrP
C
) into the pathological isoform PrP
Sc
 through unknown 
pathogenic mechanisms. Abnormally folded PrP
Sc
 is insoluble in non-denaturing 
detergents and partially resistant to protease digestion. Prion diseases generally involve 
long incubation periods, characteristic spongiform changes associated with protein 
aggregation and neuronal loss, and widespread gliosis. 
 
PrP
C
 is a glycosylphosphatidylinositol (GPI)-linked extracellular membrane protein, 
which is ubiquitously expressed in the central nervous system, in both neuronal and glial 
cells(Aguzzi et al., 2008). The biological function of PrP
C
 is poorly understood, but 
evidence suggests that this protein functions as an antioxidant and metal-binding protein 
with a role in several cellular processes in the nervous system, including neurite 
outgrowth, synapse formation, and maintenance of myelinated axons(Aguzzi et al., 2008; 
Anantharam et al., 2008; Collinge et al., 1994; Kanthasamy et al., 2012; Martin et al., 
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2011). During disease progression, abnormal conformational changes in PrP
C
 result in 
pathogenic PrP
Sc
 molecules, yet the mechanism by which this change occurs is 
unknown(Choi et al., 2006). Studies have shown that propagation of the infectious prion 
protein cannot occur in the absence of host prion proteins(Prusiner et al., 1993), 
indicating a causal role for prion proteins in pathogenesis.  
 
Prion diseases cause severe neuronal damage mainly in brain regions that coordinate 
motor function, including the basal ganglia, cerebral cortex, thalamus, and 
cerebellum. Current knowledge about the molecular mechanisms underlying 
neurodegeneration in prion disease and related prionopathies is limited. However, 
growing evidence indicates that oxidative stress and apoptosis contribute to the 
neurodegenerative process in prion disease pathogenesis(Brown, 2005; Guentchev et al., 
2000; Kim et al., 2001). Therefore, furthering our understanding of molecular signaling 
mechanisms involving early pathologic changes in prion disease is important for 
developing intervention strategies. We have previously shown that Protein kinase C-δ 
(PKC δ) is an oxidative stress-sensitive, pro-apoptotic kinase, which plays a causal role in 
apoptotic neuronal cell death(Kanthasamy et al., 2010; Kaul et al., 2005; Lin et al., 2012; 
Saminathan et al., 2011). We demonstrated that phosphorylation of tyrosine residue 311 
and caspase-3-dependent proteolytic cleavage result in a persistent increase in the kinase 
activity, which promotes neuronal apoptosis(Kaul et al., 2005). Herein, we evaluate the 
role of PKCδ in prion neurotoxicity in ex vivo brain slice culture and in vivo experimental 
models of infectious prion disease. Our results reveal that PKCδ proteolytic signaling 
plays an important role in the neuronal damage and neurological deficits of prion disease. 
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Thus, our findings provide further mechanistic insight into pathogenesis of prion 
diseases.   
 
Materials and Methods 
Prion organotypic slice culture assay (POSCA) 
Iowa State University’s (ISU) College of Veterinary Medicine is accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), 
and all procedures involving animal handling were approved by the Institutional Animal 
Care and Use Committee (IACUC) at ISU. Organotypic slice cultures were prepared as 
previously described with some modifications(Falsig and Aguzzi, 2008; Falsig et al., 
2012). Briefly, brain blocks were prepared in 2% (w/v) low-melting-point agarose 
(Invitrogen 15517-022), and 350-µm thick cerebellar slices were prepared from 9-12 day-
old C57BL/6 pups using a Compresstome™ Vf-300 microtome (Precisionary 
Instruments  Inc). Slices were inoculated with 100 ug µg of 1% normal brain homogenate 
(NBH) or Rocky Mountain Laboratory (RML)-infected brain homogenate per 10 slices in 
Gey’s balanced salt solution (GBSS: 137 mM NaCl, 5 mM KCl, 0.845 mM Na2HPO4, 
1.5 mM CaCl2.2H2O, 0.66 mM KH2PO4, 0.28 mM MgSO4.7H2O, 1.0 mM MgCl2.6H20, 
2.7 mM NaHCO3 and pH-adjusted to 7.4) supplemented with 1 mM of the glutamate 
receptor antagonist kynurenic acid. Free-floating slices were incubated for 1 h in the 
brain homogenate at 4°C and transferred to Millicell-CM Biopore PTFE membrane  
inserts (Millipore PICM03050) and maintained in slice culture medium (50% MEM, 25% 
Basal Eagle medium, 25% horse serum, 0.65% glucose supplemented with 
penicillin/streptomycin and glutamax). Organotypic slice cultures were maintained in a 
285 
 
humidified 37°C incubator with 5% CO2 and 95% air for 14 days, and 90% of the media 
was exchanged every other day. 
 
Immunohistochemistry 
For immunohistochemistry, the organotypic slices were washed with PBS and fixed with 
4% paraformaldehyde (PFA) for 1-2 h at room temperature. After fixing, the membrane 
inserts containing cerebellar slice cultures were washed with PBS and incubated with the 
blocking agent (2% goat serum, and 0.1% Triton X-100 in PBS) for 1 h. Membrane 
inserts were then incubated with the following combinations of primary antibodies: anti-
GFAP (1:1000, Millipore) and anti-PKCδ (1:1000, Santa Cruz), or anti-beta III tubulin 
(Tuj1) (1:1000, Millipore) and anti-PKCδ (1:1000, Santa Cruz) for 2-3 days at 4°C. At 
the end of the incubation, membranes were washed with PBS and incubated with Alexa 
Fluor 555-conjugated anti-mouse secondary antibody (1:2000) or Alexa Fluor 488-
conjugated anti-rabbit secondary antibody (1:2000) for 90 min in the dark. Hoechst 
44432 was used as a nuclear stain. The culture membranes were removed from the inserts 
and mounted directly on microscope slides using Fluoromount mounting medium 
(Sigma) and viewed using a Nikon TE2000 microscope (Tokyo, Japan). Images were 
captured with a SPOT color digital camera (Diagnostic Instruments, Sterling Heights, 
MI). 
 
Western blot  
Slice cultures were washed twice in ice-cold PBS and lysed with Tissue extraction 
reagent (Invitrogen FNN0071) containing protease and phosphatase inhibitor cocktail 
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(Thermo Scientific). Whole tissue lysates were prepared as described(Jin et al., 2011b). 
Protein concentrations were determined with the Bradford protein assay kit (Bio-Rad). 
Immunoblot analysis was performed as previously described(Ghosh et al., 2013; 
Kanthasamy et al., 2006). Briefly, the indicated protein lysates containing equal amounts 
of protein were separated on a 12-15% SDS-polyacrylamide gel. After separation, 
proteins were transferred to a nitrocellulose membrane, and nonspecific binding sites 
were blocked by treating with LI-COR blocking buffer. The membranes were then 
incubated overnight with primary antibody directed against PKCδ (1:1000, Santa Cruz), 
pPKCδ-Thr505 (1:1000, Santa Cruz), pPKCδ-Tyr311 (1:1000, Santa Cruz), or PrP 
(POM-1, 1:5000, Prionatis AG). The primary antibody treatments were followed by 
treatment with IR800-conjugated anti-rabbit, Alexa Fluor 680-conjugated anti-mouse or 
Alexa Fluor 680-conjugated anti-rat secondary antibody for 1 h at room temperature. To 
confirm equal protein loadings, blots were reprobed with β-actin antibody (1:15000 
dilutions). Western blot images were captured with the Odyssey IR Imaging system (LI-
COR) and data were analyzed using Odyssey 2.0 software. 
Limited proteolysis of prion protein resistance to proteinase-K digestion was measured as 
previously described with few modifications(Falsig and Aguzzi, 2008; Falsig et al., 
2012). RML-infected and NBH-inoculated slice cultures were homogenized 35 days after 
infection in lysis buffer (50 mM Tris-HCl, pH 7.4, 0.5% Triton X, and 0.5% sodium 
deoxycholate). Protein concentration was determined by Bradford assay. Next, 40 µG of 
protein was digested with 25 μG/ml of proteinase-K and incubated for 30 min. The 
reaction was stopped by boiling the samples at 95°C for 7 minutes prior to analysis by 
Western blot as described above.  
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qRT-PCR 
Organotypic slice cultures were washed once with PBS, and total RNA was isolated 
using the Absolutely RNA Miniprep kit from Agilent. Next, 500 ng of total RNA was 
converted to cDNA using the High Capacity cDNA Archive kit (Applied Biosystems). 
Quantitative real-time RT-PCR was performed using the Brilliant SYBER Green QPCR 
Master Mix kit (Qiagen) in an Mx3000P QPCR system (Agilent), as described 
previously(Jin et al., 2011a). The PKCδ primer set (Qiagen; QT00107513) was used to 
analyze relative gene expression with the 18s primer set (Qiagen; QT02448075) as the 
internal control for RNA quantity. The PCR reaction mixture included 2 µl of cDNA, 10 
µl of 2x master mix, and 0.2 µM of each primer. A negative control lacking cDNA (no 
template control) was included in each assay. The PCR cycle conditions were as follows: 
95°C for 10 min, then 40 cycles of 95°C for 15 s and 60°C for 1 min. The cycle threshold 
(Ct) values corresponding to the PCR cycle number at which fluorescence emission in 
real time reaches a threshold above the baseline emission were determined. The relative 
PKCδ expression was calculated after adjusting for 18s using 2-ΔΔCt, where ΔCt is the 
PKCδ gene Ct -18s Ct.  
 
PKCδ immunoprecipitation (IP)-kinase assays 
The PKCδ enzymatic kinase activity assay was performed as described 
previously(Latchoumycandane et al., 2011). Briefly, RML scrapie- or NBH-infected 
slices were lysed with the lysis buffer (25mM HEPES, 20mM β-Glycerophosphate, 
0.1mM  Na3VO4, 0.1% Triton-X, 300mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.5mM 
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DTT and 10mM NaF) containing protease and phosphatase inhibitor cocktail (Thermo 
Scientific). The lysates were placed on ice for 20 min, sonicated gently and centrifuged at 
12000 g for 45 min. After collecting the supernatant, protein concentration was 
determined using the Bradford assay. Next, 500 μg of total protein in a 250-μl volume 
was immunoprecipitated overnight at 4°C using 10 μg of the PKCδ antibody. After 
adding protein A-agarose beads (Sigma-Aldrich) the next day, the samples were 
incubated for 2 h at room temperature. The protein A-bound antibody complexes were 
then washed three times in 2 × kinase assay buffer (40 mM Tris, pH 7.4, 20 mM MgCl2, 
20 μM ATP, and 2.5 mM CaCl2), and then resuspended in 100 μl of the same buffer. The 
kinase reaction was started by adding 100 μl of the reaction buffer containing 0.4 mg of 
histone H1, 50 μg/ml phosphatidylserine, 4 μM dioleoylglycerol, and 10 μCi of [γ-32P] 
ATP at 3,000 Ci/mM to the immunoprecipitated samples. The samples were incubated for 
10 min at 30°C. The kinase reaction was stopped by adding 2 × SDS-loading buffer and 
boiling the samples for 5 min. The proteins were separated on a 15 % SDS-PAGE gel and 
the phosphorylated histone H1 bands were scanned using a Fujifilm FLA 5000 imager. 
Image analysis and band quantification were performed using the Fujifilm Multigauge 
software package (Fujifilm USA, Stamford, CT). 
 
Mouse models of murine scrapie  
Mouse models are a popular and versatile in vivo method for studying the effects of prion 
proteins and for providing insights into the neurodegenerative mechanisms of prion 
disease. All work with prion-infected strains and animals was performed under the 
licensure granted by a United States Department of Agriculture (USDA) permit for 
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importation and exportation of controlled materials and it conformed to guidelines of the 
IACUC at ISU. Wild type (PKCδ (+/+)  and PKCδ (-/-) C57 black mice at postnatal week 
6-8 were arranged by weight and randomized into RML and mock NBH inoculation 
groups. PKCδ knockout animals were originally obtained from Dr. Keiichi Nakayama at 
the Medical Institute of Bioregulation, Fukuoka, Japan(Miyamoto et al., 2002).  RML 
and NBH infections were performed by intracerebrally inoculating 30 μl of 1% w/v RML 
brain homogenate into deeply anesthetized mice using a 27 gauge needle. Mice were 
monitored for 48 h post-inoculation for adverse effects and euthanized if they displayed 
unequivocal neurological signs. At 60, 90, 120 and 150 days post inoculation (DPI), all 
animals were subjected to behavioral evaluations described below, then following 
euthanasia, brain tissues were extracted for biochemical evaluations.  
 
Behavioral evaluations 
Extensive neuronal loss during the course of transmissible spongiform encephalopathy 
(TSE) produces progressive motor deficits in humans and animals including ataxia, 
tremor, and postural instability. Grip stamina and motor control were evaluated using the 
horizontal bar test(Guenther et al., 2001; Mallucci et al., 2007). Each mouse was held by 
the tail and allowed to grip a 0.2 cm diameter brass rod 50 cm above a padded cage with 
its forelimbs. The padded Innovive (San Francisco, CA, USA) mouse cage was placed 
below the bar to protect the mice from injury by falling. The mouse was quickly released 
and the time it took for the mouse to fall was recorded. Scores were given based on the 
following paradigm: 0-5s = 1; 6-10s = 2; 11-20s = 3; 21-29s = 4; and 30s or reaching the 
side support = 5.  
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The Columbus Instrument (Columbus, OH, USA) grip strength meter was used to 
determine the maximal amount of force that each animal applied with its forelimbs to a 
specially designed bar (LaMonte et al., 2002; Lepore et al., 2008). For all measurements, 
the gauge was measured in PEAK mode and units were set to kgF. Animals were gripped 
firmly but gently at the base of the tail and the animal’s forelimbs were placed on the grip 
bar. Once the animal gripped the bar with both forelimbs, it was steadily pulled directly 
away from the digital strength meter. This process was repeated 2-3 times to get the peak 
strength reading. 
 
Behavioral evaluations were done by trained personnel in cooperation with ISU 
Laboratory Animal Resources. We evaluated uninfected and RML scrapie-infected 
C57BL/6 and PKCδ (-/-) mice once-weekly for differences in motor signs that reflected 
difficulty initiating ambulatory activities and changes in ambulatory activity patterns. 
Motor performance was scored on a scale from 0 to 4 with 0 = normal movement, 1 = 
slight alteration in ambulation, 2 = obvious intermittent motor signs, 3 = continuous 
pronounced motor signs, and 4 = almost complete lethargy. Test animals were monitored 
for changes in behavioral motor deficits over a period of several minutes. Mice were also 
evaluated for clasping of limbs when held aloft by the tail. 
 
Statistical analysis: 
Data analysis was performed using Prism 4.0 software (GraphPad). Raw data were first 
analyzed using one-way ANOVA, and then Tukey’s post-test was performed to compare 
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all treatment groups. Differences with *p< 0.05, **p< 0.01, and ***p< 0.001 were 
considered significantly different. 
 
RESULTS 
Upregulation of PKCδ in RML infected cerebellar organotypic slice culture model of 
prion disease 
Brain slice models preserve the tissue architecture and neural connectivity of the brain 
regions, making them ideal platforms to model the neuropathology of brain atrophy(Cho 
et al., 2007; Mewes et al., 2012). Cerebellar organotypic slice cultures (COSC) have 
recently been shown to retain and replicate prion infection and thereby serve as an 
excellent ex vivo model to study the pathogenesis of prion disease(Falsig et al., 2008; 
Falsig et al., 2012). Evidence has indicated that prion titers in COSC peaked at 4 weeks, 
while at 5 weeks of infection, the PrP
Sc
 titers correspond to terminal infection in mice 5 
months post-infection (Falsig et al., 2012). In this study, we first investigated whether 
COSCs from wild-type C57BL/6 mice reproduce pathological changes of prion diseases. 
Since gliosis is a well-established integral part of prion infections, we evaluated the glial 
cell proliferation following RML infection by immunocytochemistry after two weeks of 
infection. Astrogliosis was enhanced in RML-infected COSCs, as evidenced by an 
enhanced GFAP immunofluorescence signal (Fig.1A), indicating that the slice cultures 
undergo the neurotoxic stress at the early stages of prion infection. Next, we examined 
whether PKCδ expression was altered during two weeks of prion infection by 
immunocytochemical analysis of PKCδ.  As shown in Fig. 1A, PKCδ immunoreactivity 
in RML-infected COSCs was significantly higher than in the slices inoculated with 
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normal brain homogenate (NBH). These data suggest that PKCδ upregulation may have a 
role in prion pathogenesis.  
 
We also evaluated whether COSCs retain PrP
sc
 infection for five weeks following RML 
brain homogenate inoculation. For this purpose, RML-infected or NBH-inoculated slices 
were subjected to limited proteolysis. This process completely digests PrP
C
, whereas the 
C-terminal region of truncated PrP
Sc
 remains intact (these fragments are referred to as 
PrPcore), which is a disease-specific marker of prion infection(Bolton et al., 1982). 
Following PK digestion, protein lysates were separated by Western blot and membrane 
probed with the prion antibody POM-1, which specifically recognizes amino acid 121-
230 at the globular domain of PrP(Polymenidou et al., 2008; Sigurdson et al., 2011). As 
shown in Fig.1B, after PK digestion, characteristic di-, mono- and unglycosylated forms 
of PK-resistant bands were observed only in RML scrapie-exposed slices, while they 
were completely digested in slices exposed to uninfected NBH, confirming that COSCs 
retain the prion infection over five weeks.   
  
PKCδ activation during RML infection in organotypic slice cultures  
We have previously shown that proteolytic activation of PKCδ plays an important role in 
the oxidative stress-induced apoptotic cell death in dopaminergic neurons (Gordon et al., 
2012; Jin et al., 2011a; Kanthasamy et al., 2010; Kanthasamy et al., 2003b). It has also 
been reported that oxidative stress (Freixes et al., 2006; Pamplona et al., 2008), 
mitochondrial dysfunction (Yuan et al., 2013), and endoplasmic reticular (ER) stress 
(Anantharam et al., 2008) are involved in the pathogenesis of neurodegenerative diseases, 
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including prion diseases. In this study, we evaluated PKCδ activation in the early stages 
of RML infection in COSC exposed to NBH or RML for 14 days. Western blot analysis 
using the antibody that recognizes both native (72-74kDa) and cleaved PKCδ proteins 
(38-41kDa) showed a significant upregulation of native PKCδ as well as cleaved PKCδ 
protein fragments in RML-infected cultures (Fig. 2A). We previously demonstrated that 
phosphorylation of  tyrosine 311 is required for caspase-3-mediated proteolytic activation 
of PKCδ (Kaul et al., 2005)  and its pro-apoptotic function (Jin et al., 2011a; 
Latchoumycandane et al., 2011; Li et al., 1994; Saminathan et al., 2011) (Anantharam et 
al., 2008). In addition to tyrosine 311 phosphorylation, PKCδ-thr505 activation-loop 
phosphorylation is required for full kinase activity of PKCδ, and thus serves as a marker 
of PKCδ activation(Le Good et al., 1998). Therefore, we determined the phosphorylation 
of tyr311 and thr505 in prion-infected COSCs by Western blot using phospho-specific 
antibodies.  As shown in Fig 2 A, 2 D-E, RML infection significantly increased tyr311 
and thr505 phosphorylation compared to control NBH-inoculated slice cultures.  
 
Next, we employed the 
32
p IP-kinase assay to determine if RML-induced proteolytic 
activation of PKCδ is associated with a sustained activation of its kinase activity in 
organotypic slice cultures. PKCδ kinase assays performed in the absence of lipid 
cofactors showed a robust increase in PKCδ kinase activity in RML-infected samples 
compared to NBH-inoculated samples, indicating that proteolytic activation increases the 
kinase activity.  To further confirm the PKCδ upregulation, we quantified PKCδ mRNA 
levels upon exposure to either NBH or RML scrapie infection by quantitative-RT-PCR 
analysis. Interestingly, our results show that RML infection leads to increased levels of 
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PKCδ mRNA, suggesting the RML infection-meditated upregulation of PKCδ is through 
transcriptional induction.  Collectively, our results in the COSC model demonstrate that 
prion infection activates PKCδ kinase activity by proteolytic cleavage and upregulation 
of the kinase.  
 
Cerebellar atrophy during RML infection 
To evaluate the effect of RML infection on the cerebellum, we infected organotypic 
cerebellar cultures with either NBH or RML for two weeks, as described above. At the 
end of the incubation, cerebellar slices were analyzed for cerebellar atrophy induced by 
prion infection. As shown in Fig. 3, compared to slices inoculated with NBH, cultures 
infected by RML have more diffuse staining for TujI, a neuronal marker for neuron-
specific class III β-tubulin, indicating that RML infection induces discernible cerebellar 
degeneration. Additionally, immunostaining for PKCδ indicates an intense PKCδ 
immunoreactivity in the RML-infected cerebellar brain slices, predominantly in the 
Purkinje cells lining the molecular layer. Histological evaluation of the RML-infected 
COSCs indicates a marked cerebellar atrophy compared to NBH-inoculated slices. In 
RML-infected cerebella slices, extensive degeneration was observed in the molecular 
layer, similar to previous reports evaluating neuropathological changes in human CJD 
and GSS incidents (Yang et al., 1999).  
 
In vivo Proteolytic activation of PKCδ in murine-adapted RML scrapie-infected mice  
Apoptosis has been characterized as a major mode of neuronal cell death associated with 
spongiform degeneration(Bourteele et al., 2007; Carimalo et al., 2005), and PKCδ has 
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been identified as a key pro-apoptotic molecule involved in neuronal apoptosis 
(Kanthasamy et al., 2010). To evaluate whether PKCδ activation occurs in vivo during 
TSE-induced neurodegeneration, we examined RML scrapie- and mock NBH-inoculated 
wild-type mice at 60, 90, 120 and 150 DPI for changes in native and proteolytically 
cleaved PKCδ fragments in cerebellar tissues. As shown in Fig. 4A, increased levels of 
cleaved PKCδ in RML-infected animals were observed at preclinical stages (90 and 120 
DPI) of TSE, compared to mock-infected animals. Quantified immunoblots for the 
cleaved PKCδ protein fragment (Fig. 4C) show 75-80% induction of proteolytic 
activation in RML-infected animals beyond that expressed in NBH-inoculated animals at 
these preclinical stages, suggesting the induction of apoptotic stimuli leading to cerebellar 
atrophy-related behavioral deficits. However, we did not find increased native PKCδ 
protein levels, as observed in the RML-infected slice cultures (Fig. 2A and 2B). 
Furthermore, PKCδ protein level was slightly reduced at the time point (150 DPI) 
marking the terminal stages of TSE. 
 
Next, we examined the phosphorylation of PKCδ at two regulatory sites: Tyr311 flanking 
the caspase-3 cleavage site of PKCδ and Thr505 within the activation loop. Analysis of 
Tyr311 phosphorylation upon RML infection (Fig. 4C) indicates a slight reduction at 60 
DPI and then a significant increase in the phosphorylation signal at 90 and 120 DPI. It is 
noteworthy that the time-course pattern for this PKCδ cleavage-specific phosphorylation 
event is also reflected in the increase in cleaved PKCδ fragments at 90 and 120 DPI. This 
positive correlation indicates the potential significance of these events at these preclinical 
TSE stages. Additional quantitation of immunoblots for phosphorylated PKCδ at Thr505 
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(Fig. 4D) indicated about a 75% increase at 60 DPI and about a 25% increase of 
phosphorylation events at 90 and 120 DPI when normalized to Thr505 phosphorylation 
signals in NBH-inoculated samples at the respective time points. Together, our results in 
an animal model of prion disease revealed time-dependent alterations in PKCδ signaling.   
 
TSE-related behavioral abnormalities are delayed in PKCδ (-/-) mice 
The neurological symptoms of mice infected with mouse-adapted scrapie include 
kyphosis, tremor, cachexia, and ataxia(Aguzzi and Heikenwalder, 2006; Bessen et al., 
2011; Castilla et al., 2008; Collins et al., 2001). Additionally, infected mice display 
clasping of limbs when held aloft by the tail(O'Shea et al., 2008). If PKCδ signaling 
contributes significantly to the neurodegeneration and neurological deficits associated 
with TSE, inhibition of PKCδ function would delay the onset of the disease. To further 
validate the role of PKCδ signaling in TSE, we utilized PKCδ knockout (PKCδ-/-) C57 
black mice, as described in our previous publication(Zhang et al., 2007). Specifically, we 
evaluated the motor function in PKCδ (-/-) C57 black mice following inoculation with 
murine-adapted RML scrapie and compared with that of wild-type C57 black mice. After 
inoculation with either NBH or RML, mice were subjected to weekly behavioral analysis 
using the horizontal bar test and grip strength meter to assess grip strength, stamina, and 
coordination.  
 
Beginning at week 14, wild-type RML-infected animals displayed significantly reduced 
forelimb strength, which continued until the end of the study (Fig. 4A). Conversely, 
RML-infected PKCδ (-/-) animals retained forelimb strength until sacrifice at 150 DPI. 
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For the horizontal bar test (Fig. 5B), mice were scored from 0 to 5, reflecting increasing 
hang durations while suspended from the metal bar. Infected wild-type animals began 
showing difficulty hanging on the bar at week 18, and the score significantly decreased at 
week 21 (Fig. 5A). PKCδ (-/-) mice showed no significant reduction during the course of 
infection. In addition to grip strength and horizontal bar measurements, general clinical 
evaluation of all mice was done weekly in order to identify behavioral signs of RML 
scrapie-induced motor deficits. We evaluated both wild-type and PKCδ (-/-) mice for 
differences in motor signs that reflect difficulty initiating ambulatory activities and 
changes in ambulatory activity patterns. We scored their pathology on a scale from 0 to 4, 
with 0 indicating normal movement and 4 indicating almost complete lethargy and ataxia 
(Fig. 5C). Test animals were monitored over a period of several minutes for changes in 
behavioral motor deficits reflecting postural instability and difficulty in open field 
ambulation. Symptoms began appearing in wild-type mice at week 17 and became 
progressively more pronounced over the course of monitoring. By contrast, PKCδ (-/-) 
mice showed a delayed onset of TSE-related ataxia, and their observable motor signs 
were scored as less severe. Additionally, mice were tested for the clasping of limbs when 
held aloft by the tail. PKCδ (-/-) mice likewise showed a delay in the onset of clasping, as 
well as reduced severity scores (Fig. 5D). Taken together, these results indicate that 
PKCδ knockdown delays the onset of neurological signs associated with mouse-adapted 
scrapie in animal models.  
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Discussion 
In this study, we report that PKCδ is proteolytically activated during the preclinical 
stages of TSE in our experimental models of prion disease. Our results also demonstrate 
that phosphorylation of PKCδ at its activation loop and its catalytic domain is important 
for disease progression and neuronal cell death during the course of prion infection. To 
the best of our knowledge, we are the first to demonstrate that PKCδ (-/-) mice exhibit 
delayed onset of the behavioral symptoms associated with the prion disease. These 
findings could contribute to the development of interventional strategies for TSE-related 
motor deficits.   
One of the main limitations for characterizing the molecular mechanisms of TSE is the 
lack of suitable in vitro experimental models of infectious prion disease. Indeed, several 
in vitro experimental models, such as neuronal cell lines infected with mouse-adapted 
scrapie, have been used to investigate the biochemical properties of PrP
Sc 
with some 
success at expanding the horizons of prion biology. However, due to several limitations 
associated with cell culture systems, they are not amenable for studying in-depth 
molecular mechanisms underlying infectious prion disease. Recently, Falsig and his 
colleagues successfully developed and validated(Falsig and Aguzzi, 2008; Falsig et al., 
2008; Falsig et al., 2012) an ex vivo transmission model for prion disease using 
organotypic cerebellar slice cultures. In this study, we successfully adopted this 
organotypic cerebellar slice culture to study PKCδ-mediated neuronal cell death during 
TSE. First, we were able to reproduce the RML-infected organotypic cerebellar slice 
cultures in our laboratory with slight modifications.  We observed an improved viability 
of cerebellar slices with use of Compresstome™ Vf-300 microtome, because this 
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procedure significantly reduced the cutting time and mechanical stress associated with 
slice preparation. Our slice cultures were able to retain infection, as seen by widespread 
gliosis during early stages of the infection (2 weeks, Fig. 1A) and by the presence of PK-
resistant prion proteins after 5 weeks of RML incubation (Fig. 1B). Following 
establishment of COSCs with prion infection, we systematically studied the role of 
proteolytically activated pro-apoptotic kinase PKCδ in prion-induced neurodegeneration 
by comparing the kinase signaling in RML-infected and mock NBH-inoculated slice 
cultures. 
We have previously shown that PKCδ is a key oxidative stress-sensitive kinase that can 
be activated by caspase-3 dependent proteolytic cleavage, by tyrosine and threonine 
phosphorylation(Gordon et al., 2012; Jin et al., 2011a; Jin et al., 2011b; Kanthasamy et 
al., 2003a). Also, oxidative stress has been identified as integral to prion-induced 
neurodegeneration(Brown, 2005; Guentchev et al., 2000; Kim et al., 2001; Sinclair et al., 
2013; Sonati et al., 2013)Therefore, herein, we have evaluated PKCδ-mediated neuronal 
apoptosis in ex vivo cerebellar slice cultures and in RML-infected in vivo mice.  Our data 
support the idea of PKCδ proteolytic activation during prion infection, as noted by the 
significantly increased native and cleaved PKCδ upon RML infection in COSCs. We also 
observed increased phosphorylation of PKCδ Tyr311 and Thr505 levels in RML-infected 
COSCs, compared to mock-infected tissues. Phosphorylation of Tyr311 at the hinge 
region of PKCδ, which reportedly causes conformational changes in the structure that 
opens the catalytic domain (Kikkawa et al., 2002), mediates caspase-3-dependent 
cleavage, thereby separating the catalytic and regulatory domains (Kanthasamy et al., 
2003b; Kaul et al., 2005). This proteolytic activation of PKCδ promotes apoptosis by 
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activating downstream apoptotic cascades(Anantharam et al., 2002; Kanthasamy et al., 
2003a). In addition, the cleaved catalytically active PKCδ fragment activates upstream 
caspase signaling, constituting a positive feedback mechanism leading to a further 
amplified apoptotic pathway (Anantharam et al., 2002; Kitazawa et al., 2003; Reyland, 
2007). Furthermore, analysis of the PKCδ activation loop-specific site Thr505 indicates 
that RML infection could induce phosphorylation of Thr505 to further enhance the kinase 
activation. These observations were further validated by the upregulation of PKCδ kinase 
activity, as seen by PKCδ IP-kinase assays. We also analyzed the PKCδ mRNA and the 
native protein levels upon RML infection. Surprisingly, we observed increased PKCδ 
mRNA expression and protein levels in infected slices, indicating transcriptional 
upregulation of native PKCδ expression. Next, we performed immunohistochemical 
analysis of the extent of neurodegeneration in RML-infected cerebellar slices. We 
observed widespread neuronal cell death (Fig.3), as seen by diffused staining for the 
neuronal marker Tuj1 and increased                                                                                                                                                                                                                                                                                                                                                   
PKCδ staining in RML-infected tissues compared to mock NBH-inoculated tissues. Also, 
we morphologically discerned cerebellar atrophy in the RML-infected slices, which can 
be extrapolated to cerebellar dysfunction and locomotor deficits involved with TSE.   
Following the evaluation of PKCδ in organotypic slice cultures, we further characterized 
the role of PKCδ in in vivo experimental models of prion disease by intracerebrally 
inoculating mouse-adapted RML scrapie or NBH to wild-type C57BL/6 mice and 
analyzing PKCδ signals 60, 90, 120 and 150 days post-infection. Biochemical analysis of 
cerebellar tissues in these mice revealed significantly increased levels of cleaved PKCδ 
protein during preclinical stages, indicating the possible involvement of neuronal cell 
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death. These findings corroborate with previous reports indicating that oxidative stress is 
induced during early prion invasion, thus predisposing the brain to 
neurodegeneration(Yun et al., 2006). We also observed increased phosphorylation of 
PKCδ Tyr311 levels, via immunoblotting, which in combination with the proteolytic 
activation of PKCδ, makes neurons susceptible to downstream apoptotic cascades. Since 
PKCδ is abundantly expressed in the cerebellum(Merchenthaler et al., 1993), especially 
in Purkinje cells and the posterior cerebellar cortex (Barmack et al., 2000), these neurons 
may be more susceptible to TSE-induced neurotoxic stress and more likely to undergo 
degeneration resulting from the disease. Increased PKCδ cleavage without any significant 
change in the native kinase at 90 and 120 DPI suggests that PKCδ upregulation may have 
been compensated by increased proteolysis of the kinase at the early stages of the 
infection.  The observed decrease in native PKCδ as well as the cleaved fragment at the 
terminal stage of the disease may be due to the loss of neurons normally expressing 
higher levels of PKCδ. 
 Since TSE is a fatal neurodegenerative disease often involving motor and postural 
abnormalities associated with cerebellar dysfunction(Collins et al., 2001; Cooper et al., 
2006; Glatzel et al., 2005), we performed several behavioral tests in RML-infected mice 
throughout the study. For our behavior testing, we included the transgenic PKCδ (-/-) 
mice to evaluate whether abolition of PKCδ would alter TSE-associated neurobehavioral 
deficits. We evaluated ataxia, hind limb clasping phenotype, forelimb grip strength and 
horizontal bar performance to assess neurological damage, particularly cerebellar ataxia 
and other motor deficits(Chou et al., 2008; Deacon, 2013; Guyenet et al., 2010).  For 
most of the behavioral tests, wild-type animals infected with RML started showing 
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behavioral deficits around 14-17 weeks post-infection, whereas mice receiving the mock 
NBH inoculation did not show any behavior deficits throughout the study. Interestingly, 
PKCδ (-/-) showed a delayed onset of the motor deficits associated with TSE, suggesting 
that PKCδ signaling plays as a major role in the pathogenesis of prion disease.   We have 
previously shown that the PKCδ inhibitor rottlerin effectively protected against 
locomotor deficits in an animal model of dopaminergic neurodegeneration(Zhang et al., 
2007). Therefore, successful attenuation of scrapie-induced neurodegeneration by 
pharmacological inhibition of PKCδ could provide a basis for developing therapies 
effective prior to the onset of widespread spongiform neurodegeneration and motor 
deficits in TSE. 
In conclusion, we have demonstrated an enhanced regulatory phosphorylation and 
proteolytic activation of PKCδ during the progression of mouse-adapted scrapie 
cerebellar slice cultures and a delayed onset of scrapie-induced motor symptoms in PKCδ 
knockout mice, suggesting a possible role of PKCδ in the neurotoxicity of prion disease. 
These findings may help to further elucidate the PKCδ dependent cell signaling 
mechanism in TSE pathogenesis and to develop potential pharmacological interventions 
for TSE. 
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Figure 1:Prion replication and PKCδ upregulation in RML-scrapie infected 
organotypic cerebellar slice culture. (A) Immunohistochemical analysis of widespread 
astrogliosis and PKCδ upregulation in RML-scrapie infected cerebellar slice culture 
(right panel) as compared to control NBH inoculated cerebellar slice culture (left panel). 
(B) Western blot analysis of the proteinase-K resistant PrP
Sc
 isoform after five weeks of 
RML infection in cerebellar slice cultures. 
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Figure 2: Proteolytic activation of PKCδ in RML-scrapie infected organotypic 
cerebellar slice culture. (A) Representative Western blots for PKCδ upregulation, 
cleavage and phosphorylation upon RML-scrapie infection in cerebellar slice cultures. 
Densitometric analysis of Western blots for (B) Native PKCδ (C) Cleaved PKCδ (D) p-
PKCδ (Thr505) and (E) p-PKCδ (Tyr311) upregulation upon RML-scrapie infection. 
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Each group represented as mean ± S.E.M. from at least five separate measurements. (F) 
qRT-PCR analysis for PKCδ mRNA expression following RML-scrapie infection. Each 
group represented as mean ± S.E.M. from at least six measurements from three separate 
experiments. (G) PKCδ immunoprecipitation (IP)-kinase assay for augmented kinase 
activity upon RML-scrapie infection in organotypic slice cultures. Each group 
represented as mean ± S.E.M. from at least four measurements from two separate 
experiments (
*
p < 0.05 vs NBH, 
**
p < 0.01 vs NBH, ***p<0.001 vs NBH). 
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Figure 3: Cerebellar degeneration during RML infection in organotypic cerebellar 
slice culture. (A) Immunohistochemical analysis of pronounced cerebellar atrophy 
during RML infection (lower panel) and intact healthy histological morphology in control 
NHB-inoculated (upper panel) cerebellar slices. White dotted boxes represent regions 
magnified in slices described below. (B) Representative high magnification (20X) images 
indicating possible neuronal damage (as seen by diffuse Tuj1 staining) and PKCδ 
upregulation during RML infection (lower panel). 
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Figure 04: 
Figure 4: PKCδ activation in RML scrapie-infected mice. (A) Representative Western 
blots for native, cleaved and phosphorylated PKCδ at 60, 90, 120 and 150 days post-
infection (DPI).  Densitometric analysis of Western blots for changes in (B) Native PKCδ 
(C) Cleaved PKCδ (D) p-PKCδ (Tyr311) and (E) p-PKCδ (Thr505) upon RML infection 
at various time points. All data were normalized to NBH expression levels and are 
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represented as mean percentage (± S.E.M.) of uninfected protein expression from at least 
three separate animals.  
 
 
Figure 5:PKCδ knockout mice are resistant to RML scrapie induced motor deficits. 
RML scrapie-infected WT and PKCδ (-/-) mice were evaluated weekly for motor changes 
after inoculation. A) Forelimb grip strength was significantly reduced beginning at 14 
weeks in wild type mice, whereas PKC (-/-) animals did not differ significantly from 
mock-infected wild type animals throughout the course of infection. B) Motor function 
was evaluated using the horizontal bar test. Wild type RML scrapie-infected mice began 
to show deficits at 17 weeks, and changes became significant at 21 weeks. RML scrapie-
infected PKCδ (-/-) mice and mock-infected mice showed no significant changes. C) 
Mice were evaluated for open-field ambulation and their ability to initiate movement over 
316 
 
the course of several minutes. Slight changes in motor function were observed in infected 
WT mice beginning at 18 weeks, progressing to significant ataxia by 21 weeks. 
Conversely, PKCδ (-/-) mice displayed a delayed onset in motor signs, and changes 
remained mild throughout the monitoring period. D) The clasping of limbs when held 
aloft by the tail was evaluated in WT and PKCδ (-/-) mice. Clasping symptoms began in 
WT mice at 14 weeks and steadily progressed to severe over the course of monitoring. 
PKCδ (-/-) animals did not begin clasping limbs until 17 weeks, and symptoms were mild 
over the course of monitoring. Data represented as mean ± SEM for each group. 
 
  
317 
 
APPENDIX III 
ANTIOXIDANTS AND REDOX-BASED THERAPEUTICS IN PARKINSON’S 
DISEASE  
(In press) Inflammation, Oxidative Stress and Age-Related Disease, edited by Stephen 
C. Bondy and Arezoo Campbell. Springer press (2016). 
 
Dilshan S. Harischandra, Huajun Jin, Anamitra Ghosh, Vellareddy Anantharam, Arthi 
Kanthasamy and Anumantha G. Kanthasamy
‡
 
Parkinson’s Disorder Research Laboratory, Iowa Center for Advanced Neurotoxicology, 
Department of Biomedical Sciences, Iowa State University, Ames, Iowa 50011, USA  
‡
To whom correspondence should be addressed: Dept. of Biomedical Sciences, Iowa 
State University, 2062 College of Veterinary Medicine Building, Ames, IA 50011. Tel: 
515-294-2516; Fax: 515-294-2315; Email: akanthas@iastate.edu 
Dilshan S. Harischandra: dilshan@iastate.edu 
Huajun Jin: egb761@iastate.edu 
Anamitra Ghosh: Anamitra.Ghosh@vai.org 
Vellareddy Anantharam: anantram@iastate.edu 
Arthi Kanthasamy: arthik@iastate.edu 
Anumantha G. Kanthasamy: akanthas@iastate.edu 
318 
 
Abstract  
Parkinson’s disease (PD) is a progressing neurodegenerative disorder of the 
central nervous system (CNS) characterized by a progressive loss of dopaminergic 
neurons in the substantia nigra and their axon terminals in the striatum. Although the 
etiology of PD is not completely understood and is believed to be multifactorial, 
oxidative stress and mitochondrial dysfunction are widely considered major contributors 
offering important clues about disease mechanisms. Given the relevance of oxidative 
stress in PD, a new class of antioxidant therapeutics, including mitochondria-targeted 
antioxidants, has been receiving attention as a possible treatment for PD. Here we 
summarize the recent discoveries of potential antioxidant compounds for modulating 
oxidative damage in PD. 
 
Parkinson’s disease 
 Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting 
more than one million individuals over the age of 60 within the United States (Jankovic 
and Stacy, 2007). According to one recent article, the number of new cases increased by 
about 50,000 annually (Dauer and Przedborski, 2003). Although PD is an age-related 
disorder affecting nearly 3% of people over 60 years and 4-5% of those over age 85, 
nearly 10% of PD patients are under 40 years of age (Mizuno et al., 2001). 
Epidemiological studies suggest that sporadic PD cases (90%) are predominantly late 
onset, whereas the remainder (10%) is characterized by early onset occurring mainly in 
familial clusters (Mizuno et al., 2001; Tanner, 2003).  Familial or early onset PD has 
been linked with mutations in several genes such as parkin, ubiquitin C-terminal 
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hydrolase L1, α-synuclein, leucine-rich repeat kinase 2 (LRRK2), PINK-1 or DJ1 
(Bonifati et al., 2008; Gwinn-Hardy, 2002; Tang et al., 2006; Weng et al., 2007). The 
cause of sporadic or non-familial PD is not known, but several reports suggest 
environmental toxins, genetic factors, mitochondrial dysfunction, apoptosis, oxidative 
stress and neuroinflammation to be among the possible factors behind PD’s 
neurodegeneration (Ben-Shachar et al., 1995; Hoehn and Yahr, 1998; McGeer et al., 
2001; Schapira, 1994). Among the environmental toxins implicated in the pathogenesis 
and progression of the disease, the list includes infectious agents, pesticides, herbicides 
and heavy metals (Mizuno et al., 2001). Recent investigations have focused on 
inflammation and oxidative stress as the central players in the pathogenesis of PD.  
In both idiopathic and genetic cases of PD, oxidative stress appears to be the 
common underlying mechanism contributing to the cascade leading to selective 
neurodegeneration in substantia nigra (SN) neurons and their terminals in the striatum. 
An imbalance between reactive oxygen species (ROS) generation and elimination 
mechanisms, such as impaired cellular antioxidant machinery, contributes to the 
pathogenesis of PD and other neurodegenerative disorders. The resulting oxidative stress 
is intimately linked to the other aspects of the degenerative process such as mitochondrial 
dysfunction, inflammation, protein misfolding and DNA damage.  
 
Oxidative stress in PD 
Oxidative stress in PD is supported by post-mortem studies on the SN of PD 
patients showing increased levels of oxidized lipids (Bosco et al., 2006), proteins, nucleic 
acids (Nakabeppu et al., 2007; Zhang et al., 1999) and impaired antioxidant mechanisms 
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such as a reduced glutathione (GSH) and oxidized glutathione (GSSG) ratio (Sian et al., 
1994).  Therefore, oxidative stress appears to play a major role in the cascade of 
biological changes culminating in dopaminergic cell death even though the precise 
mechanisms involving oxidative stress-mediated nigral cell degeneration in PD are not 
clear. However, accumulating evidence indicates that dopamine (DA), a neurotransmitter 
under physiological conditions, may also serve as a neurotoxin and thereby participate in 
the neurodegenerative process. The mechanism of dopamine neurotoxicity is strongly 
linked to oxidative metabolism. Under physiological conditions, dopamine can be 
oxidized enzymatically through monoamine oxidases (MAO) to dihydroxyphenylacetic 
acid (DOPAC) and subsequently methylated by catechol-O-methyltransferase (COMT) to 
homovanillic acid (HVA), or from dopamine to 3-methoxytyramine (3-MT) via COMT 
and further oxidized to HVA through MOA.  During this MAO-mediated DA turnover 
process, hydrogen peroxide (H2O2) is produced as a byproduct of DA deamination, a 
process serving as an inherent source of oxidative stress in the nigrostriatal system. 
Dopamine can also be non-enzymatically oxidized by O2 yielding quinones and H2O2. 
These quinones also undergo intramolecular cyclization immediately followed by 
cascading oxidative reactions ending in the formation of a black, insoluble polymeric 
pigment known as neuromelanin (Graham, 1978; Hermida-Ameijeiras et al., 2004). 
 Neuromelanin renders dopaminergic neurons more susceptible to auto-oxidation through 
quinone modification of dopamine, which increases basal levels of oxidative stress in SN 
(Graham, 1978). What is becoming clear is that degrading dopamine either enzymatically 
or non-enzymatically generates H2O2, which is easily converted through the Fenton’s 
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reaction to highly toxic hydroxyl radicals (•OH) when in the presence of the high levels 
of ferrous iron (Fe
2+
) normally found in the SN (Nappi and Vass, 1997).  
 
Hydroxyl Radicals, Superoxide and Hydrogen peroxide in PD 
As mentioned above, DA oxidation plays an important role in generating 
hydroxyl radical in the central nervous system, including the degeneration of 
dopaminergic neurons. Dopamine, like many catecholamines (dihydroquinones, QH2), 
can easily be oxidized by O2 under physiological conditions. During this oxidation 
process, both semiquinones (•QH) and quinones (Q) are generated, resulting in •OH (via 
Fenton’s reaction), the most toxic free radical in living cells (Klegeris et al., 1995). The 
resulting DA quinones also exert further neurotoxicity by covalently binding to cellular 
nucleophiles such as GSH and protein cysteinyl residues, which normally function as 
antioxidants important for cell survival (Levine et al., 1996; Requejo et al., 2010).  
Moreover, DA quinones bind and modify several proteins implicated in PD 
pathophysiology such as α-synuclein, DJ-1 and parkin (Conway et al., 2001; Girotto et 
al., 2012; LaVoie et al., 2005). However, among the various types of oxidative damage in 
cellular macromolecules, damage to nucleic acids is particularly hazardous as it could 
alter the genetic information. Among the five nucleobases - uracil, thymine, cytosine, 
adenine and guanine - guanine is most susceptible to nucleic acid oxidation through 
hydroxyl radicals (Cerchiaro et al., 2009; Cooke et al., 2003). Hydroxyl radical-mediated 
lesioning of the DNA strand produces 8-hydroxyguanosine (8OHG), the most studied 
oxidized DNA product. Moreover, DNA damage in PD also appears to be at the level of 
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8OHG and 8-hydroxyl-2-deoxyguanosine (8-OHdG) as elevated 8OHG and reduced 8-
OHdG have been observed in the SN and cerebrospinal fluid (CSF) of PD patients (Isobe 
et al., 2010; Zhang et al., 1999). 
Although the human brain comprises only 2% of the total body weight, it is 
especially prone to oxidative stress as it receives 15% of the cardiac output and 20% of 
total O2 consumption of the body, making it highly metabolically active tissue that 
critically relies on oxidative phosphorylation to meet energy demands. Oxidative 
phosphorylation also produces potentially damaging radicals such as 
the superoxide anion O2
-
 as a result of a one-electron reduction of O2. Superoxide occurs 
widely in nature through a variety of enzymatic processes including xanthine oxidase and 
NADPH oxidase, a multimeric enzyme that generates both O
2-
 and H2O2 (Qureshi et al., 
1995). Superoxide has the capacity to damage components of the electron transport chain 
and other cellular constituents. Superoxides are also produced at microsomal membranes, 
with electron transport systems dependent on NADH or NADPH, via detoxification of 
toxic compounds and the catalyzed oxidation of fatty acids (Berg et al., 2004). NADPH 
oxidase (also known as PHOX) is a membrane-bound enzyme that contributes to the 
production of O2
-
 from O2 in microglial cells leading to dopaminergic neuron damage 
(Gao et al., 2003; Wu et al., 2005). NADPH oxidase is a multimeric enzyme composed of 
plasma membrane bound gp91phox and p22phox subunits and cytosolic p40phox, 
p47phox and p67phox subunits. Upon activation, the cytosolic subunits undergo 
phosphorylation and translocate to the membrane, where together with small G proteins 
they associate with the membrane-bound subunits. The assembled and active enzyme 
complex then catalyzes the transfer of a single electron from NADPH to O2 to release 
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superoxide. Moreover, O2
-
 is generated as a normal byproduct of the mitochondrial 
electron transfer chain. Depending on the availability of substrates and cofactors, O2
- 
can 
react as a one-electron oxidant, oxidizing hydroquinones to semiquinone radicals, 
ascorbate, or epinephrine with the concomitant production of H2O2 or a one-electron 
reductant, e.g., quinones or peroxides in the presence of transition metals (Berg et al., 
2004). The flux of O2
- 
is a function of the concentration of potential electron donors, the 
local concentration of O2 and the second-order rate constants for the reactions between 
them. Two modes of operation by isolated mitochondria result in significant O2
- 
production, predominantly from complex I, when 1) the mitochondria are not making 
ATP and consequently have a high Δp (proton motive force) and a reduced CoQ 
(coenzyme Q) pool, and when 2) a high NADH/NAD
+
 ratio exists in the mitochondrial 
matrix. For mitochondria that are actively making ATP, and consequently have a lower 
Δp and NADH/NAD+ ratio, the extent of O2
- 
production is far lower. 
Given the ability of mitochondria to produce superoxides and hamper a neuron’s 
ability to produce ATP, which subsequently lead to apoptosis, several toxin-based models 
are employed to study PD and related molecular mechanisms. For instance, to mimic 
oxidative stress mechanisms in PD, researchers use rotenone, a complex I inhibitor, as 
well as other chemical inhibitors of electron flow that act further downstream in the 
electron transport chain because they increase ROS production and subsequent 
mitochondria-dependent apoptosis. Rotenone binds to the ubiquinone binding site of 
complex I and disrupts the electron transfer between the terminal iron-sulfur (FeS) cluster 
N2 and ubiquinone (Scatena et al., 2012). This process interferes with NADH’s ability to 
produce ATP and pass electrons to CoQ, creating excess electrons within the 
324 
 
mitochondrial matrix (Hayes and Laws, 1991). This complex I inhibition causes electrons 
to react with O2 prematurely, incompletely reducing it to superoxide radicals instead of 
water. Therefore, rotenone-induced oxidative stress activates a downstream apoptotic 
cascade in dopaminergic cells, which helps explain the observed systemic reduction in 
complex I activity and oxidative stress in PD brains (Greenamyre et al., 2001; Mizuno et 
al., 1989; Parker et al., 1989). Another highly lipophilic, selective neurotoxicant similar 
to rotenone is 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which induces 
clinical features very similar to human PD (Jin et al., 2015). In the brain, MPTP is 
quickly metabolized to 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP
+
) via 
monoamine oxidase B (MAO-B) in astroglial cells and serotonergic cells (Chiba et al., 
1984; Kitahama et al., 1991). MPDP
+
 is an unstable molecule that undergoes spontaneous 
oxidation to its active metabolite 1-methyl-4-phenylpyridinium (MPP
+
). MPP
+
 is 
selectively taken up by dopaminergic neurons via dopaminergic transporter (DAT) where 
it exerts its neurotoxicity by inhibiting mitochondrial complex I, thereby leading to ATP 
reduction and superoxide generation (Ghosh et al., 2013). Oxidopamine or 6-
hydroxydopamine (6-OHDA) is another synthetic neurotoxicant that selectively destroys 
dopaminergic neurons by generating ROS such as superoxide radicals (Jin et al., 2014b; 
Latchoumycandane et al., 2011).  Like MPP
+
, 6-OHDA enters neurons via DAT (Bove et 
al., 2005). It activates cell death pathways by generating intracellular free radicals and 
mitochondrial inhibition (Blum et al., 2001). Therefore, 6-OHDA, like DA, could 
generate hydroxyl radicals and superoxide radicals by the deamination process via MAO 
or auto-oxidation, and iron-catalyzed via the Fenton reaction, thus further strengthening 
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the free radical hypothesis of PD. However, 6-OHDA’s exact mechanism of ROS 
production and neurotoxicity remains unclear. 
 
Alkoxy radicals (RO
•
) and peroxy radicals (ROO
•
) in PD 
The most favorable biological substrates for peroxidation are the polyunsaturated 
fatty acid (PUFA) components of cell and subcellular membranes. Lipid peroxides result 
from the addition of double bonds or hydrogen abstraction in the presence of oxygen. 
Since PUFA are more sensitive than saturated fatty acids, it is apparent that the activated 
methylene (RH) bridge represents a critical target site. The double bond adjacent to a 
methylene group weakens the methylene C-H bond, thereby rendering the hydrogen more 
susceptible to abstraction (Catala, 2014). Like many radical reactions, lipid peroxidation 
is a multi-step process with initiation, propagation and termination. At the initiation step, 
ROS such as hydroperoxyl radicals or hydroxyl radicals react with PUFA to produce 
unstable fatty acid radicals that continue reacting with O2 to produce unstable, 
intermediate fatty acid peroxy radicals. These fatty acid peroxy radicals and fatty acid 
radicals undergo chain reactions that produce organic hydroperoxides, which in turn can 
remove hydrogen from another PUFA (Halliwell and Gutteridge, 1984). This chain 
reaction is termed propagation, implying that one initiating hit can result in the 
conversion of numerous PUFA to lipid hydroperoxides. Since most biological 
membranes are composed of PUFA, lipid peroxidation is considered the main molecular 
mechanism underlying oxidative damage to cell structures and in toxicity-induced cell 
death. The end products of lipid peroxidation are reactive aldehydes such as 4-hydroxy-
trans-2-nonenal (4-HNE), 4-oxo-trans-2-nonenal (4-ONE), malondialdehyde (MDA), 
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acrolein, isoprostanes, and isofurans (Aluru et al., 2015; Esterbauer et al., 1991). These 
markers are derived from arachidonic acid (ARA), which is released from neural 
membrane glycerophospholipids through the activation of cytosolic phospholipase 
A2 (cPLA2), an enzyme coupled with NMDA receptors through a G protein-independent 
mechanism (Farooqui and Horrocks, 2007; Farooqui and Farooqui, 2011).  
The primary end product of lipid peroxidation, 4-HNE, is a highly reactive 
lipophilic α,β-alkenal that forms stable adducts with nucleophilic groups on proteins such 
as thiols and amines (Ullery and Marnett, 2012), and it chemically modifies cellular 
macromolecules and DNA. Moreover, 4-HNE shows time- and dose-dependent 
activation of caspase-8, caspase-9 and caspase-3 as well as apoptotic cell death 
accompanied by DNA fragmentation (Liu et al., 2000). Mechanistically, 4-HNE reduces 
glutathione (GSH) inhibition (Ahmed et al., 2002) of the NFκB signaling pathway (Yin et 
al., 2015), disinhibits mitochondrial complexes I and II, and it deactivates p53 (Cao et al., 
2014) and poly-(ADP-ribose) polymerase (PARP) (Raza and John, 2006). The increased 
levels of 4-HNE immunopositive neurons in the brain tissue and cerebrospinal fluid of 
PD patients indicate not only a pathophysiological role for oxidative stress in these 
diseases, but also a role for 4-HNE in neuronal apoptosis (Liu et al., 2000; Yoritaka et al., 
1996; Zarkovic, 2003). 
 
Nitric oxide (NO) in PD 
Nitric oxide (NO) is another potential source of oxidative stress. NO is produced 
by nitric oxide synthase (NOS) through converting L-arginine to L-citrulline utilizing 
NADPH oxidase and O2 as cofactors (Day et al., 1999; Duval et al., 1996). There are 3 
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isoforms of NOS: neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS 
(eNOS), of which nNOS is expressed in several neuronal subtypes except dopaminergic 
neurons. In contrast to nNOS, iNOS is not normally expressed in the brain; however, 
under pathological conditions, iNOS can be induced. Activated glial cells produce iNOS, 
which leads to increased production of NO. Indeed, elevated iNOS levels mediated by 
CD23 have been reported in the SN of patients with PD (Hunot et al., 1996). MPTP 
administration in mice also produces glial cell-mediated increases in iNOS expression 
and NO production (Liberatore et al., 1999). Consequently, mice lacking the iNOS gene 
are less susceptible to MPTP-induced losses of SN DA neurons (Itzhak et al., 1998). The 
MPTP-induced striatal dopamine depletion, however, remains intact in iNOS null mice, 
as does MPTP-induced microglial activation (Dehmer et al., 2000; Liberatore et al., 
1999). Although poorly reactive, NO and O2
-
  free radicals can combine to form the 
highly reactive nitrogen species peroxynitrite (ONOO
-
), which can cause oxidative 
damage to various proteins such as tyrosine hydroxylase (TH) and α-synuclein (Ara et al., 
1998; Przedborski and Vila, 2001). Iron content increases in the SN of PD patients and in 
animal models of the disease (Hirsch, 2006). Through a superoxide-driven Fenton’s 
reaction between hydrogen peroxide and the free ferrous iron catalyst, a substantial 
amount of highly reactive hydroxyl radicals (OH) can be produced. Reactive astrocytes 
produce myeloperoxidase (MPO), which oxidizes non-reactive nitrites (NO2
-
) that 
contribute to protein nitrosylation (van der Vliet et al., 1997). MPO is also implicated in 
the production of the non-radical oxidant hypochlorous acid (HOCl), which can damage 
macromolecules directly (Hampton et al., 1998). Altogether, an inflammatory, oxidative 
environment can be produced by activated glial cells in the SN region. 
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Antioxidants as therapeutics for PD 
PD is a multifactorial disease wherein glial activation, inflammation, oxidative 
stress and mitochondrial dysfunction play central roles in dopaminergic 
neurodegeneration, specifically in the nigrostriatum. Increasing efforts are being devoted 
to searching for neuroprotective agents that will protect against the irreversible loss of 
neurons. Administration of a dopamine agonist or levodopa has been widely used to treat 
PD symptoms, but does not alter disease pathogenesis.  Dopaminergic neuroprotection in 
animal models of PD has been demonstrated with various substances including glial cell 
line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) and 
TGF-β.  Additionally, various anti-inflammatory agents, such as NSAIDs, COX 
inhibitors, statins, pioglitazone and minocycline, have been used in different animal 
models of PD. However, most of these compounds failed in either preclinical trials or in 
human phase I trials due to their inability to cross the blood-brain barrier or to limited 
bioavailability. Moreover, they also cause side effects and toxicity in animals. Hence, 
developing successful neuroprotective therapeutic approaches to halt progression of PD 
requires a better understanding of the disease mechanism.   
 
Vitamin antioxidant therapy 
Oxidative stress is closely linked to other components of the degenerative process, 
such as mitochondrial dysfunction, excitotoxicity, nitric oxide toxicity and inflammation. 
That is, neuronal injury and cell death in both acute and chronic pathological conditions 
can result from oxidative damage, for example, through superoxide (O2
-
), hydroxyl (OH
-
), peroxyl (RO2
-
), hydrogen peroxide (H2O2), and peroxynitrite (ONOO
-
). Therefore, 
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various vitamin antioxidants have been tested for their efficacy as scavengers of oxygen 
radicals and their potential as neuroprotective agents. Naturally, dietary sources supply 
many antioxidants. Vitamins C and E, β-carotene and coenzyme Q are the best known 
dietary antioxidants, of which Vitamin E is present in vegetable oils and found 
abundantly in wheat germ (Uttara et al., 2009). This fat soluble vitamin is absorbed in the 
gut and carried in the plasma by lipoproteins. Of eight natural isomeric forms of vitamin 
E, α-tocopherol is the most common and potent isomer. Being lipid soluble, vitamin E 
can effectively prevent lipid peroxidation of plasma membranes (Uttara et al., 2009). In 
the MPTP mouse model of PD, vitamin E inhibited the iron accumulation and thus 
reversed the MPTP-induced increase in oxidized glutathione (GSSG) and lipid 
peroxidation levels in brain tissues (Lan and Jiang, 1997). Moreover, in the 6-OHDA-
induced rat model of PD, vitamin E significantly attenuated the effects of 6-OHDA on 
GSH and SOD in most brain regions (Perumal et al., 1992), indicating that vitamin 
antioxidants may serve as potential therapeutic agents in retarding the progression of 
neurodegeneration. However, epidemiological evidence regarding the associations 
between antioxidant vitamin intake and PD is limited and inconsistent. Observational 
data from humans suggest that the combined administration of high-dose α-tocopherol 
(vitamin E) and ascorbate (vitamin C) supplementation slows the progression of PD 
(Fahn, 1992) and that the dietary intake of vitamin E and β-carotene lowers the risk of 
developing PD (Miyake et al., 2011). In contrast, results from double-blind, randomized 
controlled trials found vitamin E to have no benefits in PD patients (Parkinson Study, 
1993; Scheider et al., 1997). 
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Other plant-based antioxidants 
Plants contain a wide variety of endogenous, free radical-scavenging antioxidants 
such as phenolic compounds (e.g., phenolic acids, flavonoids, quinones, coumarins, 
lignans, stilbenes, tannins), nitrogen compounds (e.g., alkaloids, amines, betalains), 
terpenoids (including carotenoids) and some other endogenous metabolites rich in 
antioxidant activity. Many of these have shown protective effects against oxidative-
induced neuronal death (Uttara et al., 2009). Although consumer demand for 
phytotherapeutic agents is growing, they need scientific validation before plant-derived 
extracts gain wider acceptance and use.  
Apocynin (4-hydroxy-3-methoxyacetophenone) is a non-toxic plant-derived 
molecule that has been well-studied in cell culture and animals models of PD in our lab 
and elsewhere (Anantharam et al., 2007; Philippens et al., 2013). Apocynin can 
effectively block NADPH oxidase and reduce ROS generation during neuronal injury or 
stress.  Recently, we demonstrated that the apocynin dimer diapocynin is also 
neuroprotective and anti-neuroinflammatory in the MPTP animal model as well as in the 
progressively degenerative LRRK2R1441G transgenic mouse model (Dranka et al., 2013; 
Ghosh et al., 2012). Importantly, we were able to demonstrate that diapocynin crosses the 
blood brain barrier, which is one of the main limitations for antioxidant therapies. Upon 
reaching the midbrain of MPTP-treated mice, it attenuates the nigral activation of 
microglial and astroglial cells, inhibits the proinflammatory molecule iNOS and the 
production of NADPH oxidase-mediated superoxide formation and decreases oxidative 
stress, thereby protecting the nigrostriatum and improving neurobehavioral performance, 
suggesting it’s potential as a therapeutic candidate for clinical trials of human PD 
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patients. In these studies, both apocynin and diapocynin were orally administered at 300 
mg/kg body weight. Although these high doses were not toxic to animals, there is a need 
for more efficacious apocynin analogs that will translate into human clinical trials. 
In recent years resveratrol has gained much attention as a therapeutic for 
prevention and treatment of neurodegeneration disorders. Resveratrol is present in a 
variety of vegetables, fruits, grains, teas, and wines. It is protective against a number of 
cardiovascular and neurodegenerative diseases and cancer. Although the mechanisms 
behind resveratrol’s health benefits have not yet been clearly elucidated, a number of 
studies have reported on its antioxidant, anti-inflammatory, and metal-chelating 
properties (Ndiaye et al., 2005; Sun et al., 2008), as well as its ability to activate Sirtuin 1 
(SIRT1) and vitagenes, which can prevent the deleterious effects triggered by oxidative 
stress (Sun et al., 2010). In fact, SIRT1 activation by resveratrol is gaining importance in 
the development of innovative treatment strategies for stroke and other neurodegenerative 
disorders (Sun et al., 2010).  
Quercetin, found abundantly in vegetables and fruits, is another natural 
antioxidant flavonoid capable of protecting cells against oxidative damage, and thus has 
therapeutic potential for the prevention and treatment of cardiovascular disease, cancer, 
and neurodegenerative disease. Importantly, there is now compelling evidence of its 
neuroprotective role in various neurodegenerative diseases (Ansari et al., 2009; 
Haleagrahara et al., 2013; Karuppagounder et al., 2013; Sabogal-Guaqueta et al., 2015). 
In nature, quercetin mainly occurs as glycosides, ethers, and to a lesser extent, sulfates. 
When tested in PC12 cells in a cell culture model of AD, a glycoside form of quercetin, 
quercetin-3’-glucoside, reduced H2O2-induced ROS generation and also protected against 
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Aβ-induced cell death (Zhu et al., 2007). Isoquercitrin, another glycoside form of 
quercetin, was neuroprotective against 6-OHDA-induced neurotoxicity in a PC12 cell 
model of PD (Magalingam et al., 2014). When the 6-OHDA-treated PC12 cells were pre-
treated with isoquercitrin, the levels of ROS-scavenging enzymes (SOD, catalase, and 
GPx) increased and lipid peroxidation decreased. Similarly, quercetin treatment reduced 
protein carbonyl content and lipid hydroperoxide (LPO) levels in the striatum of 6-
OHDA-treated rats (Haleagrahara et al., 2011). 
 
Mitochondria-targeted antioxidant therapy  
 Mitochondrial oxidative stress, mitochondrial DNA deletions, altered 
mitochondrial morphology and mitochondrial interactions with pathogenic proteins 
increase oxidative damage leading to dopaminergic neurodegeneration in PD. Therefore, 
therapeutic approaches targeting mitochondrial dysfunction and related oxidative stress 
hold great promise as potential cures for PD. MPTP and other complex-I inhibitors such 
as rotenone, maneb, paraquat, fenzaquin and trichloroethylene result in the loss of nigral 
dopaminergic neurons in mouse models of PD, implicating mitochondrial dysfunction in 
PD pathogenesis. Moreover, reduced complex-I activity and an increased susceptibility to 
MPP
+
, the toxic metabolite of MPTP, were also observed in mitochondrial DNA from PD 
patients, clearly demonstrating the mtDNA-encoded defects in PD. Based on all the 
evidence, it could be inferred that intervening in one or more of these processes could 
alleviate the harmful effects of mitochondrial dysfunction. During the past decade, 
numerous antioxidant analogs have been developed to specifically target mitochondria 
and have been shown to improve mitochondrial function in experimental models of PD. 
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To target small-molecule antioxidants to mitochondria, two general strategies have so far 
been shown to be safe and effective in pre-clinical studies: conjugations to lipophilic 
cations or incorporation into mitochondria-targeted peptides. Since lipophilic cations can 
easily pass through the lipid bilayers of plasma membranes and the mitochondrial inner 
membrane, they accumulate in the mitochondrial matrix in response to the large 
mitochondrial membrane potential (from outer positive to inner negative) (Ross et al., 
2005). The best characterized and most widely used lipophilic cation for conjugating 
small molecules is triphenylphosphonium (TPP), which has traditionally been used to 
determine mitochondrial inner membrane potential. Using TPP chemistry, Murphy and 
colleagues (Ross et al., 2005) developed a series of orally bioavailable mitochondria-
targeted antioxidants, including MitoQ10, MitoVitE and MitoTEMPOL (Jin et al., 2014a).  
 Mito-Q10 (Mito-quinone), the most studied mitochondria-targeted antioxidant, 
protects dopaminergic neurons from 6-OHDA in a  cell model (Solesio et al., 2013) and 
from MPTP-induced toxicity in a mouse model of PD (Ghosh et al., 2010). Mito-Q10 
consists of TPP covalently attached to the ubiquinone moiety of Coenzyme Q (CoQ10) 
through a ten-carbon alkyl chain. CoQ10 is a component of the electron transport chain 
enabling cellular respiration and it works as a strong endogenous antioxidant. Like its 
parent CoQ10, MitoQ continually scavenges peroxyl, peroxynitrite and superoxide, 
thereby protecting mitochondria against lipid peroxidation. MitoVitE is a TPP-conjugated 
mitochondria-targeted antioxidant, which by coupling the antioxidant phenolic moiety of 
α-tocopherol, gets taken up by mitochondria about 80 times more effectively than vitamin 
E itself and thus affords better protection against oxidative damage (Smith et al., 1999). 
MitoVitE also reduces H2O2-induced caspase activity and can prevent cell death in 
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fibroblasts in patients with Friedrich ataxia, an inherited nervous system disease 
associated with decreased frataxin and increased iron-catalyzed oxidative damage 
(Jauslin et al., 2003). In a study targeting cerebellar granule cells, MitoVitE diminished 
the ethanol-induced accumulation of intracellular oxidants and counteracted the 
suppression of not only glutathione peroxidase/glutathione reductase functions, but also 
the protein expression of γ-glutamylcysteine synthetase and total cellular glutathione 
levels (Siler-Marsiglio et al., 2005). MitoTEMPOL is another TPP derivative, but one 
with the stable piperidine nitroxide radical TEMPOL (4-hydroxy-2,2,6,6-
tetramethylpiperidine-1-oxy). MitoTEMPOL also acts as a cytosolic SOD mimetic, 
converting superoxide molecules into water, and is able to detoxify ferrous iron by 
oxidizing it to ferric iron. Although MitoTEMPOL has not yet been tested in 
experimental models of PD, it reduced protein oxidation and mitochondrial and cytosolic 
ROS production in rat models of breast cancer (Dickey et al., 2013) and diabetes (Pung et 
al., 2012), respectively. In an LRRK2
R1441G
 mouse model of PD, the novel mitochondria-
targeted antioxidant MitoApo developed with apocynin, a plant-derived antioxidant and 
NADPH oxidase inhibitor, markedly improved coordinated motor skills and olfactory 
function (Dranka et al., 2014). The authors also showed that the presence of a highly 
lipophilic and delocalized cationic moiety in MitoApo-C11 makes it more cell-permeable 
and bioavailable (Dranka et al., 2014). In our own MitoApo studies, we have observed 
significant neuroprotection against MPP
+
-induced loss of dopaminergic neurons in 
primary mesencephalic culture wherein MitoApo reduced glial cell-mediated 
inflammatory reactions. Moreover, administration of MitoApo in mice protects 
dopaminergic neurons and terminals from MPTP toxicity by reducing inflammatory 
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reactions and oxidative stress (unpublished data). MitoPBN is a TPP derivative of 
phenoxy-butyl-nitrone. The spin trap PBN was chosen based on PBN's well-known 
reactivity with carbon-centered radicals (Murphy et al., 2003). MitoPBN is rapidly taken 
up by mitochondria and can block the oxygen-induced activation of uncoupled proteins 
(Murphy et al., 2003).  
 Another major alternative approach to targeting antioxidants to mitochondria 
is through the use of small positively charged peptides call Szeto-Schiller (SS)-peptides 
(Zhao et al., 2004). SS-peptides contain an aromatic cationic sequence that facilitates the 
delivery of small molecules directly to mitochondria where they localize in the inner 
mitochondrial membrane with an approximately 1000-5000 fold accumulation (Zhao et 
al., 2003; Zhao et al., 2004). These SS-peptides can scavenge H2O2 and peroxynitrite and 
inhibit lipid peroxidation. Their antioxidant action can be attributed to the tyrosine or 
dimethyltyrosine residue (Szeto, 2006). By reducing mitochondrial ROS, these peptides 
inhibit mitochondrial permeability transition and cytochrome c release, thus preventing 
oxidant-induced neuronal apoptosis. Among the SS-peptides recently developed, SS-31 
(D-Arg-(2’6’-dimethyltyrosine)-Lys-Phe-NH2) and SS-20 (Phe-D-Arg-Phe-Lys-
NH2) have been studied most and both comprise a dimethyltyrosine residue, which reacts 
with a variety of free radicals and inhibits lipid peroxidation (Szeto, 2008). Studies with 
isolated mitochondria showed that both SS-31 and SS-20 prevented MPP
+
-induced 
inhibition of oxygen consumption and ATP production and mitochondrial swelling, 
indicating their protective effect in cell culture models of PD (Yang et al., 2009). 
Furthermore, SS-31 exhibited complete dose-dependent protection against the MPTP-
induced loss of dopamine and its metabolites in the striatum, as well as against the loss of 
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tyrosine hydroxylase immunoreactive neurons in the SN. These findings provide strong 
evidence that these neuroprotective peptides, which target both mitochondrial 
dysfunction and oxidative damage, are a promising approach for the treatment of PD 
(Yang et al., 2009). 
 
Conclusions 
 PD is a complex, multifactorial disease condition strongly influenced by 
environmental factors. Exposure to different environmental conditions including 
pesticides, heavy metals, solvents (trichloroethylene), polychlorinated biphenols (PCBs) 
and repeated head injury increases the risk of developing sporadic PD later in life. 
Although the exact mechanisms underlying neurodegeneration in PD is not well 
understood, substantial evidence has implicated mitochondrial dysfunction and oxidative 
damage as important components of PD pathogenesis. Since the brain is particularly 
vulnerable to the effects of ROS due to its high demand for oxygen and its abundance of 
highly peroxidisable substrates, mitochondria-targeted interventions have emerged as a 
tool for modulating oxidative stress in the prevention and treatment of PD. As described 
above, a series of mitochondria-targeted antioxidants have been developed over the past 
few years showing great results in in vitro and in vivo models of PD. Despite their 
efficacy in animal studies, similar outcomes for these novel antioxidant therapies have 
not been borne out in clinical studies of neurodegenerative diseases. Therefore, research 
on effective strategies targeting mitochondria with bioactive molecules capable of 
penetrating the blood brain barrier is essential. Moreover, increasing the innate cellular 
antioxidant defense through other mitochondrial drug targets may be as important. PGC-
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1α, a master regulator of mitochondrial biogenesis, and Nrf2, a natural antioxidant and 
inflammation fighter, are possible therapeutic targets for PD, with important roles in the 
function and survival of dopaminergic neurons in the SN. However, at present, 
antioxidants and mitochondria-targeted therapeutics have seen very limited success in the 
prevention or treatment of PD, and randomized clinical trials in humans, as well as 
animal studies, are urgently needed to identify and understand the effects of 
mitochondria-targeted therapeutics in the treatment of PD. 
 
Acknowledgements: This study was supported by the National Institutes of Health grants 
NS039958, NS088206, ES10586 and NS78247. The W. Eugene and Linda Lloyd 
Endowed Chair to AGK and the Dean Endowed Professorship to AK is also 
acknowledged. We also thank Mr. Gary Zenitsky for assistance in preparing this 
manuscript. 
338 
 
References 
Ahmed, I., et al., 2002. Differential modulation of growth and glutathione metabolism in 
cultured rat astrocytes by 4-hydroxynonenal and green tea polyphenol, 
epigallocatechin-3-gallate. Neurotoxicology. 23, 289-300. 
Aluru, N., et al., 2015. Targeted mutagenesis of aryl hydrocarbon receptor 2a and 2b 
genes in Atlantic killifish (Fundulus heteroclitus). Aquat Toxicol. 158, 192-201. 
Anantharam, V., et al., 2007. Pharmacological inhibition of neuronal NADPH oxidase 
protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress 
and apoptosis in mesencephalic dopaminergic neuronal cells. Neurotoxicology. 
28, 988-97. 
Ansari, M. A., et al., 2009. Protective effect of quercetin in primary neurons against 
Abeta(1-42): relevance to Alzheimer's disease. J Nutr Biochem. 20, 269-75. 
Ara, J., et al., 1998. Inactivation of tyrosine hydroxylase by nitration following exposure 
to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc 
Natl Acad Sci U S A. 95, 7659-63. 
Ben-Shachar, D., et al., 1995. Dopamine neurotoxicity: inhibition of mitochondrial 
respiration. J Neurochem. 64, 718-23. 
Berg, D., et al., 2004. Redox imbalance. Cell Tissue Res. 318, 201-13. 
Blum, D., et al., 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, 
dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. 
Prog Neurobiol. 65, 135-72. 
Bonifati, V., et al., 2008. Re: LRRK2 mutation analysis in Parkinson disease families 
with evidence of linkage to PARK8. Neurology. 70, 2348; author reply 2348-9. 
339 
 
Bosco, D. A., et al., 2006. Elevated levels of oxidized cholesterol metabolites in Lewy 
body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol. 2, 
249-53. 
Bove, J., et al., 2005. Toxin-induced models of Parkinson's disease. NeuroRx. 2, 484-94. 
Cao, Z. G., et al., 2014. Comparison of 4-hydroxynonenal-induced p53-mediated 
apoptosis in prostate cancer cells LNCaP and DU145. Contemp Oncol (Pozn). 18, 
22-8. 
Catala, A., 2014. Reactive oxygen species, lipid peroxidation, and protein oxidation. 
Nova Science Publishers, Inc., Hauppauge, New York. 
Cerchiaro, G., et al., 2009. Hydroxyl radical oxidation of guanosine 5'-triphosphate 
(GTP): requirement for a GTP-Cu(II) complex. Redox Rep. 14, 82-92. 
Chiba, K., et al., 1984. Metabolism of the neurotoxic tertiary amine, MPTP, by brain 
monoamine oxidase. Biochem Biophys Res Commun. 120, 574-8. 
Conway, K. A., et al., 2001. Kinetic stabilization of the alpha-synuclein protofibril by a 
dopamine-alpha-synuclein adduct. Science. 294, 1346-9. 
Cooke, M. S., et al., 2003. Oxidative DNA damage: mechanisms, mutation, and disease. 
FASEB J. 17, 1195-214. 
Dauer, W., Przedborski, S., 2003. Parkinson's disease: mechanisms and models. Neuron. 
39, 889-909. 
Day, B. J., et al., 1999. A mechanism of paraquat toxicity involving nitric oxide synthase. 
Proc Natl Acad Sci U S A. 96, 12760-5. 
Dehmer, T., et al., 2000. Deficiency of inducible nitric oxide synthase protects against 
MPTP toxicity in vivo. J Neurochem. 74, 2213-6. 
340 
 
Dickey, J. S., et al., 2013. Mito-tempol and dexrazoxane exhibit cardioprotective and 
chemotherapeutic effects through specific protein oxidation and autophagy in a 
syngeneic breast tumor preclinical model. PLoS One. 8, e70575. 
Dranka, B. P., et al., 2013. Diapocynin prevents early Parkinson's disease symptoms in 
the leucine-rich repeat kinase 2 (LRRK2R(1)(4)(4)(1)G) transgenic mouse. 
Neurosci Lett. 549, 57-62. 
Dranka, B. P., et al., 2014. A novel mitochondrially-targeted apocynin derivative 
prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 
(LRRK2(R1441G)) transgenic mouse model of Parkinson's disease. Neurosci 
Lett. 583, 159-64. 
Duval, D. L., et al., 1996. Characterization of hepatic nitric oxide synthase: identification 
as the cytokine-inducible form primarily regulated by oxidants. Mol Pharmacol. 
50, 277-84. 
Esterbauer, H., et al., 1991. Chemistry and biochemistry of 4-hydroxynonenal, 
malonaldehyde and related aldehydes. Free Radic Biol Med. 11, 81-128. 
Fahn, S., 1992. A pilot trial of high-dose alpha-tocopherol and ascorbate in early 
Parkinson's disease. Ann Neurol. 32 Suppl, S128-32. 
Farooqui, A. A., Horrocks, L. A., 2007. Glycerophospholipids in brain : phospholipase 
A2 in neurological disorders. Springer, New York, N.Y. 
Farooqui, T., Farooqui, A. A., 2011. Lipid-mediated oxidative stress and inflammation in 
the pathogenesis of Parkinson's disease. Parkinsons Dis. 2011, 247467. 
Gao, H. M., et al., 2003. Critical role for microglial NADPH oxidase in rotenone-induced 
degeneration of dopaminergic neurons. J Neurosci. 23, 6181-7. 
341 
 
Ghosh, A., et al., 2010. Neuroprotection by a mitochondria-targeted drug in a Parkinson's 
disease model. Free Radic Biol Med. 49, 1674-84. 
Ghosh, A., et al., 2012. Anti-inflammatory and neuroprotective effects of an orally active 
apocynin derivative in pre-clinical models of Parkinson's disease. J 
Neuroinflammation. 9, 241. 
Ghosh, A., et al., 2013. The peptidyl-prolyl isomerase Pin1 up-regulation and 
proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of 
Parkinson disease. J Biol Chem. 288, 21955-71. 
Girotto, S., et al., 2012. Dopamine-derived quinones affect the structure of the redox 
sensor DJ-1 through modifications at Cys-106 and Cys-53. J Biol Chem. 287, 
18738-49. 
Graham, D. G., 1978. Oxidative pathways for catecholamines in the genesis of 
neuromelanin and cytotoxic quinones. Mol Pharmacol. 14, 633-43. 
Greenamyre, J. T., et al., 2001. Complex I and Parkinson's disease. IUBMB Life. 52, 
135-41. 
Gwinn-Hardy, K., 2002. Genetics of parkinsonism. Mov Disord. 17, 645-56. 
Haleagrahara, N., et al., 2011. Neuroprotective effect of bioflavonoid quercetin in 6-
hydroxydopamine-induced oxidative stress biomarkers in the rat striatum. 
Neurosci Lett. 500, 139-43. 
Haleagrahara, N., et al., 2013. Effect of quercetin and desferrioxamine on 6-
hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats. J Toxicol 
Sci. 38, 25-33. 
342 
 
Halliwell, B., Gutteridge, J. M., 1984. Oxygen toxicity, oxygen radicals, transition metals 
and disease. Biochem J. 219, 1-14. 
Hampton, M. B., et al., 1998. Inside the neutrophil phagosome: oxidants, 
myeloperoxidase, and bacterial killing. Blood. 92, 3007-17. 
Hayes, W. J., Laws, E. R., 1991. Handbook of pesticide toxicology. Academic Press, San 
Diego. 
Hermida-Ameijeiras, A., et al., 2004. Autoxidation and MAO-mediated metabolism of 
dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. 
Neurochem Int. 45, 103-16. 
Hirsch, E. C., 2006. Altered regulation of iron transport and storage in Parkinson's 
disease. J Neural Transm Suppl. 201-4. 
Hoehn, M. M., Yahr, M. D., 1998. Parkinsonism: onset, progression, and mortality. 1967. 
Neurology. 50, 318 and 16 pages following. 
Hunot, S., et al., 1996. Nitric oxide synthase and neuronal vulnerability in Parkinson's 
disease. Neuroscience. 72, 355-63. 
Isobe, C., et al., 2010. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-
deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's 
disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA 
damage contributes to the neurodegenerative process. Neurosci Lett. 469, 159-63. 
Itzhak, Y., et al., 1998. Resistance of neuronal nitric oxide synthase-deficient mice to 
cocaine-induced locomotor sensitization. Psychopharmacology (Berl). 140, 378-
86. 
343 
 
Jankovic, J., Stacy, M., 2007. Medical management of levodopa-associated motor 
complications in patients with Parkinson's disease. CNS Drugs. 21, 677-92. 
Jauslin, M. L., et al., 2003. Mitochondria-targeted antioxidants protect Friedreich Ataxia 
fibroblasts from endogenous oxidative stress more effectively than untargeted 
antioxidants. FASEB J. 17, 1972-4. 
Jin, H., et al., 2014a. Mitochondria-targeted antioxidants for treatment of Parkinson's 
disease: preclinical and clinical outcomes. Biochim Biophys Acta. 1842, 1282-94. 
Jin, H., et al., 2015. Targeted toxicants to dopaminergic neuronal cell death. Methods 
Mol Biol. 1254, 239-52. 
Jin, H., et al., 2014b. Histone hyperacetylation up-regulates protein kinase Cdelta in 
dopaminergic neurons to induce cell death: relevance to epigenetic mechanisms of 
neurodegeneration in Parkinson disease. J Biol Chem. 289, 34743-67. 
Karuppagounder, S. S., et al., 2013. Quercetin up-regulates mitochondrial complex-I 
activity to protect against programmed cell death in rotenone model of 
Parkinson's disease in rats. Neuroscience. 236, 136-48. 
Kitahama, K., et al., 1991. Distribution of type B monoamine oxidase immunoreactivity 
in the cat brain with reference to enzyme histochemistry. Neuroscience. 44, 185-
204. 
Klegeris, A., et al., 1995. Autoxidation of dopamine: a comparison of luminescent and 
spectrophotometric detection in basic solutions. Free Radic Biol Med. 18, 215-22. 
Lan, J., Jiang, D. H., 1997. Desferrioxamine and vitamin E protect against iron and 
MPTP-induced neurodegeneration in mice. J Neural Transm. 104, 469-81. 
344 
 
Latchoumycandane, C., et al., 2011. Dopaminergic neurotoxicant 6-OHDA induces 
oxidative damage through proteolytic activation of PKCdelta in cell culture and 
animal models of Parkinson's disease. Toxicol Appl Pharmacol. 256, 314-23. 
LaVoie, M. J., et al., 2005. Dopamine covalently modifies and functionally inactivates 
parkin. Nat Med. 11, 1214-21. 
Levine, R. L., et al., 1996. Methionine residues as endogenous antioxidants in proteins. 
Proc Natl Acad Sci U S A. 93, 15036-40. 
Liberatore, G. T., et al., 1999. Inducible nitric oxide synthase stimulates dopaminergic 
neurodegeneration in the MPTP model of Parkinson disease. Nat Med. 5, 1403-9. 
Liu, W., et al., 2000. 4-hydroxynonenal induces a cellular redox status-related activation 
of the caspase cascade for apoptotic cell death. J Cell Sci. 113 ( Pt 4), 635-41. 
Magalingam, K. B., et al., 2014. Protective effects of flavonol isoquercitrin, against 6-
hydroxy dopamine (6-OHDA)-induced toxicity in PC12 cells. BMC Res Notes. 7, 
49. 
McGeer, P. L., et al., 2001. Inflammation in Parkinson's disease. Adv Neurol. 86, 83-9. 
Miyake, Y., et al., 2011. Dietary intake of antioxidant vitamins and risk of Parkinson's 
disease: a case-control study in Japan. Eur J Neurol. 18, 106-13. 
Mizuno, Y., et al., 2001. Parkin and Parkinson's disease. Curr Opin Neurol. 14, 477-82. 
Mizuno, Y., et al., 1989. Deficiencies in complex I subunits of the respiratory chain in 
Parkinson's disease. Biochem Biophys Res Commun. 163, 1450-5. 
Murphy, M. P., et al., 2003. Superoxide activates uncoupling proteins by generating 
carbon-centered radicals and initiating lipid peroxidation: studies using a 
345 
 
mitochondria-targeted spin trap derived from alpha-phenyl-N-tert-butylnitrone. J 
Biol Chem. 278, 48534-45. 
Nakabeppu, Y., et al., 2007. Oxidative damage in nucleic acids and Parkinson's disease. J 
Neurosci Res. 85, 919-34. 
Nappi, A. J., Vass, E., 1997. Comparative studies of enhanced iron-mediated production 
of hydroxyl radical by glutathione, cysteine, ascorbic acid, and selected catechols. 
Biochim Biophys Acta. 1336, 295-302. 
Ndiaye, M., et al., 2005. Red wine polyphenol-induced, endothelium-dependent NO-
mediated relaxation is due to the redox-sensitive PI3-kinase/Akt-dependent 
phosphorylation of endothelial NO-synthase in the isolated porcine coronary 
artery. FASEB J. 19, 455-7. 
Parker, W. D., Jr., et al., 1989. Abnormalities of the electron transport chain in idiopathic 
Parkinson's disease. Ann Neurol. 26, 719-23. 
Parkinson Study, G., 1993. Effects of tocopherol and deprenyl on the progression of 
disability in early Parkinson's disease. N Engl J Med. 328, 176-83. 
Perumal, A. S., et al., 1992. Vitamin E attenuates the toxic effects of 6-hydroxydopamine 
on free radical scavenging systems in rat brain. Brain Res Bull. 29, 699-701. 
Philippens, I. H., et al., 2013. Oral treatment with the NADPH oxidase antagonist 
apocynin mitigates clinical and pathological features of parkinsonism in the 
MPTP marmoset model. J Neuroimmune Pharmacol. 8, 715-26. 
Przedborski, S., Vila, M., 2001. The last decade in Parkinson's disease research. Basic 
sciences. Adv Neurol. 86, 177-86. 
346 
 
Pung, Y. F., et al., 2012. Resolution of mitochondrial oxidative stress rescues coronary 
collateral growth in Zucker obese fatty rats. Arterioscler Thromb Vasc Biol. 32, 
325-34. 
Qureshi, G. A., et al., 1995. Increased cerebrospinal fluid concentration of nitrite in 
Parkinson's disease. Neuroreport. 6, 1642-4. 
Raza, H., John, A., 2006. 4-hydroxynonenal induces mitochondrial oxidative stress, 
apoptosis and expression of glutathione S-transferase A4-4 and cytochrome P450 
2E1 in PC12 cells. Toxicol Appl Pharmacol. 216, 309-18. 
Requejo, R., et al., 2010. Cysteine residues exposed on protein surfaces are the dominant 
intramitochondrial thiol and may protect against oxidative damage. FEBS J. 277, 
1465-80. 
Ross, M. F., et al., 2005. Lipophilic triphenylphosphonium cations as tools in 
mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc). 70, 
222-30. 
Sabogal-Guaqueta, A. M., et al., 2015. The flavonoid quercetin ameliorates Alzheimer's 
disease pathology and protects cognitive and emotional function in aged triple 
transgenic Alzheimer's disease model mice. Neuropharmacology. 93C, 134-145. 
Scatena, R., et al., 2012. Advances in mitochondrial medicine. Springer Verlag, 
Dordrecht ; New York. 
Schapira, A. H., 1994. Evidence for mitochondrial dysfunction in Parkinson's disease--a 
critical appraisal. Mov Disord. 9, 125-38. 
Scheider, W. L., et al., 1997. Dietary antioxidants and other dietary factors in the etiology 
of Parkinson's disease. Mov Disord. 12, 190-6. 
347 
 
Sian, J., et al., 1994. Alterations in glutathione levels in Parkinson's disease and other 
neurodegenerative disorders affecting basal ganglia. Ann Neurol. 36, 348-55. 
Siler-Marsiglio, K. I., et al., 2005. Mitochondrially targeted vitamin E and vitamin E 
mitigate ethanol-mediated effects on cerebellar granule cell antioxidant defense 
systems. Brain Res. 1052, 202-11. 
Smith, R. A., et al., 1999. Selective targeting of an antioxidant to mitochondria. Eur J 
Biochem. 263, 709-16. 
Solesio, M. E., et al., 2013. The mitochondria-targeted anti-oxidant MitoQ reduces 
aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease. 
Biochim Biophys Acta. 1832, 174-82. 
Sun, A. Y., et al., 2008. Botanical phenolics and brain health. Neuromolecular Med. 10, 
259-74. 
Sun, A. Y., et al., 2010. Resveratrol as a therapeutic agent for neurodegenerative 
diseases. Mol Neurobiol. 41, 375-83. 
Szeto, H. H., 2006. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS 
J. 8, E277-83. 
Szeto, H. H., 2008. Mitochondria-targeted cytoprotective peptides for ischemia-
reperfusion injury. Antioxid Redox Signal. 10, 601-19. 
Tang, B., et al., 2006. Association of PINK1 and DJ-1 confers digenic inheritance of 
early-onset Parkinson's disease. Hum Mol Genet. 15, 1816-25. 
Tanner, C. M., 2003. Is the cause of Parkinson's disease environmental or hereditary? 
Evidence from twin studies. Adv Neurol. 91, 133-42. 
348 
 
Ullery, J. C., Marnett, L. J., 2012. Protein modification by oxidized phospholipids and 
hydrolytically released lipid electrophiles: Investigating cellular responses. 
Biochim Biophys Acta. 1818, 2424-35. 
Uttara, B., et al., 2009. Oxidative stress and neurodegenerative diseases: a review of 
upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 
7, 65-74. 
van der Vliet, A., et al., 1997. Oxidative stress in cystic fibrosis: does it occur and does it 
matter? Adv Pharmacol. 38, 491-513. 
Weng, Y. H., et al., 2007. PINK1 mutation in Taiwanese early-onset parkinsonism : 
clinical, genetic, and dopamine transporter studies. J Neurol. 254, 1347-55. 
Wu, X. F., et al., 2005. The role of microglia in paraquat-induced dopaminergic 
neurotoxicity. Antioxid Redox Signal. 7, 654-61. 
Yang, L., et al., 2009. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal. 11, 2095-104. 
Yin, G., et al., 2015. Lipid peroxidation-mediated inflammation promotes cell apoptosis 
through activation of NF-kappaB pathway in rheumatoid arthritis synovial cells. 
Mediators Inflamm. 2015, 460310. 
Yoritaka, A., et al., 1996. Immunohistochemical detection of 4-hydroxynonenal protein 
adducts in Parkinson disease. Proc Natl Acad Sci U S A. 93, 2696-701. 
Zarkovic, K., 2003. 4-hydroxynonenal and neurodegenerative diseases. Mol Aspects 
Med. 24, 293-303. 
349 
 
Zhang, J., et al., 1999. Parkinson's disease is associated with oxidative damage to 
cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol. 154, 1423-
9. 
Zhao, K., et al., 2003. Transcellular transport of a highly polar 3+ net charge opioid 
tetrapeptide. J Pharmacol Exp Ther. 304, 425-32. 
Zhao, K., et al., 2004. Cell-permeable peptide antioxidants targeted to inner 
mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and 
reperfusion injury. J Biol Chem. 279, 34682-90. 
Zhu, J. T., et al., 2007. Flavonoids possess neuroprotective effects on cultured 
pheochromocytoma PC12 cells: a comparison of different flavonoids in activating 
estrogenic effect and in preventing beta-amyloid-induced cell death. J Agric Food 
Chem. 55, 2438-45. 
 
  
350 
 
ACKNOWLEDGMENTS 
I would like to gratefully thank my major professor Dr. Anumantha G. 
Kanthasamy for providing me the opportunity to join his lab, his guidance and 
encouragement throughout my graduate studies. His profound knowledge in the field of 
neurodegenerative disorders, constructive comments and advices has been of great value 
for me and were critically important for completing this dissertation. I would also like to 
thank my committee members, Drs. Arthi Kanthasamy, Wilson Rumbeiha, Stephanie 
Hansen, and Sanjeevi Sivasankar for their help and comments to improve the quality of 
my research.  
I would like to thank Dr. Vellareddy Anantharam for his help in getting the 
resources required for my study. Also, I would like to thank Dr. Huajun Jin and Gary 
Zenitsky for their assistance and support in the preparation of my manuscripts. It has 
been an absolute pleasure to work with the Kanthasamy group and I am grateful to have 
great mentors like Drs. Anamitra Ghosh, Afeseh Hilary and Huajun Jin. In addition, I 
would like to thank all my close collaborators particularly Matthew Neal, Dharmin 
Rokad, Shivani Ghaisas, Chi-Fu Yen, Dr. Nikhil Panicker and Souvarish Sarkar. I’m also 
indebted to the past and present current lab colleagues including, Vivek Lawana, Monica 
Langley, Poojya Anantharam, Dr. Muhammet Ay, Naveen Kondru, Sireesha Manne, 
Dongsuk Kim, Adhithiya Charli, Jie Luo, Ahmed Abdalla, Qi Xu, Emir Malovic, Carrie 
Berg, Dr. Richard Gordon, Dr. Dustin Martin, Dr. Arunkumar Asaithambi and Dr. Neeraj 
Singh. 
351 
 
 I want to also gratefully acknowledge the support from Biomedical Sciences 
staff, Amy Brucker, Kim Adams, William B. Robertson, Linda Erickson, Cathy Martens, 
and Shelly Loonan. Thanks are also given to the laboratory animal resources staff for 
maintaining the mouse colony. I also want to acknowledge the National Institutes of 
Health, the Eugene and Linda Lloyd Chair endowment, and the Iowa Center for 
Advanced Neurotoxicology for the funding support.  
Foremost, I would like to thank my wife Hiruni Harischandra for standing beside me 
throughout my career and her support. She has been my inspiration and motivation for 
continuing to improve my knowledge and move my career forward. Thank you for 
always making me smile and for understanding on those weekends and nights when I was 
working in the lab instead of spending time with you. I am also thankful to my family, 
including my ever-loving brother and sister, my in-laws, my aunt and uncle, who always 
supported me throughout my career. I really appreciate it. 
Finally, my deepest gratitude goes to my parents, G.D. Harischandra and Priyani 
Jayamanne for their unconditional love, encouragement, and support, without which I 
would not have been able to get higher education of this caliber.  
 
 
 
 
 
